sibutramine has been researched along with Obesity in 556 studies
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " The body weight loss associated with sibutramine treatment was accompanied by a slight decrease in blood pressure and did not lead to any significant increases of the heart rate." | 9.27 | Body Weight Reduction Associated with the Sibutramine Treatment: Overall Results of the PRIMAVERA Primary Health Care Trial. ( Dedov, II; Galieva, MO; Mazurina, NV; Melnichenko, GA; Troshina, EA, 2018) |
| "Weight loss induced by sibutramine, diet, and exercise attenuates falls in blood glucose levels and HbA1c compared with similar weight loss with placebo, diet, and exercise." | 9.24 | Influence of sibutramine in addition to diet and exercise on the relationship between weight loss and blood glucose changes. ( Andersson, C; Caterson, ID; Finer, N; James, WPT; Kamil, S; Torp-Pedersen, C, 2017) |
| "Based on these results, it seems unlikely that the 5HT2AR 1438 /A polymorphism has a major impact on obesity and related traits or the response to sibutramine in Greek overweight/obese subjects." | 9.16 | Serotonin receptor 2A -1438G/A promoter polymorphism in relation to obesity and response to sibutramine. ( Antonoglou, C; Babouris, C; Glaros, D; Maltezos, E; Papanas, N; Papatheodorou, K; Papazoglou, D; Restas, E, 2012) |
| "The Sibutramine Cardiovascular OUTcomes trial showed that sibutramine produced greater mean weight loss than placebo but increased cardiovascular morbidity but not mortality." | 9.16 | Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. ( Caterson, ID; Coutinho, W; Finer, N; James, WP; Legler, UF; Maggioni, AP; Perdok, RJ; Renz, CL; Rode, RA; Sharma, AM; Shepherd, GM; Torp-Pedersen, C; Van Gaal, LF, 2012) |
| "Body weight reduction was greater in the sibutramine group." | 9.16 | Sibutramine administration decreases serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome. ( Armeni, AK; Georgopoulos, NA; Katsikis, I; Panidis, D; Papadakis, E; Roupas, ND; Vosnakis, C, 2012) |
| " We studied the response of weight loss therapy with sibutramine and lifestyle change on levels of total bilirubin in an overweight or obese, cardiovascular high-risk population." | 9.14 | Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. ( Andersson, C; Brendorp, B; Caterson, ID; Coutinho, W; Finer, N; Fosbøl, EL; James, WP; Køber, L; Rode, RA; Sharma, AM; Torp-Pedersen, C; Van Gaal, L; Weeke, P, 2009) |
| "We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events." | 9.14 | Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. ( Caterson, ID; Coutinho, W; Finer, N; James, WP; Maggioni, AP; Renz, CL; Rode, RA; Sharma, AM; Shepherd, GM; Torp-Pedersen, C; Van Gaal, LF, 2010) |
| "12-week sibutramine therapy caused a significant reduction in body weight, WC, HC, and BMI (p < 0." | 9.14 | [Effect of sibutramine (meridia) on body composition, peptide YY3-36 and serotonin levels in patients with exogenous constitutional obesity]. ( Ametov, AS; Vlasova, IuIu, 2010) |
| "Comparison of the effects of one year treatment with sibutramine compared to placebo on insulin resistance parameters, body weight, glycemic control, and lipid profile, in type 2 diabetic patients." | 9.14 | Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Maffioli, P; Palumbo, I; Randazzo, S, 2010) |
| "We conducted a randomized, double-blind, pharmacogenetic study of behavioral therapy and sibutramine (10 or 15 mg daily) or placebo for 12 weeks in 181 overweight or obese participants." | 9.13 | A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults. ( Braddock, AE; Burton, DD; Camilleri, M; Carlson, PJ; Clark, MM; Eckert, DJ; Graszer, KM; Grudell, AB; Kalsy, SA; Sweetser, S; Vazquez-Roque, MI; Zinsmeister, AR, 2008) |
| " Very few data exist regarding the effects of sibutramine on the mood of obese and overweight patients in general clinical samples." | 9.13 | Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study. ( Elisaf, MS; Filippatos, TD; Kiortsis, DN; Konitsiotis, S; Tsouli, S, 2008) |
| "To examine the efficacy of sibutramine together with brief lifestyle modification for weight reduction in obese women with polycystic ovary syndrome (PCOS)." | 9.13 | Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. ( Bixo, M; Björn, I; Eliasson, M; Johnson, O; Larsson, A; Lindholm, Å; Poromaa, IS; Wölner-Hanssen, P, 2008) |
| "Body weight reduced in both groups but the reduction was greater with sibutramine (-15." | 9.13 | Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. ( Diamanti-Kandarakis, E; Florakis, D; Georgopoulos, N; Karkanaki, A; Katsikis, I; Nassis, GP; Panidis, D, 2008) |
| "Obese patients have high plasma leptin concentrations that do not induce the expected responses on weight regulation, suggesting a leptin resistance in obesity." | 9.13 | Sympathetic-leptin relationship in obesity: effect of weight loss. ( Böhme, P; Quilliot, D; Zannad, F; Ziegler, O, 2008) |
| "Metformin (850-1700 mg) plus sibutramine (10-20 mg, n=13) or placebo (n=15) was administered for 12 weeks in olanzapine-treated chronic schizophrenia patients." | 9.13 | Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. ( Baptista, T; Beaulieu, S; de Baptista, EA; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E, 2008) |
| "Treatment with sibutramine plus behavioral therapy did not induce sexual dysfunction and sibutramine-induced weight reduction appeared to have a positive impact on sexual function in this small group of overweight and moderately obese women." | 9.12 | Influence of weight reduction by sibutramine on female sexual function. ( Kang, HC; Kim, KK; Kim, SS; Youn, BB, 2006) |
| "In this randomized, double-blind, placebo-controlled study, the effect of sibutramine and cognitive-behavioural weight loss (cognitive-BWL) treatment was assessed in obese subjects with and without subclinical binge eating disorder (sBED)." | 9.12 | Effect of sibutramine and of cognitive-behavioural weight loss therapy in obesity and subclinical binge eating disorder. ( Bauer, C; Fischer, A; Keller, U, 2006) |
| " Sibutramine, a serotonin and norepinephrine transporter blocker, is widely used as an adjunctive obesity treatment, but its impact on endothelial function in obese patients with CAD has not yet been investigated." | 9.12 | Short-term sibutramine therapy is associated with weight loss and improved endothelial function in obese patients with coronary artery disease. ( Beigel, R; Feinberg, MS; Freimark, D; Matetzky, S; Shechter, M, 2006) |
| "This was a 12-week double-blind, placebo controlled, randomized trial of sibutramine for weight loss in obese clozapine-treated schizophrenia or schizoaffective disorder subjects." | 9.12 | A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. ( Borba, CP; Cather, C; Copeland, PM; Daley, TB; Evins, AE; Fan, X; Freudenreich, O; Goff, DC; Hayden, D; Henderson, DC; Nguyen, DD; Zhang, H, 2007) |
| "To describe the comparative efficacy of orlistat and sibutramine in an obesity management program, with specific attention to compliance and weight regains after noncompliance." | 9.12 | Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance. ( Baskal, N; Cesur, M; Cin, MO; Erdogan, MF; Gursoy, A, 2006) |
| " The aim of this study was to test weight loss and impact on QoL after sibutramine treatment in obese subjects." | 9.12 | Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study. ( Bissoli, L; Bosello, O; Cancelli, F; Di Francesco, V; Mazzali, G; Minniti, A; Sacco, T; Salanitri, T; Zamboni, M; Zoico, E, 2007) |
| "Weight reduction with sibutramine is associated with altered gastric functions and increased peptide YY and is significantly associated with SLC6A4 genotype." | 9.12 | Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine. ( Baxter, KL; Burton, DD; Camilleri, M; Clark, MM; Graszer, KM; Jensen, MD; Kalsy, SA; Tepoel, DA; Vazquez Roque, MI; Zinsmeister, AR, 2007) |
| "In this 24-week, open-label, flexible-dose, comparison trial, 46 outpatients with bipolar disorders who had a body mass index (BMI) > or =30 kg/m(2), or > or =27 kg/m(2) with obesity-related comorbidities, and psychotropic-associated weight gain were randomly assigned to receive sibutramine (n = 18; 5-15 mg/day) or topiramate (n = 28; 25-600 mg/day)." | 9.12 | A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. ( Altshuler, LL; Black, D; Denicoff, KD; Frye, MA; Hellemann, G; Keck, PE; Kupka, R; Leverich, GS; McElroy, SL; Mintz, J; Nolen, W; Post, RM; Suppes, T, 2007) |
| "Our objective was to assess the efficacy and safety of sibutramine with a low-calorie diet (LCD) and commercial meal-replacement product in achieving weight loss and weight-loss maintenance in obese patients." | 9.12 | Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients. ( Apovian, CM; Aronne, LJ; Blakesley, V; Cwik, KM; Early, JL; Fernstrom, MH; Frank, A; Greenway, FL; Heber, D; Hewkin, AC; Kushner, RF; Walch, JK, 2007) |
| "Blockade of the NPY5R with the potent antagonist MK-0557 did not significantly increase the weight loss efficacy of either orlistat or sibutramine monotherapy." | 9.12 | NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine. ( Addy, C; Amatruda, JM; Astrup, A; Erondu, N; Gantz, I; Gottesdiener, KM; Haynes, WG; Heymsfield, SB; Kaufman, KD; Lu, K; Mallick, M; Musser, B; Proietto, J; Rissannen, AM; Tonstad, S; Toubro, S, 2007) |
| "The clinically and statistically significant weight reduction caused by sibutramine in this short-term study indicates that treatment of hypothalamic and syndromal obesity with this drug may be beneficial." | 9.12 | Impact sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromes. ( Danielsson, P; Janson, A; Marcus, C; Norgren, S, 2007) |
| "To study, in a primary healthcare setting, the effect of a standardized non-pharmacological treatment program and 15 mg sibutramine or placebo on long-term weight reduction in obese subjects with a body mass index >or= 30 and < 40 kg/m(2)." | 9.11 | Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study. ( Hauner, H; Kurscheid, T; Lauterbach, K; Meier, M; Wendland, G, 2004) |
| "The aim of this study was to evaluate the effects of sibutramine on body composition and fat distribution, insulin resistance, and serum adiponectin levels in obese women." | 9.11 | Sibutramine improves fat distribution and insulin resistance, and increases serum adiponectin levels in Korean obese nondiabetic premenopausal women. ( Ahn, CW; Cha, BS; Huh, KB; Kim, DM; Kim, KR; Lee, HC; Lim, SK; Yoon, SJ, 2004) |
| "To reveal whether baseline body mass index (BMI), and psychobehavioral and nutritional markers were significant predictors of the change in BMI observed after 4 and 12 months in obese women enrolled in a weight reduction program, including low-energy diet, increased physical activity, cognitive behavior therapy and sibutramine." | 9.11 | Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine. ( Bellisle, F; Braunerova, R; Hainer, V; Hill, M; Kunesova, M; Wagenknecht, M, 2005) |
| "The aim of the study was to study the role of initial eating behaviour for subsequent weight loss in treatment with sibutramine (Reductil, Meridia) an anti-obesity drug enhancing satiety, and also to assess changes in mood during the treatment." | 9.11 | Sibutramine treatment in obesity: initial eating behaviour in relation to weight loss results and changes in mood. ( Barkeling, B; Elfhag, K; Rooth, P; Rössner, S, 2005) |
| " The effect of sibutramine combined with hypocaloric diet and exercise on body weight, body fat mass, lipids, glycemic control, insulin secretion and insulin resistance was evaluated in a randomized, controlled, open-label study." | 9.11 | Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects. ( Dakovska, G; Dakovska, L; Kirilov, G; Koev, D; Lazarova, M; Tankova, T, 2004) |
| "Sibutramine induced greater weight reduction than placebo (6." | 9.11 | Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients. ( Faria, AN; Gouvea Ferreira, SR; Kohlmann, NE; Ribeiro Filho, FF; Zanella, MT, 2005) |
| " This study examined the effectiveness of sibutramine, an approved weight loss agent, in overweight and obese subjects taking olanzapine for schizophrenia or schizoaffective disorder." | 9.11 | A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. ( Borba, CP; Cather, C; Copeland, PM; Daley, TB; Evins, AE; Freudenreich, O; Goff, DC; Hayden, D; Henderson, DC; Louie, PM; Nguyen, DD, 2005) |
| "Combined to hypocaloric diet, sibutramine increases weight loss in obese individuals." | 9.11 | Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects. ( Contaldo, F; De Caprio, C; de Simone, G; di Luzio Paparatti, U; Pasanisi, F; Romano, C; Salanitri, T, 2005) |
| "Weight loss achieved with a VLCD is more effectively maintained with sibutramine in combination with a recommended diet and exercise program than with placebo over a follow-up period of 18 months." | 9.11 | Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study. ( Mathus-Vliegen, EM, 2005) |
| "To evaluate the effects of sibutramine on body weight, body fat mass, metabolism of plasma glucose and serum lipids, and insulin resistance (IR) in primary obesity patients." | 9.11 | [Effects of sibutramine on blood glucose and lipids, body fat mass and insulin resistance in obese patients: a multi-center clinical trial]. ( Li, QF; Li, R; Li, XJ; Liu, YP; Ran, XW; Tang, BD; Tong, NW; Yang, FY, 2005) |
| " Sibutramine can increase blood pressure and heart rate, which may attenuate the reductions in LVM associated with weight loss." | 9.10 | Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. ( Boivin, JM; Bruntz, JF; Drouin, P; Gille, B; Grentzinger, A; Hammadi, M; Hanotin, C; Igau, B; Zannad, F, 2002) |
| "To examine whether increased weight loss in obese adolescents is induced when sibutramine is added to a family-based, behavioral weight control program." | 9.10 | Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. ( Berkowitz, RI; Cronquist, JL; Tershakovec, AM; Wadden, TA, 2003) |
| "The objective of the study was to identify determinants of long-term success in weight maintenance in obese subjects who completed the Sibutramine Trial on Obesity Reduction and Maintenance (n = 261), a multicenter European study of weight loss and weight maintenance in obesity that combines sibutramine treatment with dietary restriction and advice on exercise and behavior." | 9.10 | Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial). ( Astrup, AV; Finer, N; Hilsted, J; James, WP; Kopelman, PG; Rössner, S; Saris, WH; van Baak, MA; Van Gaal, LF; van Mil, E, 2003) |
| "To assess the effect of sibutramine-assisted weight reduction program on insulin sensitivity and metabolic parameters in obese normal glucose tolerant individuals over a period of 24 weeks." | 9.10 | Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial. ( Geloneze, B; Geloneze, SR; Magro, DO; Picolo, M; Repetto, EM; Tambascia, MA, 2003) |
| "The present study shows that both sibutramine-induced and orlistat-induced weight losses result in reduction of insulin resistance, and improvements in biochemical markers and US findings of NASH." | 9.10 | The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. ( Karaoglanoglu, M; Kilic, FB; Nazligul, Y; Sabuncu, T; Ucar, E, 2003) |
| "To evaluate the effectiveness of sibutramine therapy alone and in combination with ethinyl estradiol-cyproterone acetate (EE-CPA) on the clinical and metabolic parameters of obese women with polycystic ovary syndrome (PCOS)." | 9.10 | Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. ( Harma, M; Kilic, F; Nazligul, Y; Sabuncu, T, 2003) |
| "To assess the relationship between serum leptin and insulin resistance (IR) in obesity, and to investigate the effects of sibutramine on obesity, serum leptin and IR." | 9.10 | [Serum leptin and insulin resistance in obesity and effects of sibutramine on them]. ( Chen, HL; Lei, MX; Wu, J, 2003) |
| "Sibutramine is a serotonin-noradrenaline reuptake inhibitor that is effective for long-term weight reduction and maintenance in obese patients when used as an adjunct to dietary and behavioural measures." | 9.10 | Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. ( Cutler, NR; Leibowitz, MT; Levy, B; McMahon, FG; Mendel, CM; Mullican, WS; Rowe, ED; Sramek, JJ; Toth, PD; Weinstein, SP, 2002) |
| "Sibutramine treatment in obesity results in significantly greater weight reduction compared with placebo, although weight loss with sibutramine may be accompanied by small but statistically significant mean increases in blood pressure (BP)." | 9.10 | Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. ( Ernst, KR; Fujioka, K; Johnson, F; McMahon, FG; Rowe, E; Weinstein, SP, 2002) |
| "The results of this study confirm that sibutramine, orlistat and metformin are all effective and safe medications that reduce cardiovascular risk and can decrease the risk of type 2 diabetes mellitus in obese females." | 9.10 | Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. ( BascilTutuncu, N; Gokcel, A; Gumurdulu, Y; Guvener, N; Karakose, H; Melek Ertorer, E; Tanaci, N, 2002) |
| "To assess the effects of weight reduction with 10mg of sibutramine or placebo on blood pressure during 24 hours (ambulatory blood pressure monitoring), on left ventricular mass, and on antihypertensive therapy in 86 obese and hypertensive patients for 6 months." | 9.10 | Effects of sibutramine on the treatment of obesity in patients with arterial hypertension. ( Faria, AN; Ferreira, SR; Kohlmann, N; Lerario, DD; Ribeiro Filho, FF; Zanella, MT, 2002) |
| "The aim of the present study was to evaluate the cerebrospinal fluid (CSF)/serum leptin ratio during pharmacological therapy for obesity with centrally and peripherally acting drugs." | 9.10 | The cerebrospinal fluid/serum leptin ratio during pharmacological therapy for obesity. ( Boguszewski, CL; De Almeida, SM; Niclewicz, PA; Radominski, RB; Rodrigues, AM; Suplicy, Hde L, 2002) |
| "Seven clinical centers screened 1463 patients with obesity and randomized 1047 to 24 weeks of treatment with 1 of 6 doses of sibutramine (1, 5, 10, 15, 20, or 30 mg) or placebo once daily." | 9.09 | Sibutramine produces dose-related weight loss. ( Blackburn, GL; Bray, GA; Ferguson, JM; Greenway, FL; Jain, AK; Mendel, CM; Mendels, J; Ryan, DH; Scheinbaum, ML; Schwartz, SL; Seaton, TB, 1999) |
| "Following a very-low-calorie diet, sibutramine is effective in maintaining and improving weight loss for up to 1 year." | 9.09 | Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. ( Apfelbaum, M; Hanotin, C; Leutenegger, E; Thomas, F; Vague, P; Ziegler, O, 1999) |
| "Sibutramine induces significant loss of body weight, BMI and waist, but does not significantly affect cardiovascular function." | 9.09 | A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. ( Berber, A; Cortinas, L; Fanghänel, G; Sánchez-Reyes, L, 2000) |
| "Obese patients with a body mass index (BMI, calculated as weight in kilograms divided by the square of height in meters) between 27 and 40 and a history of hypertension controlled with a calcium channel blocker (with or without concomitant thiazide diuretic treatment) were randomized to receive sibutramine (n = 150) or placebo (n = 74) with minimal behavioral intervention for 52 weeks." | 9.09 | Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. ( Fujioka, K; Johnson, F; McMahon, FG; Mendel, CM; Mooradian, AD; Rolston, K; Rowe, E; Singh, BN, 2000) |
| "To assess the efficacy and tolerability of sibutramine 15 mg once daily as a weight reduction agent in overweight and obese patients (body mass index (b." | 9.09 | Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. ( Banks, LM; Bloom, SR; Finer, N; Frost, GS; Griffiths, J, 2000) |
| ") > or =27 kg/m2) patients with poorly controlled type 2 diabetes mellitus were randomized either to sibutramine (n = 89; mean age 53." | 9.09 | Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. ( Fujioka, K; Jelinek, CA; Lebovitz, HE; Raskin, P; Rowe, E; Seaton, TB; Weinstein, SP, 2000) |
| "In this report we assess pre-treatment determinants of weight loss and maintenance outcome in The Sibutramine Trial of Obesity Reduction and Maintenance (STORM), a 2 y randomized, double-blind, placebo-controlled, European multicenter study examining the effect of sibutramine (Sib) on inducing and maintaining weight loss in obese subjects." | 9.09 | Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance. ( Astrup, A; Finer, N; Goulder, M; Hansen, D; Hilsted, J; James, W; Kopelman, P; Rössner, S; Saris, W; Toubro, S; Van Gaal, L, 2001) |
| "After Sibutramine discontinuation patients had weight gain but they did not reach the baseline body weight." | 9.09 | Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over. ( Berber, A; Cortinas, L; Fanghänel, G; Sánchez-Reyes, L, 2001) |
| "The researchers assessed the long-term weight reduction efficacy, tolerability, and safety of sibutramine used once daily in conjunction with behavior modification to treat mild to moderate obesity." | 9.09 | Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. ( Goulder, MA; Smith, IG, 2001) |
| "To evaluate the insulin, leptin, and abdominal adiposity relation during weight loss in patients with upper body obesity." | 9.09 | Insulin-leptin-visceral fat relation during weight loss. ( DeShields, S; Elashoff, R; Go, VL; Heber, D; Hershman, JM; Liu, Y; Wang, HJ; Yip, I, 2001) |
| "In overweight and obese patients with high serum triglyceride levels and low serum HDL-C levels, treatment with sibutramine was associated with significant improvements in body weight and in serum triglyceride and HDL-C levels." | 9.09 | Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. ( Dujovne, CA; Mendel, CM; Rowe, E; Zavoral, JH, 2001) |
| "To compare the effectiveness of 2 distinct sibutramine regimens with each other and with placebo for weight reduction among obese persons." | 9.09 | Long-term weight loss with sibutramine: a randomized controlled trial. ( Krause, J; Wirth, A, 2001) |
| "Sibutramine, a monoamine re-uptake inhibitor, has recently been approved by the Food and Drug Administration as a weight loss agent." | 9.08 | Effects of sibutramine on resting metabolic rate and weight loss in overweight women. ( Bessesen, DH; Hill, JO; Seagle, HM, 1998) |
| " We have compared the novel (multiple monoamine neurotransmitter reuptake inhibitor) antiobesity drug sibutramine (10 mg once daily) with the extensively studied serotonin-releasing antiobesity agent dexfenfluramine (15 mg twice daily)." | 9.08 | A comparison of sibutramine and dexfenfluramine in the treatment of obesity. ( Drouin, P; Hanotin, C; Jones, SP; Leutenegger, E; Thomas, F, 1998) |
| "To review the major trials that evaluated the efficacy and safety of the use of sibutramine for weight loss and the impact of this agent on obesity-related disorders." | 8.85 | The use of sibutramine in the management of obesity and related disorders: an update. ( Krassas, GE; Tziomalos, K; Tzotzas, T, 2009) |
| "The goal of this article is to review the available literature of pharmacological interventions for obesity and specifically to examine data with sibutramine for the short term on safety and efficacy for weight loss." | 8.84 | Sibutramine: current status as an anti-obesity drug and its future perspectives. ( Henderson, DC; Sharma, B, 2008) |
| " Sibutramine, a monoamine-reuptake inhibitor, results in mean weight losses of 4-5 kg, but is associated with increases in blood pressure and pulse rate." | 8.84 | Drug treatments for obesity: orlistat, sibutramine, and rimonabant. ( Majumdar, SR; Padwal, RS, 2007) |
| "The currently available drugs for long-term treatment of obesity are sibutramine and orlistat." | 8.84 | Currently available drugs for the treatment of obesity: Sibutramine and orlistat. ( Chaput, JP; St-Pierre, S; Tremblay, A, 2007) |
| "This review is an actualisation on efficacy, safety and tolerability of the approved drugs on the long-term treatment of obesity (orlistat and sibutramine)." | 8.84 | Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant. ( Gargallo, M; Isabel Millán, A; Moreno, B; Rubio, MA, 2007) |
| "To investigate, through a meta-analysis of clinical trials, the effect of two weight-reducing drugs, such as orlistat and sibutramine, on serum lipid profiles in overweight and obese subjects, independently of weight loss." | 8.84 | Orlistat and sibutramine beyond weight loss. ( Dicembrini, I; Mannucci, E; Rotella, CM; Rotella, F, 2008) |
| "Sibutramine is a selective serotonin and noradrenaline re-uptake inhibitor approved for the long-term management of obesity." | 8.82 | Sibutramine and the management of obesity. ( Foreyt, JP; Poston, WS, 2004) |
| " The summary mean differences in weight loss, sibutramine minus placebo, for the 3-month and 1-year trials were -2." | 8.82 | The efficacy and safety of sibutramine for weight loss: a systematic review. ( Arterburn, DE; Crane, PK; Veenstra, DL, 2004) |
| " After failure of lifestyle modifications, antiobesity drugs such as orlistat, a potent and selective inhibitor of gastric and pancreatic lipases that reduces lipid intestinal absorption, or sibutramine, a noradrenaline and 5-hydroxytryptamine reuptake inhibitor that regulates food intake, may be considered to favour weight loss and/or weight maintenance." | 8.81 | New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat. ( Ernest, P; Scheen, AJ, 2002) |
| "Sibutramine is a serotonin-norepinephrine reuptake inhibitor indicated for the management of obesity in conjunction with a reduced calorie diet." | 8.81 | The discovery and status of sibutramine as an anti-obesity drug. ( Luque, CA; Rey, JA, 2002) |
| "Sibutramine (BTS 54 524; N-[1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-N,N-dimethylamine hydrochloride monohydrate) is a novel 5-HT (serotonin) and noradrenaline reuptake inhibitor (SNRI) anti-obesity drug." | 8.80 | Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. ( Aspley, S; Cheetham, SC; Heal, DJ; Jackson, HC; Martin, KF; Prow, MR, 1998) |
| "Sibutramine is a serotonin and noradrenaline re-uptake inhibitor (SNRI) which induces weight loss via a dual mode of action: enhancing both satiety and energy expenditure." | 8.80 | Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment. ( De Leeuw, IH; Van Gaal, LF; Wauters, MA, 1998) |
| "To review the pharmacology, pharmacokinetics, efficacy data, adverse effects, and drug interactions of sibutramine as a treatment for obesity." | 8.80 | Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. ( Luque, CA; Rey, JA, 1999) |
| " This review addresses the following three topics: a brief discussion of older weight loss medications approved for short-term use (benzphetamine, phendimetrazine, diethylpropion, mazindol, and phentermine), as well as over-the-counter adrenergic drugs (phenylpropanolamine and ephedrine); recent clinical studies documenting the safety and efficacy of a new medication for obesity treatment, sibutramine, recently approved by the Food and Drug Administration for long-term use; and recent studies characterizing the valvulopathy associated with fenfluramine and dexfenfluramine, serotonergic medications for obesity which have been removed from the markets." | 8.80 | Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity. ( Ryan, DH, 2000) |
| "Sibutramine is a noradrenaline and 5-hydroxytryptamine reuptake inhibitor which causes weight loss in laboratory rodents via effects on both food intake and metabolic rate." | 8.79 | Sibutramine: a review of the pharmacology of a novel anti-obesity agent. ( Stock, MJ, 1997) |
| "Previous studies have reported on the glucose and lipid-lowering effects of ferulic acid (FA) but its anti-obesity potential has not yet been firmly established." | 7.85 | Ferulic acid lowers body weight and visceral fat accumulation via modulation of enzymatic, hormonal and inflammatory changes in a mouse model of high-fat diet-induced obesity. ( Carvalho, KM; da Cruz Fonseca, SG; de Lemos, TL; de Melo, TS; de Queiroz, MG; Fontenele, TM; Lima, PR; Rao, VS; Santos, FA; Solon, FR; Tomé, AR, 2017) |
| "Orlistat and sibutramine had early effects on weight loss, not sustained over 3 years." | 7.81 | The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United Kingdom population-based cohort. ( Batterham, RL; Bhaskaran, K; Douglas, IJ; Smeeth, L, 2015) |
| "Despite a surprising decision of the European Drug Agency to suspend the registration of sibutramine in the whole of Europe since January 2010 we can state that in our patients we have proven a positive effect of sibutramine substitution on their weight reduction (Tab." | 7.79 | The role of sibutramine in weight reduction. ( Drahokoupilova, E; Fajfrova, J; Pavlik, V; Slovacek, L, 2013) |
| "The risk of AMI, stroke and either AMI or stroke was not higher among sibutramine users than comparable non-users of sibutramine in both Germany and the UK [Germany: HR 0." | 7.78 | Safety assessment of an anti-obesity drug (sibutramine): a retrospective cohort study. ( Ferrufino, CP; Klingman, D; Lee, WC; Oleske, DM; Tyczynski, JE, 2012) |
| "Sibutramine is a novel new pharmacologic agent which is a specific reuptake inhibitor for norepinephrine and serotonin." | 7.78 | Sibutramine: a novel new agent for obesity treatment. ( Bray, GA; Kaiser, P; Ryan, DH, 1995) |
| " In addition, we demonstrated that sibutramine treatment had a favourable effect on body weight maintenance and obesity-related health risks." | 7.77 | Hypogonadotropic hypogonadism in a homozygous MC4R mutation carrier and the effect of sibutramine treatment on body weight and obesity-related health risks. ( Hainer, V; Hainerová, IA; Sedláčková, D; Zamrazilová, H, 2011) |
| "Topiramate is newly approved as anticonvulsant that seems to promote body weight loss in humans." | 7.77 | Topiramate induces weight loss and improves insulin sensitivity in dietary obese rats: comparison to sibutramine. ( Abo-Elmatty, DM; Zaitone, SA, 2011) |
| "In this study, our goal was to investigate whether a common SNP, -866G/A (rs659366), in the uncoupling protein 2 (UCP2) gene could influence weight reduction and body composition under sibutramine therapy in an obese Taiwanese population." | 7.76 | Effect of the common -866G/A polymorphism of the uncoupling protein 2 gene on weight loss and body composition under sibutramine therapy in an obese Taiwanese population. ( Hsiao, TJ; Huang, SY; Hwang, Y; Lin, E; Wu, LS, 2010) |
| "Tesofensine, a novel triple monoamine reuptake inhibitor, produces a significant weight loss in humans." | 7.76 | The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. ( Axel, AM; Hansen, G; Hansen, HH; Larsen, PJ; Mikkelsen, JD; Raben, A; Tang-Christensen, M, 2010) |
| "This study has shown an elevation in QTd, which may lead to cardiac arrhythmias, after sibutramine treatment." | 7.76 | Elevation of QT dispersion after obesity drug sibutramine. ( Algul, B; Ata, N; Dal, K; Demirel, G; Deveci, OS; Ertugrul, DT; Kucukazman, M; Tutal, E; Yalcin, AA; Yavuz, B; Yilmaz, H, 2010) |
| "The relationship between weight reduction after sibutramine treatment and a single nucleotide polymorphism, rs5443 (C825T), in the guanine nucleotide binding protein beta polypeptide 3 (GNB3) gene is currently inconsistent." | 7.75 | Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene. ( Hsiao, DJ; Huang, SY; Lin, E; Wu, LS, 2009) |
| "6-month open-label weight loss trial combining sibutramine (a serotonin and noradrenaline reuptake inhibitor) with a 600-kcal deficit diet and exercise." | 7.75 | Changes in regional adiposity and cardio-metabolic function following a weight loss program with sibutramine in obese men with obstructive sleep apnea. ( Banerjee, D; Berend, N; Grunstein, RR; Magnussen, JS; Phillips, CL; Trenell, MI; Wang, D; Yee, BJ, 2009) |
| "To characterize the interactive effects of amylin with phentermine or sibutramine on food intake, body weight/composition and gene expression in diet-induced obese (DIO) rats." | 7.74 | Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats. ( Athanacio, J; Coffey, T; Kesty, NC; Lei, C; Mack, C; Parkes, DG; Roth, JD; Trevaskis, JL; Weyer, C; Wilson, J, 2008) |
| " For subjects who had failed to lose weight via the 'Lifestyle' intervention, the addition of sibutramine resulted in a similar weight loss compared to their pair-matched 'Lifestyle' only 'successful' counterparts (9." | 7.74 | Use of sibutramine to assist obese women with weight loss can be successful in dietitian-led clinics: another tool in the dietitian's toolbox. ( Barratt, R; Frost, G; Millward, J; O'Boyle, A; Truby, H, 2008) |
| "This study was designed to examine whether prior authorization for insurer reimbursement of weight loss medication affects compliance with taking sibutramine or adherence to a medical weight control program." | 7.73 | Does prior authorization of sibutramine improve medication compliance or weight loss? ( Nieto, L; Risser, JA; Vash, PD, 2005) |
| "Sibutramine is a drug that is used in the treatment of obesity." | 7.73 | Early first-trimester sibutramine exposure : pregnancy outcome and neonatal follow-up. ( Carducci, B; Caruso, A; Cavaliere, AF; De Santis, M; Straface, G, 2006) |
| "To study personality and clinical factors in weight loss by sibutramine (Meridia and Reductil), an anti-obesity drug enhancing satiety." | 7.72 | Sibutramine treatment in obesity: predictors of weight loss including rorschach personality data. ( Barkeling, B; Carlsson, AM; Elfhag, K; Rössner, S, 2003) |
| "Aim of the study was to examine the course of body weight and cardiovascular risk parameters under the everyday life conditions in general practice after obese patients had terminated their sibutramine treatment." | 7.72 | [Sustained weight reduction after cessation of obesity treatment with Sibutramine]. ( Wirth, A, 2004) |
| "To investigate the pharmacological mechanisms underlying the induction of thermogenesis by Metabolite 2 (M2; BTS 54 505), a major pharmacologically active metabolite of the anti-obesity drug, sibutramine." | 7.71 | Mechanism of the thermogenic effect of Metabolite 2 (BTS 54 505), a major pharmacologically active metabolite of the novel anti-obesity drug, sibutramine. ( Heal, DJ; Liu, YL; Stock, MJ, 2002) |
| "We studied the effects of the novel noradrenaline and serotonin (5-HT) reuptake inhibitor sibutramine on feeding and body weight in a rat model of dietary obesity, and whether it interacts with hypothalamic neuropeptide Y (NPY) neurones." | 7.71 | Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide Y. ( Bing, C; Brown, M; Heal, D; King, P; Pickavance, L; Wilding, J, 2001) |
| "The relationship between insulin-mediated glucose disposal and daylong free fatty acid (FFA) concentrations before and after sibutramine-assisted weight loss was investigated in 24 healthy, normotensive, nondiabetic, obese women (body mass index [BMI] >30." | 7.71 | Metabolic changes following sibutramine-assisted weight loss in obese individuals: role of plasma free fatty acids in the insulin resistance of obesity. ( Abbasi, F; Kim, HS; Lamendola, C; McLaughlin, T; Reaven, GM, 2001) |
| "To determine whether (1) patients who experience greater weight loss also experience correspondingly greater improvements in health-related quality of life (HRQOL); (2) the improvement in HRQOL is noticeable for patients achieving moderate (5%-10%) weight reduction; and (3) the relationship between weight reduction and HRQOL is similar for patients receiving sibutramine hydrochloride vs placebo." | 7.71 | Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomized trials of sibutramine vs placebo. ( Kolotkin, RL; Mendel, CM; Nguyen, MH; Samsa, GP; Williams, GR, 2001) |
| "The results indicate that chronic administration of sibutramine can reduce weight gain, lower NEFA concentrations, decrease hyperinsulinaemia and ameliorate the insulin resistance of ob/ob mice." | 7.70 | Effect of the antiobesity agent sibutramine in obese-diabetic ob/ob mice. ( Bailey, CJ; Day, C, 1998) |
| "Chronic administration of sibutramine lowers body weight, presumably by altering brain monoamine metabolism." | 7.70 | Sibutramine alters the central mechanisms regulating the defended body weight in diet-induced obese rats. ( Dunn-Meynell, AA; Levin, BE, 2000) |
| "When the hypothalamic ventromedial nucleus and arcuate nucleus were destroyed in rats by treatment with monosodium glutamate in the neonatal stage, increase in the Lee index (body weight 1/3/body length) and in retroperitoneal fat as well as decreases in spontaneous motor activity, food consumption and growth hormone secretion function associated with hypothalamic low body length obesity (monosodium glutamate-treated obesity; MSG-OB) were observed as these rats grew." | 7.70 | Effects of chronic administration of sibutramine on body weight, food intake and motor activity in neonatally monosodium glutamate-treated obese female rats: relationship of antiobesity effect with monoamines. ( Gomita, Y; Nakagawa, T; Ohyama, T; Okamura, H; Ukai, K, 2000) |
| "Obesity is associated with impaired microvascular endothelial function." | 6.80 | The effects of anti-obesity intervention with orlistat and sibutramine on microvascular endothelial function. ( Al-Tahami, BA; Awang, SA; Bee, YT; Ismail, AA; Rasool, AH; Salha Wan Abdul Rani, WR; Sanip, Z, 2015) |
| "Sibutramine treatment resulted in a significantly greater decrease in body weight, body mass index, and waist circumference and a significant increase in diastolic blood pressure during 24-hour blood pressure monitoring compared with placebo treatment." | 6.73 | Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. ( Grimm, E; Herrmann, D; Kintscher, U; Scholze, J; Unger, T, 2007) |
| "The treatment of obesity is strongly recommended because many studies have shown it to be a strong risk factor for cardiovascular disease." | 6.71 | The effect of 1-yr sibutramine treatment on glucose tolerance, insulin sensitivity and serum lipid profiles in obese subjects. ( Birden, F; Sabuncu, T; Ucar, E; Yasar, O, 2004) |
| "Obesity is a chronic disease with a marked impact on health and the prevalence of obesity in Croatia is rapidly rising." | 6.71 | Croatian experience with sibutramine in the treatment of obesity--multicenter prospective study. ( Majanović, SK; Ruzić, A; Stimac, D, 2004) |
| "Sibutramine was well tolerated by most of the patients." | 6.69 | Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. ( Berber, A; Cuellar, GE; Monsalve, MC; Ruiz, AM, 2000) |
| "Future development of drugs for the treatment of obesity will be dependent on whether they can survive review for safety and effectiveness." | 6.47 | Is there a path for approval of an antiobesity drug: what did the Sibutramine Cardiovascular Outcomes Trial find? ( Downey, M; Sharma, AM; Still, C, 2011) |
| "Although pharmacological treatment of obesity is widely used in most countries, the number of available drugs is still very limited." | 6.45 | The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions. ( Coutinho, W, 2009) |
| "Sibutramine is a serotonin-noradrenaline (norepinephrine) reuptake inhibitor indicated for the management of obesity in conjunction with a reduced calorie diet." | 6.42 | A benefit-risk assessment of sibutramine in the management of obesity. ( Carruba, MO; Nisoli, E, 2003) |
| "Among methods of treatment of obesity the most known and safe is the low calories content diet." | 6.42 | [Sibutramine in treatment of obesity. Therapeutic premises in patients with essential hypertension, diabetes, hyperlipidemia]. ( Kawecka-Jaszcz, K; Rajzer, M; Wojciechowska, W, 2004) |
| "Sibutramine is a combined serotonin(5-HT) and noradrenaline (NA)re-uptake inhibitor." | 6.41 | An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. ( Carruba, MO; Nisoli, E, 2000) |
| "Weight reduction is also a cornerstone of diabetes management, improving glycaemic control and reducing other risk factors associated with this disease." | 6.41 | The importance of obesity in diabetes and its treatment with sibutramine. ( Peiffer, FW; Van Gaal, LF, 2001) |
| "Sibutramine is an orally administered centrally acting weight management agent apparently devoid of amphetamine-like abuse potential." | 6.40 | Sibutramine. A review of its contribution to the management of obesity. ( Goa, KL; McNeely, W, 1998) |
| "Linagliptin treatment profoundly reduced hepatic fat compared with vehicle, with an effect comparable to that of sibutramine." | 5.38 | Evaluation of body fat composition after linagliptin treatment in a rat model of diet-induced obesity: a magnetic resonance spectroscopy study in comparison with sibutramine. ( Cheetham, S; Ittrich, C; Kassubek, J; Klein, T; Mark, M; Mayoux, E; Mueller, HP; Niessen, HG; Stiller, D, 2012) |
| "Sibutramine is a serotonergic and adrenergic drug that reduces food intake and increases thermogenesis." | 5.37 | Drug treatment for obesity in the post-sibutramine era. ( Cheung, BM, 2011) |
| "Sibutramine is a selective inhibitor of the reuptake of monoamines." | 5.36 | An obesity drug sibutramine reduces brain natriuretic peptide (BNP) levels in severely obese patients. ( Algul, B; Arif Yalcin, A; Ata, N; Dal, K; Kucukazman, M; Okhan Akin, K; Sinan Deveci, O; Taner Ertugrul, D; Tutal, E; Yavuz, B, 2010) |
| "Obesity was induced by high-fat diet (HFD) in healthy male Sprague-Dawley rats." | 5.35 | Evaluation of anti-obesity activity of duloxetine in comparison with sibutramine along with its anti-depressant activity: an experimental study in obese rats. ( Bhatt, PA; Chudasama, HP, 2009) |
| "Sibutramine has been increasingly used in the management of obesity, but is relatively contraindicated in patients with hypertension." | 5.34 | The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea. ( Banerjee, D; Caterson, I; Grunstein, RR; Hedner, JA; Phillips, CL; Yee, BJ, 2007) |
| "Obesity is considered important factor contributing development of PCOS." | 5.32 | [Sibutramine administration in polycystic ovary syndrome treatment]. ( Banaś, M; Jochemczyk-Banek, U; Olszanecka-Glinianowicz, M; Zahorska-Markiewicz, B; Zurakowski, A, 2004) |
| " The body weight loss associated with sibutramine treatment was accompanied by a slight decrease in blood pressure and did not lead to any significant increases of the heart rate." | 5.27 | Body Weight Reduction Associated with the Sibutramine Treatment: Overall Results of the PRIMAVERA Primary Health Care Trial. ( Dedov, II; Galieva, MO; Mazurina, NV; Melnichenko, GA; Troshina, EA, 2018) |
| "Weight loss induced by sibutramine, diet, and exercise attenuates falls in blood glucose levels and HbA1c compared with similar weight loss with placebo, diet, and exercise." | 5.24 | Influence of sibutramine in addition to diet and exercise on the relationship between weight loss and blood glucose changes. ( Andersson, C; Caterson, ID; Finer, N; James, WPT; Kamil, S; Torp-Pedersen, C, 2017) |
| "To compare the efficacy and safety of diethylpropion (DEP), fenproporex (FEN), mazindol (MZD), fluoxetine (FXT) and sibutramine (SIB) in promoting weight loss." | 5.19 | A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. ( Boguszewski, CL; Cunha, DR; do Desterro de Figueiredo, M; dos Santos, CM; Radominski, R; Suplicy, H, 2014) |
| "The Sibutramine Cardiovascular OUTcomes (SCOUT) trial showed a significantly increased relative risk of nonfatal cardiovascular events, but not mortality, in overweight and obese subjects receiving long-term sibutramine treatment with diet and exercise." | 5.19 | Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease. ( Caterson, ID; Coutinho, W; Espinoza, D; Finer, N; Gebski, V; Ivers, L; James, WP; Legler, UF; Seimon, RV; Sharma, AM, 2014) |
| " This study compared the effectiveness of self-help cognitive-behavioral therapy (shCBT) and an anti-obesity medication (sibutramine), alone and in combination, and it is only the second placebo-controlled trial of any medication for BED to evaluate longer-term effects after treatment discontinuation." | 5.19 | Treatment of binge eating disorder in racially and ethnically diverse obese patients in primary care: randomized placebo-controlled clinical trial of self-help and medication. ( Barnes, RD; Garcia, R; Genao, I; Grilo, CM; Gueorguieva, R; Masheb, RM; McKenzie, KC; Walsh, BT; White, MA, 2014) |
| "This analysis included 8,192 overweight patients with type 2 diabetes from the Sibutramine Cardiovascular Outcomes (SCOUT) trial randomized to lifestyle intervention with or without sibutramine for up to 6 years." | 5.17 | Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial. ( Andersson, C; Caterson, I; Coutinho, W; Finer, N; Ghotbi, AA; James, WP; Køber, L; Sharma, AM; Torp-Pedersen, C; Van Gaal, LF, 2013) |
| " We assessed serum lipocalin-2 levels in polycystic ovary syndrome (PCOS) and the effects of weight loss or metformin on these levels." | 5.16 | Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome. ( Delkos, D; Kalaitzakis, E; Kandaraki, EA; Katsikis, I; Koiou, E; Panidis, D; Tziomalos, K; Vosnakis, C, 2012) |
| "Based on these results, it seems unlikely that the 5HT2AR 1438 /A polymorphism has a major impact on obesity and related traits or the response to sibutramine in Greek overweight/obese subjects." | 5.16 | Serotonin receptor 2A -1438G/A promoter polymorphism in relation to obesity and response to sibutramine. ( Antonoglou, C; Babouris, C; Glaros, D; Maltezos, E; Papanas, N; Papatheodorou, K; Papazoglou, D; Restas, E, 2012) |
| "The Sibutramine Cardiovascular OUTcomes trial showed that sibutramine produced greater mean weight loss than placebo but increased cardiovascular morbidity but not mortality." | 5.16 | Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. ( Caterson, ID; Coutinho, W; Finer, N; James, WP; Legler, UF; Maggioni, AP; Perdok, RJ; Renz, CL; Rode, RA; Sharma, AM; Shepherd, GM; Torp-Pedersen, C; Van Gaal, LF, 2012) |
| "Sibutramine, a centrally-acting selective monoamine reuptake inhibitor, has been used as an appetite suppressant drug in obesity." | 5.16 | Sibutramine promotes amygdala activity under fasting conditions in obese women. ( Daul, S; Heinze, HJ; Heldmann, M; Klose, S; Lehnert, H; Münte, TF; Oltmanns, KM; Rotte, M; Schäfer, M, 2012) |
| "To develop statistical models for predicting weight loss and regain, we analyzed the phenotypic responses in an outpatient study of 60 obese subjects randomized to one of three 12-week interventions, diet (-600 kcal) alone, diet with exercise, and diet with sibutramine." | 5.16 | Prediction of weight loss and regain following dietary, lifestyle, and pharmacologic intervention. ( Brooke, A; Delafont, B; Elkhawad, M; Miller, SR; Murgatroyd, PR; Napolitano, A; Nunez, DJ; Tan, CY; Vidal-Puig, A; Virtue, S, 2012) |
| "Body weight reduction was greater in the sibutramine group." | 5.16 | Sibutramine administration decreases serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome. ( Armeni, AK; Georgopoulos, NA; Katsikis, I; Panidis, D; Papadakis, E; Roupas, ND; Vosnakis, C, 2012) |
| "We observed a decrease of body weight after 9 and 12 months in the group treated with sibutramine, but not in the control group." | 5.15 | Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Maffioli, P; Palumbo, I; Randazzo, S, 2011) |
| " Therefore, we could not find any additional effects of Diacerein on weight loss and inflammatory variables in this study." | 5.15 | Changes of body weight and inflammatory markers after 12-week intervention trial: results of a double-blind, placebo-control pilot study. ( Joo, NS; Kim, BT; Kim, CW; Kim, KM; Kim, SM; Lee, DJ, 2011) |
| "The aim of the present study was to compare the efficacy of 1 yr of sibutramine-induced weight loss versus continuous positive airway pressure (CPAP) treatment on sleep-disordered breathing, cardiac autonomic function and systemic blood pressure in obese patients with obstructive sleep apnoea." | 5.14 | Sibutramine versus continuous positive airway pressure in obese obstructive sleep apnoea patients. ( Ferland, A; Poirier, P; Sériès, F, 2009) |
| " We studied the response of weight loss therapy with sibutramine and lifestyle change on levels of total bilirubin in an overweight or obese, cardiovascular high-risk population." | 5.14 | Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. ( Andersson, C; Brendorp, B; Caterson, ID; Coutinho, W; Finer, N; Fosbøl, EL; James, WP; Køber, L; Rode, RA; Sharma, AM; Torp-Pedersen, C; Van Gaal, L; Weeke, P, 2009) |
| "Sibutramine and metformin are drugs commonly used to obtain weight loss." | 5.14 | Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women. ( Akbas, H; Coban, E; Eray, E; Ozdem, S; Sari, R, 2010) |
| "Electric-heat needle combined with acupoint stic-king therapy has better therapeutic effect on simple obesity of spleen deficiency and dampness stagnation type than that of oral administration of Sibutramine Hydrochloride capsules." | 5.14 | [Clinical observation on therapeutic effect of electric-heat needle combined with acupoint sticking therapy for treatment of simple obesity]. ( Li, B; Song, P; Zhang, FX; Zhang, P; Zhu, Y, 2010) |
| "We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events." | 5.14 | Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. ( Caterson, ID; Coutinho, W; Finer, N; James, WP; Maggioni, AP; Renz, CL; Rode, RA; Sharma, AM; Shepherd, GM; Torp-Pedersen, C; Van Gaal, LF, 2010) |
| "12-week sibutramine therapy caused a significant reduction in body weight, WC, HC, and BMI (p < 0." | 5.14 | [Effect of sibutramine (meridia) on body composition, peptide YY3-36 and serotonin levels in patients with exogenous constitutional obesity]. ( Ametov, AS; Vlasova, IuIu, 2010) |
| "Comparison of the effects of one year treatment with sibutramine compared to placebo on insulin resistance parameters, body weight, glycemic control, and lipid profile, in type 2 diabetic patients." | 5.14 | Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Maffioli, P; Palumbo, I; Randazzo, S, 2010) |
| "We conducted a randomized, double-blind, pharmacogenetic study of behavioral therapy and sibutramine (10 or 15 mg daily) or placebo for 12 weeks in 181 overweight or obese participants." | 5.13 | A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults. ( Braddock, AE; Burton, DD; Camilleri, M; Carlson, PJ; Clark, MM; Eckert, DJ; Graszer, KM; Grudell, AB; Kalsy, SA; Sweetser, S; Vazquez-Roque, MI; Zinsmeister, AR, 2008) |
| " Very few data exist regarding the effects of sibutramine on the mood of obese and overweight patients in general clinical samples." | 5.13 | Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study. ( Elisaf, MS; Filippatos, TD; Kiortsis, DN; Konitsiotis, S; Tsouli, S, 2008) |
| "To examine the efficacy of sibutramine together with brief lifestyle modification for weight reduction in obese women with polycystic ovary syndrome (PCOS)." | 5.13 | Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. ( Bixo, M; Björn, I; Eliasson, M; Johnson, O; Larsson, A; Lindholm, Å; Poromaa, IS; Wölner-Hanssen, P, 2008) |
| "Body weight reduced in both groups but the reduction was greater with sibutramine (-15." | 5.13 | Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. ( Diamanti-Kandarakis, E; Florakis, D; Georgopoulos, N; Karkanaki, A; Katsikis, I; Nassis, GP; Panidis, D, 2008) |
| "Obese patients have high plasma leptin concentrations that do not induce the expected responses on weight regulation, suggesting a leptin resistance in obesity." | 5.13 | Sympathetic-leptin relationship in obesity: effect of weight loss. ( Böhme, P; Quilliot, D; Zannad, F; Ziegler, O, 2008) |
| " We did not find any influence of 5% body weight loss induced by sibutramine on circulating levels of endocannabinoids and adipose-tissue expression of endocannabinoid genes in obese subjects." | 5.13 | Peripheral endocannabinoid system activity in patients treated with sibutramine. ( Bátkai, S; Engeli, S; Gorzelniak, K; Harvey-White, J; Heusser, K; Janke, J; Jordan, J; Luft, FC; Pacher, P, 2008) |
| "Metformin (850-1700 mg) plus sibutramine (10-20 mg, n=13) or placebo (n=15) was administered for 12 weeks in olanzapine-treated chronic schizophrenia patients." | 5.13 | Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. ( Baptista, T; Beaulieu, S; de Baptista, EA; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E, 2008) |
| "Treatment with sibutramine plus behavioral therapy did not induce sexual dysfunction and sibutramine-induced weight reduction appeared to have a positive impact on sexual function in this small group of overweight and moderately obese women." | 5.12 | Influence of weight reduction by sibutramine on female sexual function. ( Kang, HC; Kim, KK; Kim, SS; Youn, BB, 2006) |
| "In this randomized, double-blind, placebo-controlled study, the effect of sibutramine and cognitive-behavioural weight loss (cognitive-BWL) treatment was assessed in obese subjects with and without subclinical binge eating disorder (sBED)." | 5.12 | Effect of sibutramine and of cognitive-behavioural weight loss therapy in obesity and subclinical binge eating disorder. ( Bauer, C; Fischer, A; Keller, U, 2006) |
| "Sibutramine, a serotonin and norepinephrine transporter blocker, is used as adjunctive obesity treatment." | 5.12 | Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. ( Diedrich, A; Engeli, S; Heusser, K; Jordan, J; Klaua, S; Krüger, N; Luft, FC; Stoffels, G; Strauss, A; Tank, J, 2006) |
| " Sibutramine, a serotonin and norepinephrine transporter blocker, is widely used as an adjunctive obesity treatment, but its impact on endothelial function in obese patients with CAD has not yet been investigated." | 5.12 | Short-term sibutramine therapy is associated with weight loss and improved endothelial function in obese patients with coronary artery disease. ( Beigel, R; Feinberg, MS; Freimark, D; Matetzky, S; Shechter, M, 2006) |
| "This was a 12-week double-blind, placebo controlled, randomized trial of sibutramine for weight loss in obese clozapine-treated schizophrenia or schizoaffective disorder subjects." | 5.12 | A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. ( Borba, CP; Cather, C; Copeland, PM; Daley, TB; Evins, AE; Fan, X; Freudenreich, O; Goff, DC; Hayden, D; Henderson, DC; Nguyen, DD; Zhang, H, 2007) |
| "To describe the comparative efficacy of orlistat and sibutramine in an obesity management program, with specific attention to compliance and weight regains after noncompliance." | 5.12 | Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance. ( Baskal, N; Cesur, M; Cin, MO; Erdogan, MF; Gursoy, A, 2006) |
| "Open-label sibutramine treatment decreased body weight 4." | 5.12 | Sympathetic vasomotor tone determines blood pressure response to long-term sibutramine treatment. ( Diedrich, A; Engeli, S; Heusser, K; Janke, J; Jordan, J; Luft, FC; Tank, J; Wiesner, S, 2007) |
| " The aim of this study was to test weight loss and impact on QoL after sibutramine treatment in obese subjects." | 5.12 | Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study. ( Bissoli, L; Bosello, O; Cancelli, F; Di Francesco, V; Mazzali, G; Minniti, A; Sacco, T; Salanitri, T; Zamboni, M; Zoico, E, 2007) |
| "To evaluate the effects of weight loss on the risk of having metabolic syndrome after 1 year of treatment with lifestyle modification alone, pharmacotherapy alone (sibutramine) or the combination of the two." | 5.12 | Impact of weight loss on the metabolic syndrome. ( Berkowitz, RI; Cato, RK; Phelan, S; Rothman, R; Sarwer, DB; Wadden, TA; Womble, LG, 2007) |
| "Weight reduction with sibutramine is associated with altered gastric functions and increased peptide YY and is significantly associated with SLC6A4 genotype." | 5.12 | Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine. ( Baxter, KL; Burton, DD; Camilleri, M; Clark, MM; Graszer, KM; Jensen, MD; Kalsy, SA; Tepoel, DA; Vazquez Roque, MI; Zinsmeister, AR, 2007) |
| "In this 24-week, open-label, flexible-dose, comparison trial, 46 outpatients with bipolar disorders who had a body mass index (BMI) > or =30 kg/m(2), or > or =27 kg/m(2) with obesity-related comorbidities, and psychotropic-associated weight gain were randomly assigned to receive sibutramine (n = 18; 5-15 mg/day) or topiramate (n = 28; 25-600 mg/day)." | 5.12 | A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. ( Altshuler, LL; Black, D; Denicoff, KD; Frye, MA; Hellemann, G; Keck, PE; Kupka, R; Leverich, GS; McElroy, SL; Mintz, J; Nolen, W; Post, RM; Suppes, T, 2007) |
| "Our objective was to assess the efficacy and safety of sibutramine with a low-calorie diet (LCD) and commercial meal-replacement product in achieving weight loss and weight-loss maintenance in obese patients." | 5.12 | Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients. ( Apovian, CM; Aronne, LJ; Blakesley, V; Cwik, KM; Early, JL; Fernstrom, MH; Frank, A; Greenway, FL; Heber, D; Hewkin, AC; Kushner, RF; Walch, JK, 2007) |
| "Blockade of the NPY5R with the potent antagonist MK-0557 did not significantly increase the weight loss efficacy of either orlistat or sibutramine monotherapy." | 5.12 | NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine. ( Addy, C; Amatruda, JM; Astrup, A; Erondu, N; Gantz, I; Gottesdiener, KM; Haynes, WG; Heymsfield, SB; Kaufman, KD; Lu, K; Mallick, M; Musser, B; Proietto, J; Rissannen, AM; Tonstad, S; Toubro, S, 2007) |
| "The clinically and statistically significant weight reduction caused by sibutramine in this short-term study indicates that treatment of hypothalamic and syndromal obesity with this drug may be beneficial." | 5.12 | Impact sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromes. ( Danielsson, P; Janson, A; Marcus, C; Norgren, S, 2007) |
| "Addition of low-dose metoprolol to sibutramine therapy increased patient compliance to the treatment, and decreased the frequency and severity of side effects including hypertension and palpitations, without decreasing the drug efficacy or causing significant deleterious changes in metabolic parameters." | 5.11 | Effect of low-dose metoprolol in combination with sibutramine therapy in normotensive obese patients: a randomized controlled study. ( Baykan, M; Durmus, I; Erem, C; Ersoz, HO; Hacihasanoglu, A; Telatar, M; Ukinc, K, 2004) |
| "The mean weight loss was greater in the sibutramine group (-7." | 5.11 | Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes. ( Kaukua, JK; Pekkarinen, TA; Rissanen, AM, 2004) |
| "To study, in a primary healthcare setting, the effect of a standardized non-pharmacological treatment program and 15 mg sibutramine or placebo on long-term weight reduction in obese subjects with a body mass index >or= 30 and < 40 kg/m(2)." | 5.11 | Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study. ( Hauner, H; Kurscheid, T; Lauterbach, K; Meier, M; Wendland, G, 2004) |
| "Sibutramine of the dosage of 10 mg/day is an effective and safe therapy for weight reduction in obese subjects." | 5.11 | [A multicenter and open study on efficacy and safety of sibutramine in obese subjects]. ( Ning, G, 2004) |
| "Sibutramine and orlistat are currently used for weight loss." | 5.11 | Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. ( Altunbas, H; Balci, MK; Cakir, M; Karayalcin, U; Sari, R, 2004) |
| "In this population of obese Hispanic patients with type 2 diabetes, sibutramine combined with glibenclamide therapy achieved weight loss for up to 12 months and was associated with better glycemic control than placebo." | 5.11 | Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial. ( Berber, A; Campos-Franco, E; Fanghänel, G; Martínez-Rivas, L; Sánchez-Reyes, L; Yamamoto, J, 2004) |
| "Aim of this study was to compare the effects of metformin and a body weight reduction regimen using sibutramine on insulinemia, insulin sensitivity, and ovarian function in women with anovulatory cycles or infertility." | 5.11 | Metformin versus sibutramine in the treatment of hyperinsulinemia in chronically anovulating women. ( Dravecka, I; Kraus, V; Lazurova, I; Petrovicova, J, 2004) |
| "The aim of this study was to evaluate the effects of sibutramine on body composition and fat distribution, insulin resistance, and serum adiponectin levels in obese women." | 5.11 | Sibutramine improves fat distribution and insulin resistance, and increases serum adiponectin levels in Korean obese nondiabetic premenopausal women. ( Ahn, CW; Cha, BS; Huh, KB; Kim, DM; Kim, KR; Lee, HC; Lim, SK; Yoon, SJ, 2004) |
| "Both orlistat and sibutramine were effective on anthropometric variables and on metabolic pattern during the 12-month treatment; in our sample, orlistat appears to be slightly more efficacious as an anti-obesity drug, while sibutramine intake was not associated to any cardiovascular effect and was generally better tolerated than orlistat." | 5.11 | Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. ( Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, R; Murdolo, G, 2004) |
| "To reveal whether baseline body mass index (BMI), and psychobehavioral and nutritional markers were significant predictors of the change in BMI observed after 4 and 12 months in obese women enrolled in a weight reduction program, including low-energy diet, increased physical activity, cognitive behavior therapy and sibutramine." | 5.11 | Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine. ( Bellisle, F; Braunerova, R; Hainer, V; Hill, M; Kunesova, M; Wagenknecht, M, 2005) |
| " Sibutramine and sibutramine in combination with orlistat seemed to be equally effective in terms of weight reduction compared to orlistat monotherapy." | 5.11 | Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. ( Aydin, N; Dağar, A; Ekmekcioglu, C; Filiz, M; Kaya, A; Kilinç, E; Oztürk, A; Topsever, P, 2004) |
| "The aim of the study was to study the role of initial eating behaviour for subsequent weight loss in treatment with sibutramine (Reductil, Meridia) an anti-obesity drug enhancing satiety, and also to assess changes in mood during the treatment." | 5.11 | Sibutramine treatment in obesity: initial eating behaviour in relation to weight loss results and changes in mood. ( Barkeling, B; Elfhag, K; Rooth, P; Rössner, S, 2005) |
| " The effect of sibutramine combined with hypocaloric diet and exercise on body weight, body fat mass, lipids, glycemic control, insulin secretion and insulin resistance was evaluated in a randomized, controlled, open-label study." | 5.11 | Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects. ( Dakovska, G; Dakovska, L; Kirilov, G; Koev, D; Lazarova, M; Tankova, T, 2004) |
| "Sibutramine induced greater weight reduction than placebo (6." | 5.11 | Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients. ( Faria, AN; Gouvea Ferreira, SR; Kohlmann, NE; Ribeiro Filho, FF; Zanella, MT, 2005) |
| " This study examined the effectiveness of sibutramine, an approved weight loss agent, in overweight and obese subjects taking olanzapine for schizophrenia or schizoaffective disorder." | 5.11 | A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. ( Borba, CP; Cather, C; Copeland, PM; Daley, TB; Evins, AE; Freudenreich, O; Goff, DC; Hayden, D; Henderson, DC; Louie, PM; Nguyen, DD, 2005) |
| "Combined to hypocaloric diet, sibutramine increases weight loss in obese individuals." | 5.11 | Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects. ( Contaldo, F; De Caprio, C; de Simone, G; di Luzio Paparatti, U; Pasanisi, F; Romano, C; Salanitri, T, 2005) |
| "This study aims to determine the efficacy and tolerability of sibutramine hydrochloride in overweight and obese patients with cardiovascular risk factors." | 5.11 | Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study. ( Gaciong, Z; Placha, G, 2005) |
| "Sibutramine, a serotonin and norepinephrine transporter blocker, is a common adjunctive obesity treatment." | 5.11 | Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients--sibutramine and blood pressure. ( Birkenfeld, AL; Jordan, J; Luft, FC; Pischon, T; Schroeder, C; Sharma, AM; Tank, J, 2005) |
| "To assess the efficacy of sibutramine 15 mg once daily as weight reduction in overweight and obese (body mass index > 25 kg/m2) Chinese female type 2 diabetic patients and to evaluate the influence of weight loss on diabetic control, a randomised, double-blind, placebo-control, 12-week study was conducted." | 5.11 | Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study. ( Chang, ET; Hsieh, MC; Kuo, SW; Li, JC; Pei, D; Su, KY; Tsai, CC; Tsai, WC; Wang, TF; Yao, CY, 2005) |
| "After 6 months of sibutramine treatment statistically significant changes from baseline were observed for body weight (85." | 5.11 | Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes. ( Chen, YC; Fan, SC; He, CT; Hsieh, CH; Hung, YJ; Kuo, SW; Lee, CH; Pei, D; Sheu, WH; Wu, LY, 2005) |
| "Weight loss achieved with a VLCD is more effectively maintained with sibutramine in combination with a recommended diet and exercise program than with placebo over a follow-up period of 18 months." | 5.11 | Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study. ( Mathus-Vliegen, EM, 2005) |
| " The antiobesity agent sibutramine, unlike anorectic agents, decreases food intake mainly by stimulating satiety." | 5.11 | [Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents]. ( Appolinário, JC; Carraro, L; Corrêa, LL; Coutinho, WF; Faria Júnior, R; Godoy-Matos, AF; Meirelles, RM; Moreira, RO; Platt, MW; Póvoa, LC, 2005) |
| "To evaluate the effects of sibutramine on body weight, body fat mass, metabolism of plasma glucose and serum lipids, and insulin resistance (IR) in primary obesity patients." | 5.11 | [Effects of sibutramine on blood glucose and lipids, body fat mass and insulin resistance in obese patients: a multi-center clinical trial]. ( Li, QF; Li, R; Li, XJ; Liu, YP; Ran, XW; Tang, BD; Tong, NW; Yang, FY, 2005) |
| " Sibutramine (BTS54524; N-[1-[1(4-chloro phenyl) cyclobutyl]-3methyl N,N-dimethylamine hydrochloride monohydrate) is a new 5-HT serotonin and noradrenaline reuptake inhibitor (SNRI), antiobesity drug." | 5.11 | Sibutramine therapy in obese women--effects on plasma neuropeptide Y (NPY), insulin, leptin and beta-endorphin concentrations. ( Baranowska, B; Baranowska-Bik, A; Boguradzka, A; Chmielowska, M; Martyńska, L; Mazurczak-Pluta, T; Wolińska-Witort, E, 2005) |
| " Sibutramine can increase blood pressure and heart rate, which may attenuate the reductions in LVM associated with weight loss." | 5.10 | Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. ( Boivin, JM; Bruntz, JF; Drouin, P; Gille, B; Grentzinger, A; Hammadi, M; Hanotin, C; Igau, B; Zannad, F, 2002) |
| "To examine whether increased weight loss in obese adolescents is induced when sibutramine is added to a family-based, behavioral weight control program." | 5.10 | Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. ( Berkowitz, RI; Cronquist, JL; Tershakovec, AM; Wadden, TA, 2003) |
| "The objective of the study was to identify determinants of long-term success in weight maintenance in obese subjects who completed the Sibutramine Trial on Obesity Reduction and Maintenance (n = 261), a multicenter European study of weight loss and weight maintenance in obesity that combines sibutramine treatment with dietary restriction and advice on exercise and behavior." | 5.10 | Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial). ( Astrup, AV; Finer, N; Hilsted, J; James, WP; Kopelman, PG; Rössner, S; Saris, WH; van Baak, MA; Van Gaal, LF; van Mil, E, 2003) |
| "To assess the effect of sibutramine-assisted weight reduction program on insulin sensitivity and metabolic parameters in obese normal glucose tolerant individuals over a period of 24 weeks." | 5.10 | Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial. ( Geloneze, B; Geloneze, SR; Magro, DO; Picolo, M; Repetto, EM; Tambascia, MA, 2003) |
| "The present study shows that both sibutramine-induced and orlistat-induced weight losses result in reduction of insulin resistance, and improvements in biochemical markers and US findings of NASH." | 5.10 | The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. ( Karaoglanoglu, M; Kilic, FB; Nazligul, Y; Sabuncu, T; Ucar, E, 2003) |
| "To evaluate the effectiveness of sibutramine therapy alone and in combination with ethinyl estradiol-cyproterone acetate (EE-CPA) on the clinical and metabolic parameters of obese women with polycystic ovary syndrome (PCOS)." | 5.10 | Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. ( Harma, M; Kilic, F; Nazligul, Y; Sabuncu, T, 2003) |
| "Although antidepressants are the pharmacological agents most often studied in the treatment of binge-eating disorder (BED), preliminary evidence from an open trial suggests that the antiobesity agent sibutramine hydrochloride may be effective." | 5.10 | A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. ( Appolinario, JC; Bacaltchuk, J; Claudino, AM; Coutinho, W; Godoy-Matos, A; Morgan, C; Sichieri, R; Zanella, MT, 2003) |
| "To assess the relationship between serum leptin and insulin resistance (IR) in obesity, and to investigate the effects of sibutramine on obesity, serum leptin and IR." | 5.10 | [Serum leptin and insulin resistance in obesity and effects of sibutramine on them]. ( Chen, HL; Lei, MX; Wu, J, 2003) |
| "Sibutramine is a serotonin-noradrenaline reuptake inhibitor that is effective for long-term weight reduction and maintenance in obese patients when used as an adjunct to dietary and behavioural measures." | 5.10 | Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. ( Cutler, NR; Leibowitz, MT; Levy, B; McMahon, FG; Mendel, CM; Mullican, WS; Rowe, ED; Sramek, JJ; Toth, PD; Weinstein, SP, 2002) |
| "Sibutramine treatment in obesity results in significantly greater weight reduction compared with placebo, although weight loss with sibutramine may be accompanied by small but statistically significant mean increases in blood pressure (BP)." | 5.10 | Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. ( Ernst, KR; Fujioka, K; Johnson, F; McMahon, FG; Rowe, E; Weinstein, SP, 2002) |
| "To investigate whether the satiety-inducing agent sibutramine affected body weight and associated anthropometry in overweight and obese (body mass index (BMI) > 27) Type 2 diabetic patients on sulphonylurea therapy." | 5.10 | Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy. ( Melchionda, N; Moreno-Carretero, E; Serrano-Rios, M, 2002) |
| "The results of this study confirm that sibutramine, orlistat and metformin are all effective and safe medications that reduce cardiovascular risk and can decrease the risk of type 2 diabetes mellitus in obese females." | 5.10 | Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. ( BascilTutuncu, N; Gokcel, A; Gumurdulu, Y; Guvener, N; Karakose, H; Melek Ertorer, E; Tanaci, N, 2002) |
| "To assess the effects of weight reduction with 10mg of sibutramine or placebo on blood pressure during 24 hours (ambulatory blood pressure monitoring), on left ventricular mass, and on antihypertensive therapy in 86 obese and hypertensive patients for 6 months." | 5.10 | Effects of sibutramine on the treatment of obesity in patients with arterial hypertension. ( Faria, AN; Ferreira, SR; Kohlmann, N; Lerario, DD; Ribeiro Filho, FF; Zanella, MT, 2002) |
| "The aim of the present study was to evaluate the cerebrospinal fluid (CSF)/serum leptin ratio during pharmacological therapy for obesity with centrally and peripherally acting drugs." | 5.10 | The cerebrospinal fluid/serum leptin ratio during pharmacological therapy for obesity. ( Boguszewski, CL; De Almeida, SM; Niclewicz, PA; Radominski, RB; Rodrigues, AM; Suplicy, Hde L, 2002) |
| " To illustrate how we may in the future be able to achieve longer-term weight maintenance, a brief outline of 1 study--the 2-year, randomized, double-blind, placebo-controlled study: Sibutramine Trial of Obesity Reduction and Maintenance--will be described." | 5.09 | Achieving weight-loss maintenance. ( James, WP, 2001) |
| "Seven clinical centers screened 1463 patients with obesity and randomized 1047 to 24 weeks of treatment with 1 of 6 doses of sibutramine (1, 5, 10, 15, 20, or 30 mg) or placebo once daily." | 5.09 | Sibutramine produces dose-related weight loss. ( Blackburn, GL; Bray, GA; Ferguson, JM; Greenway, FL; Jain, AK; Mendel, CM; Mendels, J; Ryan, DH; Scheinbaum, ML; Schwartz, SL; Seaton, TB, 1999) |
| "Following a very-low-calorie diet, sibutramine is effective in maintaining and improving weight loss for up to 1 year." | 5.09 | Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. ( Apfelbaum, M; Hanotin, C; Leutenegger, E; Thomas, F; Vague, P; Ziegler, O, 1999) |
| "Sibutramine, an inhibitor of serotonin and noradrenaline uptake, reduces appetite to cause weight loss." | 5.09 | The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females. ( Lean, ME; Leen, E; Walsh, KM, 1999) |
| "To assess the contribution of a thermogenic effect to weight loss induced by eight weeks treatment with sibutramine (15mg/d) vs placebo in obese subjects." | 5.09 | The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. ( Astrup, A; Hansen, DL; Macdonald, IA; Stock, MJ; Toubro, S, 1999) |
| "Sibutramine induces significant loss of body weight, BMI and waist, but does not significantly affect cardiovascular function." | 5.09 | A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. ( Berber, A; Cortinas, L; Fanghänel, G; Sánchez-Reyes, L, 2000) |
| "Obese patients with a body mass index (BMI, calculated as weight in kilograms divided by the square of height in meters) between 27 and 40 and a history of hypertension controlled with a calcium channel blocker (with or without concomitant thiazide diuretic treatment) were randomized to receive sibutramine (n = 150) or placebo (n = 74) with minimal behavioral intervention for 52 weeks." | 5.09 | Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. ( Fujioka, K; Johnson, F; McMahon, FG; Mendel, CM; Mooradian, AD; Rolston, K; Rowe, E; Singh, BN, 2000) |
| "To assess the efficacy and tolerability of sibutramine 15 mg once daily as a weight reduction agent in overweight and obese patients (body mass index (b." | 5.09 | Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. ( Banks, LM; Bloom, SR; Finer, N; Frost, GS; Griffiths, J, 2000) |
| ") > or =27 kg/m2) patients with poorly controlled type 2 diabetes mellitus were randomized either to sibutramine (n = 89; mean age 53." | 5.09 | Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. ( Fujioka, K; Jelinek, CA; Lebovitz, HE; Raskin, P; Rowe, E; Seaton, TB; Weinstein, SP, 2000) |
| "Sibutramine 10 mg once daily is a useful, effective therapy for obesity in the presence of stable hypertension." | 5.09 | Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. ( Hazenberg, BP, 2000) |
| "In this report we assess pre-treatment determinants of weight loss and maintenance outcome in The Sibutramine Trial of Obesity Reduction and Maintenance (STORM), a 2 y randomized, double-blind, placebo-controlled, European multicenter study examining the effect of sibutramine (Sib) on inducing and maintaining weight loss in obese subjects." | 5.09 | Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance. ( Astrup, A; Finer, N; Goulder, M; Hansen, D; Hilsted, J; James, W; Kopelman, P; Rössner, S; Saris, W; Toubro, S; Van Gaal, L, 2001) |
| "After Sibutramine discontinuation patients had weight gain but they did not reach the baseline body weight." | 5.09 | Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over. ( Berber, A; Cortinas, L; Fanghänel, G; Sánchez-Reyes, L, 2001) |
| "The researchers assessed the long-term weight reduction efficacy, tolerability, and safety of sibutramine used once daily in conjunction with behavior modification to treat mild to moderate obesity." | 5.09 | Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. ( Goulder, MA; Smith, IG, 2001) |
| "To evaluate the insulin, leptin, and abdominal adiposity relation during weight loss in patients with upper body obesity." | 5.09 | Insulin-leptin-visceral fat relation during weight loss. ( DeShields, S; Elashoff, R; Go, VL; Heber, D; Hershman, JM; Liu, Y; Wang, HJ; Yip, I, 2001) |
| "In overweight and obese patients with high serum triglyceride levels and low serum HDL-C levels, treatment with sibutramine was associated with significant improvements in body weight and in serum triglyceride and HDL-C levels." | 5.09 | Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. ( Dujovne, CA; Mendel, CM; Rowe, E; Zavoral, JH, 2001) |
| "To compare the effectiveness of 2 distinct sibutramine regimens with each other and with placebo for weight reduction among obese persons." | 5.09 | Long-term weight loss with sibutramine: a randomized controlled trial. ( Krause, J; Wirth, A, 2001) |
| "The addition of sibutramine to oral hypoglycemic therapy resulted in significant weight loss and improvement in metabolic parameters in this patient group." | 5.09 | Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. ( Ertorer, EM; Gokcel, A; Guvener, N; Karakose, H; Tanaci, N; Tutuncu, NB, 2001) |
| "Sibutramine 10 mg once a day is an effective and safe therapy for weight reduction in simple over-weighted and obese subjects." | 5.09 | [A randomized, double-blind, placebo-controlled, multicenter study on sibutramine in over-weighted and obese subjects]. ( Wang, X; Yan, Z; Zhao, Y, 2001) |
| "An open, non-comparative study was carried out to assess the efficacy and toleration profile of sibutramine, a new antiobesity drug, in promoting weight loss in obese type 2 diabetes mellitus subject who failed to reduce weight after strict dietary control." | 5.09 | Clinical evaluation of sibutramine in obese type 2 diabetic patients refractory to dietary management. ( Kumar, A; Lal, M; Sircar, AR, 2001) |
| "These data demonstrate dose-related weight loss with sibutramine treatment for up to 12 weeks in obese patients." | 5.08 | Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study. ( Drouin, P; Hanotin, C; Jones, SP; Leutenegger, E; Thomas, F, 1998) |
| "Sibutramine, a monoamine re-uptake inhibitor, has recently been approved by the Food and Drug Administration as a weight loss agent." | 5.08 | Effects of sibutramine on resting metabolic rate and weight loss in overweight women. ( Bessesen, DH; Hill, JO; Seagle, HM, 1998) |
| " We have compared the novel (multiple monoamine neurotransmitter reuptake inhibitor) antiobesity drug sibutramine (10 mg once daily) with the extensively studied serotonin-releasing antiobesity agent dexfenfluramine (15 mg twice daily)." | 5.08 | A comparison of sibutramine and dexfenfluramine in the treatment of obesity. ( Drouin, P; Hanotin, C; Jones, SP; Leutenegger, E; Thomas, F, 1998) |
| " This paper examines the effect of sibutramine, a new serotonin and noradrenaline re-uptake inhibitor, on weight reduction and changes in fat distribution." | 5.08 | Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction? ( De Leeuw, IH; Peiffer, FW; Van Gaal, LF; Wauters, MA, 1998) |
| " Carriers of leptin gene mutations are able to normalize their body weight after daily subcutaneous leptin administration." | 4.89 | Treatment options for children with monogenic forms of obesity. ( Hainerová, IA; Lebl, J, 2013) |
| " Sibutramine is a serotonin-noradrenaline reuptake inhibitor, which acts centrally by promoting the feeling of satiety and decreasing caloric intake, thus resulting in weight loss." | 4.85 | Effect of antiobesity medications in patients with type 2 diabetes mellitus. ( Choussein, S; Daskalopoulou, SS; Frangos, CC; Makri, AA; Petridou, ET, 2009) |
| "To review the major trials that evaluated the efficacy and safety of the use of sibutramine for weight loss and the impact of this agent on obesity-related disorders." | 4.85 | The use of sibutramine in the management of obesity and related disorders: an update. ( Krassas, GE; Tziomalos, K; Tzotzas, T, 2009) |
| "The goal of this article is to review the available literature of pharmacological interventions for obesity and specifically to examine data with sibutramine for the short term on safety and efficacy for weight loss." | 4.84 | Sibutramine: current status as an anti-obesity drug and its future perspectives. ( Henderson, DC; Sharma, B, 2008) |
| " Two medications (sibutramine, orlistat) combined with behavioral interventions can result in small to moderate short-term weight loss in obese adolescents with potential side effects that range in severity." | 4.84 | Effectiveness of weight management programs in children and adolescents. ( Beil, T; Lutz, K; O'Connor, E; Whitlock, E; Williams, S, 2008) |
| " Sibutramine, a monoamine-reuptake inhibitor, results in mean weight losses of 4-5 kg, but is associated with increases in blood pressure and pulse rate." | 4.84 | Drug treatments for obesity: orlistat, sibutramine, and rimonabant. ( Majumdar, SR; Padwal, RS, 2007) |
| "The currently available drugs for long-term treatment of obesity are sibutramine and orlistat." | 4.84 | Currently available drugs for the treatment of obesity: Sibutramine and orlistat. ( Chaput, JP; St-Pierre, S; Tremblay, A, 2007) |
| " Key words included adolescents, overweight, obesity, anti-obesity agents, drug therapy, orlistat, sibutramine, and metformin." | 4.84 | Pharmacotherapeutic options for overweight adolescents. ( Desilets, AR; Dunican, KC; Montalbano, JK, 2007) |
| "This review is an actualisation on efficacy, safety and tolerability of the approved drugs on the long-term treatment of obesity (orlistat and sibutramine)." | 4.84 | Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant. ( Gargallo, M; Isabel Millán, A; Moreno, B; Rubio, MA, 2007) |
| "To investigate, through a meta-analysis of clinical trials, the effect of two weight-reducing drugs, such as orlistat and sibutramine, on serum lipid profiles in overweight and obese subjects, independently of weight loss." | 4.84 | Orlistat and sibutramine beyond weight loss. ( Dicembrini, I; Mannucci, E; Rotella, CM; Rotella, F, 2008) |
| "Acceptable adverse effects and a clinical relevant weight loss of 3 to 5 kilograms have been found in long-term randomized clinical trials for sibutramine (Reductil) and orlistat (Xenical); these drugs may be prescribed for treatment of obesity for a duration of one and four years, respectively." | 4.83 | [Drug treatment of obesity]. ( Astrup, AV; Breum, L; Bruun, JM; Svendsen, OL; Toubro, S, 2006) |
| "We have re-analysed pooled data from seven randomized, controlled studies of sibutramine-induced weight loss and maintenance in which patients (n = 928; 75% female) had taken sibutramine 10 or 15 mg continuously for 12 months, in order to determine the predictors of success in weight loss (defined as loss of at least 5% of initial body weight at Month 12) in both diabetic and non-diabetic patients." | 4.83 | Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients. ( Finer, N; Hewkin, AC; Renz, CL; Ryan, DH, 2006) |
| "Currently, the substances orlistat and sibutramine are approved drugs for the pharmacotherapy of obesity." | 4.83 | [Pharmacotherapy in the treatment of obesity]. ( Hamann, A, 2006) |
| " Food and Drug Administration has approved three weight loss agents: sibutramine, orlistat, and phentermine." | 4.83 | Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors. ( Pi-Sunyer, FX, 2006) |
| "This article describes the pharmacologic management of obesity, concentrating on orlistat and sibutramine." | 4.82 | Weight management and current options in pharmacotherapy: orlistat and sibutramine. ( Chan, JC; Leung, WY; Thomas, GN; Tomlinson, B, 2003) |
| "Of the eight anti-obesity agents investigated, only orlistat and sibutramine trials met inclusion criteria." | 4.82 | Long-term pharmacotherapy for obesity and overweight. ( Lau, DC; Li, SK; Padwal, R, 2003) |
| " Evidence-based anti-obesity drugs such as sibutramine and orlistat facilitate the start of weight reduction, thus providing additional motivation of success, and support the long-term effect by stabilizing the weight loss." | 4.82 | [New therapeutic options in obesity]. ( Heufelder, AE, 2003) |
| " Currently approved pharmacologic treatments for obesity include sibutramine and orlistat, which have been associated with significantly greater weight loss than that seen with dieting alone." | 4.82 | Obesity and pharmacologic therapy. ( Aronne, LJ; Thearle, M, 2003) |
| "Sibutramine is a selective serotonin and noradrenaline re-uptake inhibitor approved for the long-term management of obesity." | 4.82 | Sibutramine and the management of obesity. ( Foreyt, JP; Poston, WS, 2004) |
| " The summary mean differences in weight loss, sibutramine minus placebo, for the 3-month and 1-year trials were -2." | 4.82 | The efficacy and safety of sibutramine for weight loss: a systematic review. ( Arterburn, DE; Crane, PK; Veenstra, DL, 2004) |
| "The drugs orlistat and sibutramine appear beneficial for the treatment of adults with obesity, and metformin for obese patients with type 2 diabetes." | 4.82 | Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. ( Aucott, L; Avenell, A; Broom, J; Brown, TJ; Campbell, MK; Grant, AM; Jung, RT; Poobalan, A; Smith, WC; Stearns, SC, 2004) |
| "Of the eight anti-obesity agents investigated, only orlistat and sibutramine trials met inclusion criteria." | 4.82 | Long-term pharmacotherapy for obesity and overweight. ( Lau, DC; Li, SK; Padwal, R, 2004) |
| " The two available drugs, orlistat and sibutramine, are capable of reducing body weight by 10%." | 4.82 | [Pharmacotherapy of obesity]. ( Ludvik, B; Tripp, B, 2004) |
| "Fluoxetine, orlistat, and sibutramine can achieve statistically significant weight loss over 12 to 57 weeks." | 4.82 | Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. ( Avenell, A; Gregg, E; Lau, J; Norris, SL; Schmid, CH; Zhang, X, 2005) |
| " In the United States, only sibutramine and orlistat are available for the long-term treatment of obesity." | 4.82 | Long-term pharmacotherapy for obesity. ( Klein, S, 2004) |
| "Weight loss with sibutramine treatment is associated with improved insulin sensitivity and a fall in glycosylated haemoglobin levels in type 2 diabetic patients." | 4.82 | A review of the metabolic effects of sibutramine. ( Elisaf, MS; Filippatos, TD; Kiortsis, DN; Liberopoulos, EN; Mikhailidis, DP, 2005) |
| "Sibutramine-induced weight loss and weight maintenance lead to clinically relevant reductions in risk factors associated with the metabolic syndrome." | 4.81 | Metabolic benefits associated with sibutramine therapy. ( Krejs, GJ, 2002) |
| " After failure of lifestyle modifications, antiobesity drugs such as orlistat, a potent and selective inhibitor of gastric and pancreatic lipases that reduces lipid intestinal absorption, or sibutramine, a noradrenaline and 5-hydroxytryptamine reuptake inhibitor that regulates food intake, may be considered to favour weight loss and/or weight maintenance." | 4.81 | New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat. ( Ernest, P; Scheen, AJ, 2002) |
| "Sibutramine offers three types of benefit in weight management: by enhancing weight loss, by improving weight maintenance and by reducing the comorbidities of obesity." | 4.81 | How does sibutramine work? ( Lean, ME, 2001) |
| "Sibutramine is a serotonin-norepinephrine reuptake inhibitor indicated for the management of obesity in conjunction with a reduced calorie diet." | 4.81 | The discovery and status of sibutramine as an anti-obesity drug. ( Luque, CA; Rey, JA, 2002) |
| "Sibutramine (BTS 54 524; N-[1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-N,N-dimethylamine hydrochloride monohydrate) is a novel 5-HT (serotonin) and noradrenaline reuptake inhibitor (SNRI) anti-obesity drug." | 4.80 | Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. ( Aspley, S; Cheetham, SC; Heal, DJ; Jackson, HC; Martin, KF; Prow, MR, 1998) |
| "Sibutramine is a serotonin and noradrenaline re-uptake inhibitor (SNRI) which induces weight loss via a dual mode of action: enhancing both satiety and energy expenditure." | 4.80 | Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment. ( De Leeuw, IH; Van Gaal, LF; Wauters, MA, 1998) |
| " The USA, the European Union and Norway have approved orlistat, a pancreatic lipase inhibitor for weight reduction for up to two years." | 4.80 | [The obesity epidemics--do diet pills have a place in the treatment?]. ( Birkeland, KI; Tonstad, S, 2000) |
| " In the late sixties, aminorex caused an epidemic of pulmonary hypertension with high mortality rates." | 4.80 | [Obesity: principles of drug therapy]. ( Ballmer, PE; Imoberdorf, R, 2000) |
| " This review addresses the following three topics: a brief discussion of older weight loss medications approved for short-term use (benzphetamine, phendimetrazine, diethylpropion, mazindol, and phentermine), as well as over-the-counter adrenergic drugs (phenylpropanolamine and ephedrine); recent clinical studies documenting the safety and efficacy of a new medication for obesity treatment, sibutramine, recently approved by the Food and Drug Administration for long-term use; and recent studies characterizing the valvulopathy associated with fenfluramine and dexfenfluramine, serotonergic medications for obesity which have been removed from the markets." | 4.80 | Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity. ( Ryan, DH, 2000) |
| "Sibutramine is a noradrenaline and 5-hydroxytryptamine reuptake inhibitor which causes weight loss in laboratory rodents via effects on both food intake and metabolic rate." | 4.79 | Sibutramine: a review of the pharmacology of a novel anti-obesity agent. ( Stock, MJ, 1997) |
| "Controlled studies have shown that sibutramine produces dose-related weight loss when given in the range 5-30 mg per day, with optimal doses of 10 and 15 mg per day." | 4.79 | Sibutramine--a review of clinical efficacy. ( Lean, ME, 1997) |
| "Previous studies have reported on the glucose and lipid-lowering effects of ferulic acid (FA) but its anti-obesity potential has not yet been firmly established." | 3.85 | Ferulic acid lowers body weight and visceral fat accumulation via modulation of enzymatic, hormonal and inflammatory changes in a mouse model of high-fat diet-induced obesity. ( Carvalho, KM; da Cruz Fonseca, SG; de Lemos, TL; de Melo, TS; de Queiroz, MG; Fontenele, TM; Lima, PR; Rao, VS; Santos, FA; Solon, FR; Tomé, AR, 2017) |
| "Orlistat and sibutramine had early effects on weight loss, not sustained over 3 years." | 3.81 | The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United Kingdom population-based cohort. ( Batterham, RL; Bhaskaran, K; Douglas, IJ; Smeeth, L, 2015) |
| "The marketing authorization for the weight loss drug sibutramine was suspended in 2010 following a major trial that showed increased rates of non-fatal myocardial infarction and cerebrovascular events in patients with pre-existing cardiovascular disease." | 3.81 | The effect of sibutramine prescribing in routine clinical practice on cardiovascular outcomes: a cohort study in the United Kingdom. ( Batterham, R; Bhaskaran, K; Douglas, I; Hayes, JF; Smeeth, L, 2015) |
| "To determine the impact of FDA safety communications regarding the weight loss medications sibutramine and orlistat." | 3.80 | Time series analyses of the effect of FDA communications on use of prescription weight loss medications. ( Block, JP; Brennan, TA; Carpenter, DP; Choudhry, NK; Fischer, MA; Matlin, OS; Shrank, WH; Tong, AY, 2014) |
| "Despite a surprising decision of the European Drug Agency to suspend the registration of sibutramine in the whole of Europe since January 2010 we can state that in our patients we have proven a positive effect of sibutramine substitution on their weight reduction (Tab." | 3.79 | The role of sibutramine in weight reduction. ( Drahokoupilova, E; Fajfrova, J; Pavlik, V; Slovacek, L, 2013) |
| "Sibutramine is widely used as a weight-loss substance in the treatment of obesity and is a selective inhibitor of the neuronal reuptake of serotonin and noradrenaline." | 3.79 | Rats on a high-energy diet showing no weight gain present with ultrastructural changes associated with liver fibrosis. ( Bester, MJ; Oberholzer, HM; van der Schoor, C, 2013) |
| "The risk of AMI, stroke and either AMI or stroke was not higher among sibutramine users than comparable non-users of sibutramine in both Germany and the UK [Germany: HR 0." | 3.78 | Safety assessment of an anti-obesity drug (sibutramine): a retrospective cohort study. ( Ferrufino, CP; Klingman, D; Lee, WC; Oleske, DM; Tyczynski, JE, 2012) |
| "Sibutramine is a novel new pharmacologic agent which is a specific reuptake inhibitor for norepinephrine and serotonin." | 3.78 | Sibutramine: a novel new agent for obesity treatment. ( Bray, GA; Kaiser, P; Ryan, DH, 1995) |
| "The health and longevity effects of body weight reduction resulting from exercise and caloric restriction in rodents are well known, but less is known about whether similar effects occur with weight reduction from the use of a pharmaceutical agent such as sibutramine, a serotonin-norepinephrine reuptake inhibitor." | 3.77 | No compelling evidence that sibutramine prolongs life in rodents despite providing a dose-dependent reduction in body weight. ( Allison, DB; Desmond, RA; Nagy, TR; Robertson, HT; Smith, DL, 2011) |
| "In eight studies included in the present Cochrane review the effects of orlistat or sibutramine versus placebo on mortality, cardiovascular mortality and adverse events were investigated in obese people with hypertension." | 3.77 | [Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review]. ( Madsbad, S, 2011) |
| "Sibutramine is an anti-obesity agent that induces weight loss by selective inhibition of neuronal reuptake of serotonin and norepinephrine; however, it is associated with the risk of cardiovascular diseases (CVD), including heart attack and stroke." | 3.77 | Proteome changes in rat plasma in response to sibutramine. ( Choi, DK; Choi, JW; Joo, JI; Kim, DH; Oh, TS; Wang, X; Yun, JW, 2011) |
| " In addition, we demonstrated that sibutramine treatment had a favourable effect on body weight maintenance and obesity-related health risks." | 3.77 | Hypogonadotropic hypogonadism in a homozygous MC4R mutation carrier and the effect of sibutramine treatment on body weight and obesity-related health risks. ( Hainer, V; Hainerová, IA; Sedláčková, D; Zamrazilová, H, 2011) |
| " We evaluate 1-year pharmacological interventions with sibutramine and orlistat targeting obese Australian adults free of obesity-related disease." | 3.77 | Cost-effectiveness of pharmacotherapy to reduce obesity. ( Barendregt, JJ; Forster, M; Veerman, JL; Vos, T, 2011) |
| "Topiramate is newly approved as anticonvulsant that seems to promote body weight loss in humans." | 3.77 | Topiramate induces weight loss and improves insulin sensitivity in dietary obese rats: comparison to sibutramine. ( Abo-Elmatty, DM; Zaitone, SA, 2011) |
| "In this study, our goal was to investigate whether a common SNP, -866G/A (rs659366), in the uncoupling protein 2 (UCP2) gene could influence weight reduction and body composition under sibutramine therapy in an obese Taiwanese population." | 3.76 | Effect of the common -866G/A polymorphism of the uncoupling protein 2 gene on weight loss and body composition under sibutramine therapy in an obese Taiwanese population. ( Hsiao, TJ; Huang, SY; Hwang, Y; Lin, E; Wu, LS, 2010) |
| "Tesofensine, a novel triple monoamine reuptake inhibitor, produces a significant weight loss in humans." | 3.76 | The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. ( Axel, AM; Hansen, G; Hansen, HH; Larsen, PJ; Mikkelsen, JD; Raben, A; Tang-Christensen, M, 2010) |
| "This study has shown an elevation in QTd, which may lead to cardiac arrhythmias, after sibutramine treatment." | 3.76 | Elevation of QT dispersion after obesity drug sibutramine. ( Algul, B; Ata, N; Dal, K; Demirel, G; Deveci, OS; Ertugrul, DT; Kucukazman, M; Tutal, E; Yalcin, AA; Yavuz, B; Yilmaz, H, 2010) |
| "The relationship between weight reduction after sibutramine treatment and a single nucleotide polymorphism, rs5443 (C825T), in the guanine nucleotide binding protein beta polypeptide 3 (GNB3) gene is currently inconsistent." | 3.75 | Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene. ( Hsiao, DJ; Huang, SY; Lin, E; Wu, LS, 2009) |
| "4 kg/m2) completed a 6-month weight loss intervention program by following either low calorie diet suggestions (LCDS; n=18), LCDS plus sibutramine (SG; n=27), LCDS plus orlistat (OG; n=41), or very low calorie diet (VLCD; n=33)." | 3.75 | What extent of weight loss can benefit the health-related quality of life in motivated obese Chinese? ( Chang, CS; Kuo, HC; Wu, CH; Yu, C, 2009) |
| "6-month open-label weight loss trial combining sibutramine (a serotonin and noradrenaline reuptake inhibitor) with a 600-kcal deficit diet and exercise." | 3.75 | Changes in regional adiposity and cardio-metabolic function following a weight loss program with sibutramine in obese men with obstructive sleep apnea. ( Banerjee, D; Berend, N; Grunstein, RR; Magnussen, JS; Phillips, CL; Trenell, MI; Wang, D; Yee, BJ, 2009) |
| "* The antiobesity drugs sibutramine and orlistat are not licensed for use in children and adolescents in the UK or USA." | 3.75 | Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study. ( Hsia, Y; Neubert, A; Viner, RM; Wong, IC, 2009) |
| "To characterize the interactive effects of amylin with phentermine or sibutramine on food intake, body weight/composition and gene expression in diet-induced obese (DIO) rats." | 3.74 | Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats. ( Athanacio, J; Coffey, T; Kesty, NC; Lei, C; Mack, C; Parkes, DG; Roth, JD; Trevaskis, JL; Weyer, C; Wilson, J, 2008) |
| "A previously well 51-year-old woman with obesity but no other relevant past medical history or cardiac risk factors was prescribed sibutramine (initial dose 10 mg daily, increased to 15 mg daily after 10 wk)." | 3.74 | Sibutramine-associated QT interval prolongation and cardiac arrest. ( Corallo, CE; Ernest, D; Gershenzon, A; Nagappan, R, 2008) |
| "To investigate how the antiobesity drugs orlistat and sibutramin are prescribed in relation to the approved indications and the Swedish subsidiary rules." | 3.74 | Incorrect use of orlistat and sibutramine in clinical practice. ( Beermann, B; Dahlin, A, 2007) |
| "Orlistat and sibutramine are widely prescribed antiobesity agents that are approved for 2 years of continuous use." | 3.74 | Long-term persistence with orlistat and sibutramine in a population-based cohort. ( Etminan, M; Kezouh, A; Levine, M; Padwal, R, 2007) |
| "To study the associations between weight loss with sibutramine and orlistat with psychological aspects that may interact with patients' response to these drugs." | 3.74 | Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success. ( Elfhag, K; Finer, N; Rössner, S, 2008) |
| "Observational cohort studies were conducted using prescription-event monitoring (PEM) to examine the safety profiles of the anti-obesity agents orlistat and sibutramine." | 3.74 | The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England. ( Perrio, MJ; Shakir, SA; Wilton, LV, 2007) |
| "The spironolactone Y5 antagonist significantly reduced body weight in C57BL DIO mice, but not in Npy5r(-/-) DIO mice." | 3.74 | Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine. ( Fukami, T; Gomori, A; Ishihara, A; Ito, J; Iwaasa, H; Kanatani, A; Kitazawa, H; MacNeil, DJ; Mashiko, S; Matsushita, H; Mitobe, Y; Moriya, R; Takahashi, T; Van der Ploeg, LH, 2008) |
| " For subjects who had failed to lose weight via the 'Lifestyle' intervention, the addition of sibutramine resulted in a similar weight loss compared to their pair-matched 'Lifestyle' only 'successful' counterparts (9." | 3.74 | Use of sibutramine to assist obese women with weight loss can be successful in dietitian-led clinics: another tool in the dietitian's toolbox. ( Barratt, R; Frost, G; Millward, J; O'Boyle, A; Truby, H, 2008) |
| "Sibutramine reduced body weight regardless of basal blood pressure." | 3.73 | Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials. ( Hauner, H; Jordan, J; Matiba, B; Scholze, J; Sharma, AM; Wirth, A, 2005) |
| "This study was designed to examine whether prior authorization for insurer reimbursement of weight loss medication affects compliance with taking sibutramine or adherence to a medical weight control program." | 3.73 | Does prior authorization of sibutramine improve medication compliance or weight loss? ( Nieto, L; Risser, JA; Vash, PD, 2005) |
| "Sibutramine is a drug that is used in the treatment of obesity." | 3.73 | Early first-trimester sibutramine exposure : pregnancy outcome and neonatal follow-up. ( Carducci, B; Caruso, A; Cavaliere, AF; De Santis, M; Straface, G, 2006) |
| " The centrally acting antiobesity drug, sibutramine, was used as the reference comparator." | 3.73 | Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats. ( Buschmann, H; Codony, X; Dordal, A; Fisas, A; Giraldo, J; Heal, D; Holenz, J; Mercé, R; Pauwels, PJ; Romero, G; Sørensen, RV; Vrang, N, 2006) |
| "Dexfenfluramine (DEX) and sibutramine (SIB) are effective antiobesity agents." | 3.73 | Chronic treatment with either dexfenfluramine or sibutramine in diet-switched diet-induced obese mice. ( Brune, ME; Bush, EN; Droz, BA; Fey, T; Jacobson, PB; Knourek-Segel, VE; Lin, E; Shapiro, R, 2006) |
| "The homozygosity/heterozygosity of the PNMT gene was highly predictive of significant weight loss with sibutramine during the first 3 months, which highlights the need for specific pharmacotherapy." | 3.72 | Phenylethanolamine N-methyltransferase G-148A genetic variant and weight loss in obese women. ( Comings, DE; Giese, RJ; MacMurry, JP; Peters, WR; Walker, J, 2003) |
| "To study personality and clinical factors in weight loss by sibutramine (Meridia and Reductil), an anti-obesity drug enhancing satiety." | 3.72 | Sibutramine treatment in obesity: predictors of weight loss including rorschach personality data. ( Barkeling, B; Carlsson, AM; Elfhag, K; Rössner, S, 2003) |
| "Aim of the study was to examine the course of body weight and cardiovascular risk parameters under the everyday life conditions in general practice after obese patients had terminated their sibutramine treatment." | 3.72 | [Sustained weight reduction after cessation of obesity treatment with Sibutramine]. ( Wirth, A, 2004) |
| "The results of the "Sibutramine Trial of Obesity Reduction and Maintenance" (STORM) published in the last issue of December 2000 of the Lancet are summarized." | 3.71 | [Clinical study of the month. After the storm over central anorectic agents, the "STORM" study of sibutramine]. ( Scheen, AJ, 2001) |
| "We studied the effects of the novel noradrenaline and serotonin (5-HT) reuptake inhibitor sibutramine on feeding and body weight in a rat model of dietary obesity, and whether it interacts with hypothalamic neuropeptide Y (NPY) neurones." | 3.71 | Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide Y. ( Bing, C; Brown, M; Heal, D; King, P; Pickavance, L; Wilding, J, 2001) |
| "The relationship between insulin-mediated glucose disposal and daylong free fatty acid (FFA) concentrations before and after sibutramine-assisted weight loss was investigated in 24 healthy, normotensive, nondiabetic, obese women (body mass index [BMI] >30." | 3.71 | Metabolic changes following sibutramine-assisted weight loss in obese individuals: role of plasma free fatty acids in the insulin resistance of obesity. ( Abbasi, F; Kim, HS; Lamendola, C; McLaughlin, T; Reaven, GM, 2001) |
| "To determine whether (1) patients who experience greater weight loss also experience correspondingly greater improvements in health-related quality of life (HRQOL); (2) the improvement in HRQOL is noticeable for patients achieving moderate (5%-10%) weight reduction; and (3) the relationship between weight reduction and HRQOL is similar for patients receiving sibutramine hydrochloride vs placebo." | 3.71 | Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomized trials of sibutramine vs placebo. ( Kolotkin, RL; Mendel, CM; Nguyen, MH; Samsa, GP; Williams, GR, 2001) |
| "Sibutramine (Reductil, Abbott-Knoll, 10 mg and 15 mg) is a new appetite regulator recommended in the treatment of obesity." | 3.71 | [Pharma-clinics. Medication of the month. Sibutramine (Reductil)]. ( Scheen, AJ, 2001) |
| " Sibutramine is a new anorectic drug used for the treatment of obesity." | 3.71 | [Study of heart valve function on obese patients treated with sibutramine]. ( Astorga, R; García-Luna, PP; López-Pardo, F; Parejo, J; Pereira, JL; Rodríguez-Puras, MJ, 2002) |
| "The results indicate that chronic administration of sibutramine can reduce weight gain, lower NEFA concentrations, decrease hyperinsulinaemia and ameliorate the insulin resistance of ob/ob mice." | 3.70 | Effect of the antiobesity agent sibutramine in obese-diabetic ob/ob mice. ( Bailey, CJ; Day, C, 1998) |
| "Chronic administration of sibutramine lowers body weight, presumably by altering brain monoamine metabolism." | 3.70 | Sibutramine alters the central mechanisms regulating the defended body weight in diet-induced obese rats. ( Dunn-Meynell, AA; Levin, BE, 2000) |
| "When the hypothalamic ventromedial nucleus and arcuate nucleus were destroyed in rats by treatment with monosodium glutamate in the neonatal stage, increase in the Lee index (body weight 1/3/body length) and in retroperitoneal fat as well as decreases in spontaneous motor activity, food consumption and growth hormone secretion function associated with hypothalamic low body length obesity (monosodium glutamate-treated obesity; MSG-OB) were observed as these rats grew." | 3.70 | Effects of chronic administration of sibutramine on body weight, food intake and motor activity in neonatally monosodium glutamate-treated obese female rats: relationship of antiobesity effect with monoamines. ( Gomita, Y; Nakagawa, T; Ohyama, T; Okamura, H; Ukai, K, 2000) |
| " The first group received three daily 120 mg dosages of orlistat for nine months (n=39), and the second group received a once daily 10 or 15 mg dosage of sibutramine for nine months (n=37)." | 2.84 | Metabolic and Inflammatory Changes with Orlistat and Sibutramine Treatment in Obese Malaysian Subjects. ( Al-Safi Ismail, AA; Al-Tahami, BAM; Rasool, AHG; Sanip, Z; Shihabudin, TMT; Singh, TSP; Yusoff, Z, 2017) |
| "Extent of weight loss was described successfully using a sigmoidal exposure-response relationship of the drug with a constant placebo effect in each individual." | 2.80 | Exposure-response model for sibutramine and placebo: suggestion for application to long-term weight-control drug development. ( Bae, SH; Han, S; Hong, T; Jang, DY; Jeon, S; Kim, KS; Lee, J; Park, GJ; Park, WS; Yim, DS; Youn, S, 2015) |
| " The effects of 7 days dosing with sibutramine 10 mg and 15 mg a day on appetite and energy balance were determined in 30 obese women (BMI 34." | 2.75 | The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women. ( Boyland, EJ; Cooper, SJ; Dawson, GR; Dourish, CT; Dovey, TM; Halford, JC; Huda, MS; Wilding, JP, 2010) |
| "Five hundred and seventy-six consecutive Caucasian obese type 2 diabetic patients were evaluated during a 12-months period and fifty-two patients were resulted intolerant to metformin at maximum dosage (3,000 mg/day)." | 2.74 | Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine. ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Maffioli, P; Mereu, R; Piccinni, MN; Salvadeo, SA, 2009) |
| "Sibutramine use has raised concerns regarding a potential increase in subjects' blood pressure and heart rate." | 2.73 | Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients. ( Elisaf, MS; Filippatos, TD; Kiortsis, DN; Liberopoulos, EN; Mikhailidis, DP; Nakou, E; Tselepis, AD, 2008) |
| "Childhood obesity is now considered to be an epidemic." | 2.73 | The effect of sibutramine on energy expenditure and body composition in obese adolescents. ( Delemarre-van de Waal, HA; Gerver, WJ; Kester, AD; Saris, WH; Van Mil, EG; Westerterp, KR, 2007) |
| "Sibutramine treatment resulted in a significantly greater decrease in body weight, body mass index, and waist circumference and a significant increase in diastolic blood pressure during 24-hour blood pressure monitoring compared with placebo treatment." | 2.73 | Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. ( Grimm, E; Herrmann, D; Kintscher, U; Scholze, J; Unger, T, 2007) |
| "Adolescent obesity is a major public health problem." | 2.73 | Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study. ( Blakesley, V; Crow, S; Cwik, K; Daniels, SR; Harris, L; Hewkin, A; Jasinsky, O; Long, B; Sothern, M; Styne, D; Vargas-Rodriguez, I; Walch, J, 2007) |
| "In obesity, left ventricular hypertrophy is frequently observed, especially in the presence of hypertension." | 2.72 | Reduced left ventricular mass after treatment of obese patients with sibutramine: An echocardiographic multicentre study. ( Boenner, G; Matiba, B; Scholze, J; Sharma, AM; Wirth, A, 2006) |
| "Sibutramine treatment raised sitting diastolic blood pressure by > or = 5 mmHg in a higher proportion of patients than did placebo (43% with 15 mg/day vs." | 2.71 | A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. ( McNulty, SJ; Ur, E; Williams, G, 2003) |
| "Sibutramine is an anti-obesity agent." | 2.71 | Effects of the sibutramine therapy on pulmonary artery pressure in obese patients. ( Cetinkaya, A; Guven, A; Koksal, N; Ozdemir, R; Sokmen, G, 2004) |
| "Sibutramine mono-therapy was significantly more effective in inducing BMI decrease compared with orlistat mono-therapy (p=0." | 2.71 | Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients? ( Aydin, N; Dağar, A; Duman, C; Karasakal, M; Kaya, A; Topsever, P, 2004) |
| "The treatment of obesity is strongly recommended because many studies have shown it to be a strong risk factor for cardiovascular disease." | 2.71 | The effect of 1-yr sibutramine treatment on glucose tolerance, insulin sensitivity and serum lipid profiles in obese subjects. ( Birden, F; Sabuncu, T; Ucar, E; Yasar, O, 2004) |
| "Sibutramine treatment significantly increased resting metabolic rate compared to the placebo condition." | 2.71 | Comparison of the acute pharmacodynamic responses after single doses of ephedrine or sibutramine in healthy, overweight volunteers. ( Balderson, DE; Brouwer, KL; Lancaster, ME; Ng, C; Paulik, MA; Persky, AM; Song, MH, 2004) |
| "Adolescent obesity is becoming a health problem in both developed and developing countries." | 2.71 | Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. ( Appolinario, JC; Carraro, L; Coutinho, W; Godoy-Matos, A; Guedes, EP; Mattos, L; Moreira, RO; Oliveira, J; Rangel, C; Vieira, A, 2005) |
| "Sibutramine caused an increase in blood pressure (both SBP and DBP) in two patients, but it has been controlled by antihypertensive treatment." | 2.71 | Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. ( Bertone, G; Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, E; Fogari, R; Murdolo, G; Piccinni, MN, 2005) |
| "Treatment with sibutramine, 15 mg/day, was administered for 12 weeks." | 2.70 | An open-label trial of sibutramine in obese patients with binge-eating disorder. ( Appolinario, JC; Cabral, M; Carraro, L; Coutinho, W; Fontenelle, LF; Godoy-Matos, A; Vieira, A, 2002) |
| "Obese patients with type 2 diabetes mellitus enrolled in an ongoing double-blind, placebo-controlled, parallel-arm, 12-month study of sibutramine (followed by a 12-month open label extension) underwent transthoracic echocardiographic imaging and color Doppler interrogation for assessment of cardiac valve anatomy and function." | 2.69 | Absence of cardiac valve dysfunction in obese patients treated with sibutramine. ( Armstrong, WF; Bach, DS; Kelly, F; Mendel, CM; Patel, B; Pekkarinen, TA; Rissanen, AM; Seaton, TB; Shepherd, G; Weinstein, SP, 1999) |
| "Sibutramine was well tolerated by most of the patients." | 2.69 | Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. ( Berber, A; Cuellar, GE; Monsalve, MC; Ruiz, AM, 2000) |
| "Sibutramine is a beta-phenethylamine which blocks reuptake of norepinephrine and serotonin." | 2.68 | A double-blind randomized placebo-controlled trial of sibutramine. ( Bray, GA; Cerise, F; Gordon, D; Heidingsfelder, S; Ryan, DH; Wilson, K, 1996) |
| "While treating obesity, those conditions are also managed." | 2.49 | Obesity drug therapy. ( Baretić, M, 2013) |
| "Drug treatment of obesity offer a possible adjunct, but it may only have modest results, limited by side effects; furthermore, the weight lowering effects last only as long as the drug is being taken and, unfortunately, as soon as the administration is stopped, the weight is regained." | 2.48 | [The pharmacological treatment of obesity: past, present and future]. ( Bedros, JR; Medvegy, M; Pados, G; Simonyi, G, 2012) |
| "Future development of drugs for the treatment of obesity will be dependent on whether they can survive review for safety and effectiveness." | 2.47 | Is there a path for approval of an antiobesity drug: what did the Sibutramine Cardiovascular Outcomes Trial find? ( Downey, M; Sharma, AM; Still, C, 2011) |
| "Obesity is a serious problem for modern medicine." | 2.47 | [The obesity and way for treatment]. ( Góra, A; Równicka-Zubik, J; Sułkowska, A, 2011) |
| "24 SD) with a high prevalence of gastrointestinal adverse effects." | 2.46 | Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis. ( Hsia, Y; Tomsic, T; Viner, RM; Wong, IC, 2010) |
| "For sibutramine, higher on-treatment elevations in SBP (1." | 2.46 | Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis. ( Johansson, K; Neovius, K; Neovius, M; Rössner, S; Sundström, J, 2010) |
| "Obesity is one of the greatest public health challenges of the twenty-first century." | 2.45 | Current pharmacotherapeutic concepts for the treatment of obesity in adults. ( Idelevich, E; Kirch, W; Schindler, C, 2009) |
| "Obesity is considered a worldwide epidemic." | 2.45 | Recent advances in obesity pharmacotherapy. ( Höcht, C; Mayer, MA; Puyó, A; Taira, CA, 2009) |
| "Although pharmacological treatment of obesity is widely used in most countries, the number of available drugs is still very limited." | 2.45 | The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions. ( Coutinho, W, 2009) |
| "Childhood obesity is emerging as a major public health threat, with adverse implications on the health of individuals and long-term costs to society." | 2.45 | Pharmacotherapy in pediatric obesity: current agents and future directions. ( Uli, NK; Wald, AB, 2009) |
| "Obesity is epidemic; new medications and therapeutic options are urgently needed to reduce the associated health care burden." | 2.45 | What are the risks and the benefits of current and emerging weight-loss medications? ( Niswender, KD; Robinson, JR, 2009) |
| "Obesity increases the risk of type 2 diabetes." | 2.44 | Pharmacotherapy for obesity in menopausal women. ( Barnett, A; Rahim, A; Samat, A, 2008) |
| " Currently only a small number of antiobesity drugs are approved for long-term use and only a few compounds are in clinical development." | 2.44 | The obesity epidemic: current and future pharmacological treatments. ( Boss, O; Hofbauer, KG; Nicholson, JR, 2007) |
| "Most patients with type 2 diabetes mellitus are overweight or obese, and the relation between obesity, especially of the visceral compartment, and the risk for developing diabetes is well recognized." | 2.44 | Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction. ( Aronne, LJ; Lee, M, 2007) |
| "For sibutramine, there is a rise in blood pressure and heart rate that may require discontinuation of the drug in a small percent of patients." | 2.44 | Drug treatment of the overweight patient. ( Bray, GA; Ryan, DH, 2007) |
| "Sibutramine is a noradrenaline and serotonin reuptake inhibitor which reduces body weight by about 4-5 kg but increases heart rate and arterial blood pressure." | 2.44 | [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development]. ( Zieba, R, 2007) |
| " These potentially adverse effects as well as other sibutramine-associated side effects and their possible underlying mechanisms are reviewed in the present article." | 2.44 | Sibutramine-associated adverse effects: a practical guide for its safe use. ( Elisaf, MS; Florentin, M; Liberopoulos, EN, 2008) |
| "Obesity is associated with an increased risk of developing several comorbid diseases, ranging from cardiovascular diseases to cholelithiasis and nonalcoholic fatty liver disease." | 2.44 | Obesity: a review of pathogenesis and management strategies. ( Kaila, B; Raman, M, 2008) |
| "Reduction of BP was higher in patients treated with weight loss diets (systolic BP [SBP]: weighted mean difference [WMD], -6." | 2.44 | Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis. ( Gratzer, TW; Horvath, K; Jeitler, K; Siebenhofer, A; Siering, U; Skipka, G; Stich, AK, 2008) |
| "Obesity is a chronic metabolic disorder that affects one third of American adults." | 2.44 | Pharmacotherapy for obesity. ( Aronne, LJ; Neff, LM, 2007) |
| "Obesity is unlikely to resolve spontaneously." | 2.43 | Childhood obesity. Treatment options. ( Steinbeck, K, 2005) |
| "Obesity is strongly associated with conditions such as hypertension, diabetes mellitus and osteoarthritis that have known adverse health outcomes." | 2.43 | Pharmacologic treatment of obesity. ( Cheskin, LJ; Sidhaye, A, 2006) |
| "Sibutramine, however, is an exception." | 2.43 | Central nervous system biogenic amine targets for control of appetite and energy expenditure. ( Gehlert, DR; Nelson, DL, 2006) |
| "Obesity is associated with significant increase in cardiovascular risk." | 2.43 | The obesity epidemic and its cardiovascular consequences. ( Behn, A; Ur, E, 2006) |
| "Obesity is a chronic disease requiring a similar long term approach to management as that of other chronic conditions." | 2.43 | Weight loss medications--where do they fit in? ( Dixon, JB, 2006) |
| "Obesity has been described as the greatest current threat to human health." | 2.43 | Current and novel approaches to the drug therapy of obesity. ( Chaput, JP; Tremblay, A, 2006) |
| "In recent years, obesity has become a major public health problem in Western countries." | 2.43 | Medical strategies for weight loss in the overweight and obese patient. ( Bonanomi, G; Di Caro, S; Fernstrom, MH; Hamad, GG; Schauer, PR, 2006) |
| "Obesity has become a significant health problem in industrialised and developing countries, and despite all nutritional and behavioural approaches, its prevalence is still increasing." | 2.43 | Pharmacotherapy of obesity. ( Hofbauer, KG; Nicholson, JR, 2006) |
| "The prevalence of obesity is growing at an alarming rate." | 2.43 | Obesity. ( Fabricatore, AN; Wadden, TA, 2006) |
| " By subgroup analysis, the effect sizes on weight loss were significantly larger when the dosage was > or = 15 mg." | 2.42 | Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. ( Jee, SH; Kim, SH; Lee, YM; Nam, CM, 2003) |
| "Obesity is a chronic disease resulting from various genetic factors and environmental conditions (nutrition, sedentary life-style, psychological factors)." | 2.42 | [Effectiveness of therapeutic interventions in obesity]. ( Keller, U; Stöckli, R, 2003) |
| "Obesity infrequently associated with type 2 diabetes mellitus and may cause insulin resistance, hypertension and other complications of obesity." | 2.42 | Obesity management in patients with type 2 diabetes mellitus. ( Mannan, MA; Rahman, MS; Siddiqui, NI, 2004) |
| "Obesity is a chronic medical disorder that is not going away anytime soon." | 2.42 | What role for weight-loss medication? Weighing the pros and cons for obese patients. ( Hill, JO; Wyatt, HR, 2004) |
| "Sibutramine is a US Food and Drug Administration- and European Committee for Proprietary Medicinal Products-approved medication with demonstrated efficacy in long-term obesity management." | 2.42 | Clinical use of sibutramine. ( Ryan, DH, 2004) |
| "Among methods of treatment of obesity the most known and safe is the low calories content diet." | 2.42 | [Sibutramine in treatment of obesity. Therapeutic premises in patients with essential hypertension, diabetes, hyperlipidemia]. ( Kawecka-Jaszcz, K; Rajzer, M; Wojciechowska, W, 2004) |
| "Without adequate prevention and treatment of obesity, government agencies have suggested that the direct and indirect costs associated with obesity may overwhelm the healthcare system." | 2.42 | A perspective on the current strategies for the treatment of obesity. ( Joyal, SV, 2004) |
| "Obesity is the most important modifiable risk factor for type 2 diabetes mellitus and most patients with diabetes are overweight or obese." | 2.42 | Managing type 2 diabetes mellitus in patients with obesity. ( Hauner, H, 2004) |
| "Sibutramine is a combined serotonin(5-HT) and noradrenaline (NA)re-uptake inhibitor." | 2.41 | An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. ( Carruba, MO; Nisoli, E, 2000) |
| "Obesity is associated with considerable morbidity and decreased life expectancy." | 2.41 | Options for pharmacological management of obesity in patients treated with atypical antipsychotics. ( Sanders, TA; Taylor, D; Werneke, U, 2002) |
| "Obesity is a general medical condition associated with an increase in morbidity and mortality." | 2.41 | Add-on combination and maintenance treatment: case series of five obese patients with different eating behavior. ( Anghelescu, I; Klawe, C; Szegedi, A, 2002) |
| "Obesity has now been identified as a chronic disease, a global epidemic (globesity) and a serious public health issue that leads to reduced life expectancy, an increased risk for many serious medical conditions and enormous healthcare costs." | 2.41 | Sibutramine lost and found. ( Bosello, O; Carruba, MO; Ferrannini, E; Rotella, CM, 2002) |
| "Sibutramine has a dual mode of action." | 2.41 | Sibutramine: its mode of action and efficacy. ( Finer, N, 2002) |
| "Sibutramine has actions on both energy intake and expenditure and had been shown to enhance weight loss and weight maintenance achieved by diet, in simple obesity as well as when accompanied by complications of diabetes or hypertension." | 2.41 | Pharmacotherapy of obesity. ( Finer, N, 2002) |
| "Sibutramine is a centrally-acting agent which enhances satiety and thermogenesis by inhibiting serotonin and noradrenaline re-uptake." | 2.41 | Pharmacological management of obesity. ( Hanif, MW; Kumar, S, 2002) |
| "Obesity is a multi-factorial, chronic disorder that has reached epidemic proportions in most industrialized countries and is threatening to become a global epidemic." | 2.41 | New pharmacological tools for obesity. ( Carruba, MO; Nisoli, E, 2002) |
| "The pathogenesis of obesity is complex and miscellaneous endogenous as well exogenous factors modulate body weight." | 2.41 | [Drug therapy of obesity. Strategies for general practice]. ( Suter, PM; Vetter, W, 2000) |
| "Obesity is one of the most common medical problems in the United States and a risk factor for illnesses such as hypertension, diabetes, degenerative arthritis and myocardial infarction." | 2.41 | Medical management of obesity. ( Berke, EM; Morden, NE, 2000) |
| "Obesity is epidemic and dangerous." | 2.41 | How to help your patients lose weight: current therapy for obesity. ( Weiss, D, 2000) |
| "Obesity has long been known to accompany a host of chronic diseases, e." | 2.41 | Treating obesity: a new target for prevention of coronary heart disease. ( Aronne, LJ, 2001) |
| "Sibutramine is a centrally acting inhibitor of noradrenaline and serotonine reuptake, thereby decreasing caloric intake and increasing energy expenditure." | 2.41 | Current pharmacological approaches to the treatment of obesity. ( Hauner, H, 2001) |
| "Obesity is a growing public health problem worldwide." | 2.41 | Obesity: a rational target for managing diabetes mellitus. ( Mooradian, AD, 2001) |
| "Overweight and obesity have not only a significant psychological impact but also result in an increased risk for development of numerous chronic and sometimes fatal diseases." | 2.41 | Epidemiology, morbidity, and treatment of overweight and obesity. ( Aronne, LJ, 2001) |
| "Numerous options for treating obesity exist, and the clinician should be made aware of their strengths and limitations." | 2.41 | Current methods used for defining, measuring, and treating obesity. ( Moyad, MA, 2001) |
| "Obesity and hypertension are closely associated risk factors for cardiovascular disease." | 2.41 | Sibutramine in overweight/obese hypertensive patients. ( Sharma, AM, 2001) |
| "Weight reduction is also a cornerstone of diabetes management, improving glycaemic control and reducing other risk factors associated with this disease." | 2.41 | The importance of obesity in diabetes and its treatment with sibutramine. ( Peiffer, FW; Van Gaal, LF, 2001) |
| "Obesity is a major risk factor for morbidity and mortality, and a series of pharmacologic approaches are available for helping to manage the problem." | 2.40 | The pharmacologic approach to the treatment of obesity. ( Abdeen, MA; Frishman, WH; Michaelson, MD; Weiser, M, 1997) |
| "Obesity is increasing at an alarming rate." | 2.40 | Challenges in obesity management. ( Borrell, L; Foreyt, JP; Haddock, CK; Poston, WS, 1998) |
| "Obesity is among the key promoters of a number of other highly prevalent and often fatal diseases." | 2.40 | The cost implications of obesity for health care and society. ( Kurscheid, T; Lauterbach, K, 1998) |
| "The future of the pharmacologic treatment of obesity is promising." | 2.40 | Modern medical management of obesity: the role of pharmaceutical intervention. ( Aronne, LJ, 1998) |
| "Obesity is characterised by pathophysiological defects affecting both sides of the energy balance equation." | 2.40 | What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice. ( Astrup, A; Lundsgaard, C, 1998) |
| "Sibutramine is an orally administered centrally acting weight management agent apparently devoid of amphetamine-like abuse potential." | 2.40 | Sibutramine. A review of its contribution to the management of obesity. ( Goa, KL; McNeely, W, 1998) |
| "Treatment with sibutramine may be particularly efficient in these patients, because sibutramine normalizes sympathoadrenal activity and thereby stimulates thermogenesis." | 2.40 | [Sibutramine, an upcoming drug for weight loss acting on energy consumption and energy expenditure]. ( Astrup, A, 1998) |
| "Obesity is a major risk factor for the development of type 2 diabetes and is an important obstacle to the management of this disease." | 2.40 | Obesity and type 2 diabetes: a conflict of interests? ( Williams, G, 1999) |
| " A multifaceted approach to the obese patient should include identifying potential causes for weight gain, outlining medical conditions that would benefit by weight loss, and tailoring a weight loss program that is safe and effective for the individual." | 2.40 | Safe and effective management of the obese patient. ( Collazo-Clavell, ML, 1999) |
| "Promising approaches to the treatment of obesity include increasing energy expenditure and slowing down fibrogenesis of adipose tissue." | 1.91 | Tissue and Circulating MicroRNAs 378 and 142 as Biomarkers of Obesity and Its Treatment Response. ( Babenko, AY; Khromova, NV; Kononova, YA; Matveev, GA; Shlyakhto, EV; Vasilyeva, EY; Zasypkin, GG, 2023) |
| " Screening of novel bicyclic motifs with high intrinsic binding affinity for MCHR1 identified the imidazo[1,2-a]pyridine ring (represented in compounds 6a and 6b), and subsequent cyclization of the central aliphatic amide linkage led to the discovery of a potent, orally bioavailable MCHR1 antagonist 4-[(4-chlorobenzyl)oxy]-1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one 10a." | 1.43 | Melanin-Concentrating Hormone Receptor 1 Antagonists Lacking an Aliphatic Amine: Synthesis and Structure-Activity Relationships of Novel 1-(Imidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one Derivatives. ( Aida, J; Ashina, S; Hirabayashi, H; Igawa, H; Ikoma, M; Kakegawa, K; Kasai, S; Kawata, Y; Khamrai, U; Kina, A; Kundu, M; Maekawa, T; Nagisa, Y; Nakayama, M; Takahashi, M; Yamamoto, S; Yasuma, T, 2016) |
| "Although obesity is highly prevalent, only a small percentage of obese Americans are on anti-obesity medication." | 1.38 | Management of obesity in the National Health and Nutrition Examination Survey (NHANES), 2007-2008. ( Cheung, BM; Leung, RY; Ong, KL; Samaranayake, NR, 2012) |
| "Linagliptin treatment profoundly reduced hepatic fat compared with vehicle, with an effect comparable to that of sibutramine." | 1.38 | Evaluation of body fat composition after linagliptin treatment in a rat model of diet-induced obesity: a magnetic resonance spectroscopy study in comparison with sibutramine. ( Cheetham, S; Ittrich, C; Kassubek, J; Klein, T; Mark, M; Mayoux, E; Mueller, HP; Niessen, HG; Stiller, D, 2012) |
| " The model could also be used to assess dose-response relationships." | 1.38 | Assessment of maximum weight change and duration of therapeutic effect for non-surgical treatment of obesity using an exponential model. ( Chan, LS; Kaptein, EM; Kaptein, JS, 2012) |
| "Weight loss during pregnancy is therefore considered a risk factor." | 1.38 | Appetite suppressants in pregnancy. ( Hubičková Heringová, L; Kralova, T; Manakova, E, 2012) |
| "After 14 weeks of treatment, body weight, abdominal fat, blood lipid and serum insulin level were measured, and the protein and gene expression of PTP1B in liver tissue was tested." | 1.37 | Hepatic PTP1B expression involvement in the effects of Chinese medicine formula xiao-gao-jiang-zhuo using an obese rat model. ( Chang, B; Li, M; Liu, WK; Qin, PJ; Tong, XL; Zhen, Z, 2011) |
| "Sibutramine is a serotonergic and adrenergic drug that reduces food intake and increases thermogenesis." | 1.37 | Drug treatment for obesity in the post-sibutramine era. ( Cheung, BM, 2011) |
| "Sibutramine is a selective inhibitor of the reuptake of monoamines." | 1.36 | An obesity drug sibutramine reduces brain natriuretic peptide (BNP) levels in severely obese patients. ( Algul, B; Arif Yalcin, A; Ata, N; Dal, K; Kucukazman, M; Okhan Akin, K; Sinan Deveci, O; Taner Ertugrul, D; Tutal, E; Yavuz, B, 2010) |
| "Long-term pharmacologic treatments for weight loss maintenance have been studied and were found to have modest success, with some weight regain typically reported." | 1.36 | Weight loss maintenance. ( Grief, SN; Miranda, RL, 2010) |
| "Sibutramine is a centrally acting serotonin/noradrenaline reuptake inhibitor that mainly increases satiety." | 1.35 | [Pharmacological therapy of obesity]. ( Pagotto, U; Pasquali, R; Vanuzzo, D; Vicennati, V, 2008) |
| "Obesity is a major health problem in the United States and many other countries because of its high prevalence and causal relationship with serious medical comorbidities." | 1.35 | Fundamentals of cardiometabolic risk factor reduction: achieving and maintaining weight loss with pharmacotherapy or bariatric surgery. ( Fabbrini, E; Klein, S, 2008) |
| "Overweight and obesity are major factors contributing to the development of type 2 diabetes mellitus (DM) and cardiovascular disease (CVD)." | 1.35 | The endocannabinoid system as a target for obesity treatment. ( Aronne, LJ; Davis, SN; Foster, GD; Pagotto, U, 2008) |
| "Obesity is frequently associated with other pathologies: cardiovascular, oncologic, systemic (diabetes) or oral." | 1.35 | [Obesity and oral health: risk factors of obese patients in dental practice]. ( Godlewski, AE; Nicolas, E; Veyrune, JL, 2008) |
| "Obesity is a multifactorial, chronic disorder that has reached epidemic proportions in most industrialised countries and is threatening to become a global epidemic." | 1.35 | Sibutramine--its impact on health-related quality of life and depression among adult obese non-diabetic patients. ( Pavlik, V; Slanska, I; Slovacek, L; Slovackova, B, 2009) |
| "Obesity was induced by high-fat diet (HFD) in healthy male Sprague-Dawley rats." | 1.35 | Evaluation of anti-obesity activity of duloxetine in comparison with sibutramine along with its anti-depressant activity: an experimental study in obese rats. ( Bhatt, PA; Chudasama, HP, 2009) |
| "Sibutramine has been increasingly used in the management of obesity, but is relatively contraindicated in patients with hypertension." | 1.34 | The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea. ( Banerjee, D; Caterson, I; Grunstein, RR; Hedner, JA; Phillips, CL; Yee, BJ, 2007) |
| "Sibutramine usage was predominantly short-term: 59% of the cohort used sibutramine for 90 days or less, half of whom used it for only 1 month." | 1.34 | Sibutramine usage in New Zealand: an analysis of prescription data by the Intensive Medicines Monitoring Programme. ( Ashton, J; Harrison-Woolrych, M; Hill, GR, 2007) |
| "The interest in the use of drugs in the treatment of obesity has grown in recent years, upon our knowledge of the biological basis of obesity having increased, and also because non-pharmacological treatments have not succeeded stopping the constant increase of obesity incidence in western countries." | 1.33 | [Obesity pharmacological treatment]. ( Astorga Jiménez, R; Pereira Cunill, JL, 2005) |
| "Obesity and overweight are affecting increasing numbers of Canadians and have received considerable amounts of medical, governmental, and media attention in recent years." | 1.33 | Trends in obesity and overweight-related office visits and drug prescriptions in Canada, 1998 to 2004. ( Padwal, RS, 2005) |
| "Sibutramine is a satiety-inducing serotonin-noradrenaline reuptake inhibitor that acts predominantly via its primary and secondary metabolites." | 1.33 | The primary amine metabolite of sibutramine stimulates lipolysis in adipocytes isolated from lean and obese mice and in isolated human adipocytes. ( Bailey, CJ; Jones, RB; Richardson, DK, 2006) |
| "The orlistat-treated group had a mean weight loss of 2." | 1.32 | Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. ( Al Daghri, N; Barnett, AH; Chetty, R; Field, A; Hanif, W; Kumar, S; McTernan, PG; Valsamakis, G, 2004) |
| "Obesity is considered important factor contributing development of PCOS." | 1.32 | [Sibutramine administration in polycystic ovary syndrome treatment]. ( Banaś, M; Jochemczyk-Banek, U; Olszanecka-Glinianowicz, M; Zahorska-Markiewicz, B; Zurakowski, A, 2004) |
| "Obesity is a chronic condition with complex, multiple causes involving physiologic, genetic, and behavioral components, all of which must be addressed for successful treatment." | 1.31 | Treating obesity in the family practice setting. ( Fernstrom, MH, 2001) |
| "Obesity is a significant health problem in the United States today and is associated with increased risk of cardiovascular disease, diabetes, and other chronic conditions." | 1.31 | Emerging strategies for weight management. Summary. ( Hansen, BC, 2001) |
| "Obesity is one of the pathologies with ever-increasing prevalence in modern societies." | 1.31 | [The role of pharmacotherapy for treatment of obesity in adults]. ( Czupryniak, L; Drzewoski, J, 2000) |
| " After four weeks this treatment could be continued, terminated or increased to a dosage of 15 mg sibutramine per day." | 1.31 | [Sibutramine in clinical practice - a PMS-study with positive effects on blood pressure and metabolic parameters]. ( Scholze, J, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 53 (9.53) | 18.2507 |
| 2000's | 391 (70.32) | 29.6817 |
| 2010's | 109 (19.60) | 24.3611 |
| 2020's | 3 (0.54) | 2.80 |
| Authors | Studies |
|---|---|
| Igawa, H | 2 |
| Takahashi, M | 2 |
| Kakegawa, K | 2 |
| Kina, A | 2 |
| Ikoma, M | 2 |
| Aida, J | 2 |
| Yasuma, T | 2 |
| Kawata, Y | 2 |
| Ashina, S | 1 |
| Yamamoto, S | 2 |
| Kundu, M | 2 |
| Khamrai, U | 2 |
| Hirabayashi, H | 1 |
| Nakayama, M | 2 |
| Nagisa, Y | 2 |
| Kasai, S | 2 |
| Maekawa, T | 2 |
| Shirasaki, M | 1 |
| Okuda, S | 1 |
| Noguchi, T | 1 |
| Fujioka, Y | 1 |
| Shakeel Khan, MK | 1 |
| Matveev, GA | 1 |
| Khromova, NV | 1 |
| Zasypkin, GG | 1 |
| Kononova, YA | 1 |
| Vasilyeva, EY | 1 |
| Babenko, AY | 1 |
| Shlyakhto, EV | 1 |
| Hansen, HH | 2 |
| Perens, J | 1 |
| Roostalu, U | 1 |
| Skytte, JL | 1 |
| Salinas, CG | 1 |
| Barkholt, P | 1 |
| Thorbek, DD | 1 |
| Rigbolt, KTG | 1 |
| Vrang, N | 4 |
| Jelsing, J | 2 |
| Hecksher-Sørensen, J | 1 |
| Shin, HY | 1 |
| Park, S | 1 |
| Lee, JW | 1 |
| Lucchetta, RC | 1 |
| Riveros, BS | 1 |
| Pontarolo, R | 1 |
| Radominski, RB | 2 |
| Otuki, MF | 1 |
| Fernandez-Llimos, F | 1 |
| Correr, CJ | 1 |
| Al-Tahami, BAM | 1 |
| Al-Safi Ismail, AA | 1 |
| Sanip, Z | 2 |
| Yusoff, Z | 1 |
| Shihabudin, TMT | 1 |
| Singh, TSP | 1 |
| Rasool, AHG | 1 |
| Devan, SRK | 1 |
| Arumugam, S | 1 |
| Shankar, G | 1 |
| Poosala, S | 1 |
| Dedov, II | 1 |
| Melnichenko, GA | 1 |
| Troshina, EA | 1 |
| Mazurina, NV | 1 |
| Galieva, MO | 1 |
| Pavlik, V | 3 |
| Fajfrova, J | 1 |
| Slovacek, L | 3 |
| Drahokoupilova, E | 1 |
| Hainerová, IA | 2 |
| Lebl, J | 1 |
| Müller, HP | 1 |
| Niessen, HG | 2 |
| Kaulisch, T | 1 |
| Ludolph, AC | 1 |
| Kassubek, J | 2 |
| Stiller, D | 2 |
| Oberholzer, HM | 1 |
| Bester, MJ | 1 |
| van der Schoor, C | 1 |
| Trigueros, L | 1 |
| Peña, S | 1 |
| Ugidos, AV | 1 |
| Sayas-Barberá, E | 1 |
| Pérez-Álvarez, JA | 1 |
| Sendra, E | 1 |
| Winther, SA | 1 |
| Finer, N | 25 |
| Sharma, AM | 17 |
| Torp-Pedersen, C | 12 |
| Andersson, C | 4 |
| Block, JP | 1 |
| Choudhry, NK | 1 |
| Carpenter, DP | 1 |
| Fischer, MA | 1 |
| Brennan, TA | 1 |
| Tong, AY | 1 |
| Matlin, OS | 1 |
| Shrank, WH | 1 |
| Al-Tahami, BA | 1 |
| Ismail, AA | 1 |
| Bee, YT | 1 |
| Awang, SA | 1 |
| Salha Wan Abdul Rani, WR | 1 |
| Rasool, AH | 1 |
| Ghotbi, AA | 1 |
| Køber, L | 2 |
| James, WP | 12 |
| Caterson, I | 5 |
| Coutinho, W | 16 |
| Van Gaal, LF | 9 |
| Baretić, M | 1 |
| Suplicy, H | 1 |
| Boguszewski, CL | 2 |
| dos Santos, CM | 1 |
| do Desterro de Figueiredo, M | 1 |
| Cunha, DR | 1 |
| Radominski, R | 1 |
| Seimon, RV | 2 |
| Espinoza, D | 2 |
| Ivers, L | 1 |
| Gebski, V | 2 |
| Legler, UF | 3 |
| Caterson, ID | 9 |
| Kim, KK | 3 |
| Suh, HS | 2 |
| Hwang, IC | 2 |
| Ko, KD | 1 |
| Grilo, CM | 2 |
| Masheb, RM | 2 |
| White, MA | 2 |
| Gueorguieva, R | 2 |
| Barnes, RD | 1 |
| Walsh, BT | 1 |
| McKenzie, KC | 1 |
| Genao, I | 1 |
| Garcia, R | 1 |
| Gur'yanova, NN | 1 |
| Bugaeva, LI | 2 |
| Lebedeva, SA | 2 |
| Tekutova, TV | 1 |
| Dugina, YL | 1 |
| Petrov, VI | 2 |
| Epshtein, OI | 1 |
| Van Gaal, L | 7 |
| Maggioni, AP | 6 |
| Sweeting, A | 1 |
| Douglas, IJ | 1 |
| Bhaskaran, K | 2 |
| Batterham, RL | 1 |
| Smeeth, L | 2 |
| Hayes, JF | 1 |
| Batterham, R | 1 |
| Douglas, I | 1 |
| Kitka, T | 1 |
| Tuza, S | 1 |
| Varga, B | 1 |
| Horváth, C | 1 |
| Kovács, P | 1 |
| Han, S | 1 |
| Jeon, S | 1 |
| Hong, T | 1 |
| Lee, J | 1 |
| Bae, SH | 1 |
| Park, WS | 1 |
| Park, GJ | 1 |
| Youn, S | 1 |
| Jang, DY | 1 |
| Kim, KS | 1 |
| Yim, DS | 1 |
| Kamil, S | 1 |
| James, WPT | 1 |
| de Melo, TS | 1 |
| Lima, PR | 1 |
| Carvalho, KM | 1 |
| Fontenele, TM | 1 |
| Solon, FR | 1 |
| Tomé, AR | 1 |
| de Lemos, TL | 1 |
| da Cruz Fonseca, SG | 1 |
| Santos, FA | 1 |
| Rao, VS | 1 |
| de Queiroz, MG | 1 |
| Samat, A | 1 |
| Rahim, A | 1 |
| Barnett, A | 1 |
| Roth, JD | 1 |
| Trevaskis, JL | 1 |
| Wilson, J | 1 |
| Lei, C | 1 |
| Athanacio, J | 1 |
| Mack, C | 1 |
| Kesty, NC | 1 |
| Coffey, T | 1 |
| Weyer, C | 1 |
| Parkes, DG | 1 |
| Nakou, E | 1 |
| Filippatos, TD | 3 |
| Liberopoulos, EN | 3 |
| Tselepis, AD | 1 |
| Kiortsis, DN | 3 |
| Mikhailidis, DP | 2 |
| Elisaf, MS | 4 |
| Sharma, B | 1 |
| Henderson, DC | 3 |
| Bacher, HP | 1 |
| Shepherd, GM | 4 |
| Slovackova, B | 2 |
| Grudell, AB | 1 |
| Sweetser, S | 1 |
| Camilleri, M | 3 |
| Eckert, DJ | 1 |
| Vazquez-Roque, MI | 1 |
| Carlson, PJ | 1 |
| Burton, DD | 2 |
| Braddock, AE | 1 |
| Clark, MM | 2 |
| Graszer, KM | 2 |
| Kalsy, SA | 2 |
| Zinsmeister, AR | 2 |
| Ernest, D | 1 |
| Gershenzon, A | 1 |
| Corallo, CE | 1 |
| Nagappan, R | 1 |
| Halford, JC | 4 |
| Boyland, EJ | 1 |
| Cooper, SJ | 1 |
| Dovey, TM | 1 |
| Huda, MS | 1 |
| Dourish, CT | 2 |
| Dawson, GR | 1 |
| Wilding, JP | 1 |
| Figueroa C, RA | 1 |
| Castaño C, C | 1 |
| Pagotto, U | 2 |
| Vanuzzo, D | 1 |
| Vicennati, V | 1 |
| Pasquali, R | 1 |
| Svacina, S | 1 |
| Owen, K | 1 |
| Hendl, J | 1 |
| Matoulek, M | 1 |
| Brychta, T | 1 |
| Dogangun, B | 1 |
| Bolat, N | 1 |
| Rustamov, I | 1 |
| Kayaalp, L | 1 |
| Derosa, G | 6 |
| D'Angelo, A | 4 |
| Salvadeo, SA | 2 |
| Ferrari, I | 4 |
| Gravina, A | 2 |
| Fogari, E | 2 |
| Maffioli, P | 4 |
| Cicero, AF | 6 |
| Neovius, M | 3 |
| Narbro, K | 1 |
| Taylor, VH | 1 |
| Powers, PS | 1 |
| Bruty, H | 1 |
| Gaal, LV | 1 |
| Bacher, P | 1 |
| Shepherd, G | 4 |
| Sun, R | 1 |
| James, P | 3 |
| Fabbrini, E | 1 |
| Klein, S | 2 |
| Aronne, LJ | 12 |
| Foster, GD | 2 |
| Davis, SN | 1 |
| Rocha, FF | 1 |
| Bamberg, TO | 1 |
| Pinto, FC | 1 |
| Gomes, LM | 1 |
| Silveira, S | 1 |
| Idelevich, E | 1 |
| Kirch, W | 1 |
| Schindler, C | 2 |
| Mayer, MA | 1 |
| Höcht, C | 1 |
| Puyó, A | 1 |
| Taira, CA | 1 |
| Faulconbridge, LF | 1 |
| Wadden, TA | 12 |
| Berkowitz, RI | 9 |
| Sarwer, DB | 7 |
| Womble, LG | 6 |
| Hesson, LA | 2 |
| Stunkard, AJ | 2 |
| Fabricatore, AN | 3 |
| Rihmer, Z | 1 |
| Purebl, G | 1 |
| Faludi, G | 1 |
| Halmy, L | 1 |
| Digenio, AG | 1 |
| Mancuso, JP | 1 |
| Gerber, RA | 1 |
| Dvorak, RV | 1 |
| Choussein, S | 1 |
| Makri, AA | 1 |
| Frangos, CC | 1 |
| Petridou, ET | 1 |
| Daskalopoulou, SS | 1 |
| Mereu, R | 1 |
| Ciccarelli, L | 3 |
| Piccinni, MN | 2 |
| Godlewski, AE | 1 |
| Veyrune, JL | 1 |
| Nicolas, E | 1 |
| de Lemos, HP | 1 |
| Atallah, AN | 1 |
| de Lemos, AL | 1 |
| Oh, KS | 1 |
| Ryu, SY | 1 |
| Lee, S | 1 |
| Seo, HW | 1 |
| Oh, BK | 1 |
| Kim, YS | 1 |
| Lee, BH | 1 |
| Ferland, A | 1 |
| Poirier, P | 1 |
| Sériès, F | 1 |
| Georgopoulos, NA | 2 |
| Katsikis, I | 4 |
| Florakis, D | 2 |
| Panidis, D | 4 |
| Kandarakis, ED | 1 |
| Whitlock, E | 1 |
| O'Connor, E | 1 |
| Williams, S | 1 |
| Beil, T | 1 |
| Lutz, K | 1 |
| Weeke, P | 1 |
| Fosbøl, EL | 1 |
| Brendorp, B | 1 |
| Rode, RA | 3 |
| Tziomalos, K | 2 |
| Krassas, GE | 1 |
| Tzotzas, T | 1 |
| Moore, RH | 1 |
| Butryn, ML | 1 |
| Heymsfield, SB | 3 |
| Nguyen, AM | 1 |
| Czernichow, S | 2 |
| Lee, CM | 1 |
| Barzi, F | 1 |
| Greenfield, JR | 1 |
| Baur, LA | 1 |
| Chalmers, J | 1 |
| Woodward, M | 1 |
| Huxley, RR | 1 |
| Fernstrom, MH | 5 |
| Hansen, BC | 1 |
| Hsiao, DJ | 1 |
| Wu, LS | 2 |
| Huang, SY | 2 |
| Lin, E | 3 |
| Wald, AB | 1 |
| Uli, NK | 1 |
| Krishna, R | 1 |
| Gumbiner, B | 1 |
| Stevens, C | 1 |
| Musser, B | 2 |
| Mallick, M | 2 |
| Suryawanshi, S | 1 |
| Maganti, L | 1 |
| Zhu, H | 1 |
| Han, TH | 1 |
| Scherer, L | 1 |
| Simpson, B | 1 |
| Cosgrove, D | 1 |
| Gottesdiener, K | 1 |
| Amatruda, J | 1 |
| Rolls, BJ | 2 |
| Blundell, J | 1 |
| Bray, GA | 7 |
| Fujioka, K | 6 |
| Wagner, JA | 1 |
| Herman, GA | 1 |
| Slanska, I | 1 |
| Ge, H | 2 |
| Moran, SA | 1 |
| Wu, CH | 2 |
| Kuo, HC | 1 |
| Chang, CS | 1 |
| Yu, C | 1 |
| Robinson, JR | 1 |
| Niswender, KD | 1 |
| Maggioni, A | 2 |
| Santoro, D | 1 |
| Viner, RM | 2 |
| Hsia, Y | 2 |
| Tomsic, T | 1 |
| Wong, IC | 2 |
| Chudasama, HP | 1 |
| Bhatt, PA | 1 |
| Sari, R | 2 |
| Eray, E | 1 |
| Ozdem, S | 1 |
| Akbas, H | 1 |
| Coban, E | 1 |
| Phillips, CL | 2 |
| Yee, BJ | 2 |
| Trenell, MI | 1 |
| Magnussen, JS | 1 |
| Wang, D | 1 |
| Banerjee, D | 2 |
| Berend, N | 1 |
| Grunstein, RR | 2 |
| Neubert, A | 1 |
| Johansson, K | 2 |
| Sundström, J | 1 |
| Neovius, K | 1 |
| Rössner, S | 11 |
| Whitlock, EP | 1 |
| O'Connor, EA | 1 |
| Williams, SB | 1 |
| Beil, TL | 1 |
| Lutz, KW | 1 |
| Halseth, AE | 1 |
| Burns, CM | 1 |
| Miller, S | 1 |
| Shen, LZ | 1 |
| Sayburn, A | 1 |
| Gómez-Barrado, JJ | 1 |
| Turégano, S | 1 |
| Garcipérez de Vargas, FJ | 1 |
| Porras, Y | 1 |
| Williams, G | 3 |
| Nau, JY | 1 |
| Kaplan, LM | 1 |
| Zhu, Y | 1 |
| Zhang, FX | 1 |
| Li, B | 1 |
| Zhang, P | 1 |
| Song, P | 1 |
| Garrow, JS | 1 |
| Hsiao, TJ | 1 |
| Hwang, Y | 1 |
| Hansen, G | 3 |
| Tang-Christensen, M | 2 |
| Larsen, PJ | 2 |
| Axel, AM | 1 |
| Raben, A | 1 |
| Mikkelsen, JD | 1 |
| Taner Ertugrul, D | 1 |
| Yavuz, B | 2 |
| Okhan Akin, K | 1 |
| Arif Yalcin, A | 1 |
| Ata, N | 2 |
| Kucukazman, M | 2 |
| Algul, B | 2 |
| Dal, K | 2 |
| Sinan Deveci, O | 1 |
| Tutal, E | 2 |
| Madsen, AN | 1 |
| Paulsen, SJ | 1 |
| Lykkegaard, K | 1 |
| Hansen, HS | 1 |
| Levin, BE | 2 |
| Knudsen, LB | 1 |
| Fosgerau, K | 1 |
| Saraç, S | 1 |
| Saraç, F | 1 |
| Rao, G | 1 |
| Scheen, AJ | 4 |
| Galhardo, J | 1 |
| Davis, N | 1 |
| Matthai, S | 1 |
| Shield, JP | 1 |
| Batty, GD | 1 |
| Astrup, A | 10 |
| Yalcin, AA | 1 |
| Ertugrul, DT | 1 |
| Yilmaz, H | 1 |
| Deveci, OS | 1 |
| Demirel, G | 1 |
| Westly, E | 1 |
| Curfman, GD | 1 |
| Morrissey, S | 1 |
| Drazen, JM | 1 |
| Renz, CL | 4 |
| Grief, SN | 1 |
| Miranda, RL | 1 |
| Vlasova, IuIu | 1 |
| Ametov, AS | 1 |
| Palumbo, I | 2 |
| Randazzo, S | 2 |
| Smith, DL | 1 |
| Robertson, HT | 1 |
| Desmond, RA | 1 |
| Nagy, TR | 1 |
| Allison, DB | 1 |
| Joo, NS | 1 |
| Kim, SM | 1 |
| Kim, KM | 1 |
| Kim, CW | 1 |
| Kim, BT | 1 |
| Lee, DJ | 1 |
| Madsbad, S | 1 |
| Choi, JW | 1 |
| Joo, JI | 1 |
| Kim, DH | 1 |
| Wang, X | 2 |
| Oh, TS | 1 |
| Choi, DK | 1 |
| Yun, JW | 1 |
| Janhunen, SK | 1 |
| van der Zwaal, EM | 1 |
| la Fleur, SE | 1 |
| Adan, RA | 1 |
| Li, M | 1 |
| Chang, B | 1 |
| Zhen, Z | 1 |
| Qin, PJ | 1 |
| Liu, WK | 1 |
| Tong, XL | 1 |
| Paumgartten, FJ | 2 |
| Hainer, V | 5 |
| Cheung, BM | 2 |
| Koiou, E | 1 |
| Kandaraki, EA | 1 |
| Kalaitzakis, E | 1 |
| Delkos, D | 1 |
| Vosnakis, C | 2 |
| Nagayama, D | 1 |
| Shirai, K | 1 |
| Chavakis, T | 1 |
| Lamounier-Zepter, V | 1 |
| Bornstein, SR | 1 |
| Cohen, PA | 1 |
| Benner, C | 1 |
| McCormick, D | 1 |
| Downey, M | 1 |
| Still, C | 1 |
| Farina, MG | 1 |
| Baratta, R | 1 |
| Nigro, A | 1 |
| Vinciguerra, F | 1 |
| Puglisi, C | 1 |
| Schembri, R | 1 |
| Virgilio, C | 1 |
| Vigneri, R | 1 |
| Frittitta, L | 1 |
| Hemo, B | 1 |
| Endevelt, R | 1 |
| Porath, A | 1 |
| Stampfer, MJ | 1 |
| Shai, I | 1 |
| Zamrazilová, H | 1 |
| Sedláčková, D | 1 |
| Papazoglou, D | 1 |
| Restas, E | 1 |
| Papanas, N | 1 |
| Papatheodorou, K | 1 |
| Babouris, C | 1 |
| Glaros, D | 1 |
| Antonoglou, C | 1 |
| Maltezos, E | 1 |
| van Hunsel, F | 1 |
| van Grootheest, K | 1 |
| Veerman, JL | 1 |
| Barendregt, JJ | 1 |
| Forster, M | 1 |
| Vos, T | 1 |
| Abo-Elmatty, DM | 1 |
| Zaitone, SA | 1 |
| Perdok, RJ | 1 |
| Oltmanns, KM | 1 |
| Heldmann, M | 1 |
| Daul, S | 1 |
| Klose, S | 1 |
| Rotte, M | 1 |
| Schäfer, M | 1 |
| Heinze, HJ | 1 |
| Münte, TF | 1 |
| Lehnert, H | 1 |
| Gray, LJ | 1 |
| Cooper, N | 2 |
| Dunkley, A | 2 |
| Warren, FC | 1 |
| Ara, R | 3 |
| Abrams, K | 2 |
| Davies, MJ | 1 |
| Khunti, K | 2 |
| Sutton, A | 2 |
| Samaranayake, NR | 1 |
| Ong, KL | 1 |
| Leung, RY | 1 |
| Równicka-Zubik, J | 1 |
| Góra, A | 1 |
| Sułkowska, A | 1 |
| Napolitano, A | 1 |
| Miller, SR | 1 |
| Murgatroyd, PR | 1 |
| Delafont, B | 1 |
| Brooke, A | 1 |
| Elkhawad, M | 1 |
| Tan, CY | 1 |
| Virtue, S | 1 |
| Vidal-Puig, A | 1 |
| Nunez, DJ | 1 |
| Blake, L | 1 |
| Gray, L | 1 |
| Hernández, M | 1 |
| Crowther, M | 1 |
| Warren, F | 1 |
| Jackson, R | 1 |
| Rees, A | 1 |
| Stevenson, M | 1 |
| Davies, M | 1 |
| Simonyi, G | 1 |
| Pados, G | 1 |
| Medvegy, M | 1 |
| Bedros, JR | 1 |
| Hiatt, WR | 1 |
| Thomas, A | 1 |
| Goldfine, AB | 1 |
| Schamroth, CL | 1 |
| Suliburska, J | 1 |
| Bogdański, P | 1 |
| Szulińska, M | 1 |
| Pupek-Musialik, D | 1 |
| Colman, E | 1 |
| Armeni, AK | 1 |
| Papadakis, E | 1 |
| Roupas, ND | 1 |
| Klein, T | 1 |
| Ittrich, C | 1 |
| Mayoux, E | 1 |
| Mueller, HP | 1 |
| Cheetham, S | 1 |
| Mark, M | 1 |
| Tyczynski, JE | 1 |
| Oleske, DM | 1 |
| Klingman, D | 1 |
| Ferrufino, CP | 1 |
| Lee, WC | 1 |
| Kheyfets, IA | 1 |
| Vorob'eva, TM | 1 |
| Dugina, JL | 1 |
| Sergeeva, SA | 1 |
| Epstein, OI | 1 |
| Kaptein, EM | 1 |
| Chan, LS | 1 |
| Kaptein, JS | 1 |
| Kautzky-Willer, A | 1 |
| Lemmens-Gruber, R | 1 |
| Ahn, HY | 1 |
| Oh, SW | 1 |
| Manakova, E | 1 |
| Kralova, T | 1 |
| Hubičková Heringová, L | 1 |
| Nisoli, E | 3 |
| Carruba, MO | 4 |
| Werneke, U | 1 |
| Taylor, D | 1 |
| Sanders, TA | 1 |
| Liu, YL | 1 |
| Heal, DJ | 3 |
| Stock, MJ | 3 |
| Matiba, B | 3 |
| Zannad, F | 2 |
| Gille, B | 1 |
| Grentzinger, A | 1 |
| Bruntz, JF | 1 |
| Hammadi, M | 1 |
| Boivin, JM | 1 |
| Hanotin, C | 4 |
| Igau, B | 1 |
| Drouin, P | 3 |
| Anghelescu, I | 1 |
| Klawe, C | 1 |
| Szegedi, A | 1 |
| Lieberman, JA | 1 |
| Bosello, O | 2 |
| Ferrannini, E | 1 |
| Rotella, CM | 2 |
| Krejs, GJ | 1 |
| Ruilope, LM | 1 |
| Garcia-Robles, R | 1 |
| Moreno, B | 2 |
| Fernstrom, JD | 2 |
| Hanif, MW | 1 |
| Kumar, S | 3 |
| McNulty, SJ | 1 |
| Ur, E | 2 |
| Ernest, P | 1 |
| Gura, T | 1 |
| Peters, WR | 1 |
| MacMurry, JP | 1 |
| Walker, J | 1 |
| Giese, RJ | 1 |
| Comings, DE | 1 |
| Leung, WY | 1 |
| Thomas, GN | 1 |
| Chan, JC | 1 |
| Tomlinson, B | 1 |
| Haynes, WG | 3 |
| Vastag, B | 1 |
| Tershakovec, AM | 1 |
| Cronquist, JL | 1 |
| Wirth, A | 7 |
| Casado, A | 1 |
| Rodríguez, VM | 1 |
| Portillo, MP | 1 |
| Macarulla, MT | 1 |
| Abecia, LC | 1 |
| Echevarría, E | 1 |
| Casis, L | 1 |
| Saiz Ruiz, J | 1 |
| Saiz González, D | 1 |
| Antón Fructuoso, P | 1 |
| Jordan, J | 6 |
| Weigle, DS | 1 |
| Clerbaux, G | 1 |
| Goffin, E | 1 |
| Pirson, Y | 1 |
| Barkeling, B | 4 |
| Elfhag, K | 5 |
| Rooth, P | 2 |
| Hauner, H | 6 |
| Matsumoto, K | 1 |
| Iijima, H | 1 |
| van Baak, MA | 1 |
| van Mil, E | 1 |
| Astrup, AV | 2 |
| Hilsted, J | 2 |
| Kopelman, PG | 1 |
| Saris, WH | 2 |
| Meier, M | 2 |
| Jöckel, KH | 1 |
| Frey, UH | 1 |
| Siffert, W | 1 |
| Brunton, S | 1 |
| Peter, P | 1 |
| Tambascia, MA | 1 |
| Geloneze, B | 1 |
| Repetto, EM | 1 |
| Geloneze, SR | 1 |
| Picolo, M | 1 |
| Magro, DO | 1 |
| Kim, SH | 1 |
| Lee, YM | 1 |
| Jee, SH | 1 |
| Nam, CM | 1 |
| Padwal, R | 4 |
| Li, SK | 3 |
| Lau, DC | 3 |
| Sabuncu, T | 3 |
| Nazligul, Y | 2 |
| Karaoglanoglu, M | 1 |
| Ucar, E | 2 |
| Kilic, FB | 1 |
| Ryan, DH | 10 |
| Engeli, S | 4 |
| Harma, M | 2 |
| Kilic, F | 1 |
| Appolinario, JC | 4 |
| Bacaltchuk, J | 1 |
| Sichieri, R | 1 |
| Claudino, AM | 1 |
| Godoy-Matos, A | 3 |
| Morgan, C | 1 |
| Zanella, MT | 3 |
| Clark, VL | 1 |
| Carlsson, AM | 2 |
| Heufelder, AE | 1 |
| Stöckli, R | 1 |
| Keller, U | 2 |
| Guven, A | 1 |
| Koksal, N | 1 |
| Cetinkaya, A | 1 |
| Sokmen, G | 1 |
| Ozdemir, R | 1 |
| Thearle, M | 1 |
| Ersoz, HO | 1 |
| Ukinc, K | 1 |
| Baykan, M | 1 |
| Erem, C | 1 |
| Durmus, I | 1 |
| Hacihasanoglu, A | 1 |
| Telatar, M | 1 |
| Mannan, MA | 1 |
| Rahman, MS | 1 |
| Siddiqui, NI | 1 |
| Wyatt, HR | 1 |
| Hill, JO | 2 |
| Kaukua, JK | 1 |
| Pekkarinen, TA | 2 |
| Rissanen, AM | 2 |
| Poston, WS | 3 |
| Foreyt, JP | 3 |
| Lindgren, T | 1 |
| Valsamakis, G | 1 |
| McTernan, PG | 1 |
| Chetty, R | 1 |
| Al Daghri, N | 1 |
| Field, A | 1 |
| Hanif, W | 1 |
| Barnett, AH | 1 |
| Aydin, N | 2 |
| Topsever, P | 2 |
| Kaya, A | 2 |
| Karasakal, M | 1 |
| Duman, C | 1 |
| Dağar, A | 2 |
| Wendland, G | 1 |
| Kurscheid, T | 2 |
| Lauterbach, K | 2 |
| Arterburn, DE | 1 |
| Crane, PK | 1 |
| Veenstra, DL | 1 |
| Avenell, A | 2 |
| Broom, J | 1 |
| Brown, TJ | 1 |
| Poobalan, A | 1 |
| Aucott, L | 1 |
| Stearns, SC | 1 |
| Smith, WC | 1 |
| Jung, RT | 1 |
| Campbell, MK | 1 |
| Grant, AM | 1 |
| Porter, JA | 1 |
| Raebel, MA | 1 |
| Conner, DA | 1 |
| Lanty, FA | 1 |
| Vogel, EA | 1 |
| Gay, EC | 1 |
| Merenich, JA | 1 |
| Rajzer, M | 1 |
| Wojciechowska, W | 1 |
| Kawecka-Jaszcz, K | 1 |
| Birden, F | 1 |
| Yasar, O | 1 |
| Sahelijo, L | 1 |
| Katz, DA | 1 |
| Spear, BB | 1 |
| Einarson, A | 1 |
| Bonari, L | 1 |
| Sarkar, M | 1 |
| McKenna, K | 1 |
| Koren, G | 1 |
| Persky, AM | 1 |
| Ng, C | 1 |
| Song, MH | 1 |
| Lancaster, ME | 1 |
| Balderson, DE | 1 |
| Paulik, MA | 1 |
| Brouwer, KL | 1 |
| Tripp, B | 1 |
| Ludvik, B | 1 |
| Ning, G | 1 |
| Balci, MK | 1 |
| Cakir, M | 1 |
| Altunbas, H | 1 |
| Karayalcin, U | 1 |
| Olszanecka-Glinianowicz, M | 1 |
| Zahorska-Markiewicz, B | 1 |
| Jochemczyk-Banek, U | 1 |
| Banaś, M | 1 |
| Zurakowski, A | 1 |
| Shekelle, PG | 1 |
| Morton, SC | 1 |
| Maglione, M | 1 |
| Suttorp, M | 1 |
| Tu, W | 1 |
| Li, Z | 1 |
| Maggard, M | 1 |
| Mojica, WA | 1 |
| Shugarman, L | 1 |
| Solomon, V | 1 |
| Sánchez-Reyes, L | 3 |
| Fanghänel, G | 3 |
| Yamamoto, J | 1 |
| Martínez-Rivas, L | 1 |
| Campos-Franco, E | 1 |
| Berber, A | 5 |
| Lazurova, I | 1 |
| Dravecka, I | 1 |
| Kraus, V | 1 |
| Petrovicova, J | 1 |
| Künnecke, B | 1 |
| Verry, P | 1 |
| Bénardeau, A | 1 |
| von Kienlin, M | 1 |
| Svendsen, OL | 3 |
| Joyal, SV | 1 |
| Arterburn, D | 3 |
| Mertens, I | 1 |
| Ballaux, D | 1 |
| Verkade, HJ | 1 |
| Kim, DM | 1 |
| Yoon, SJ | 1 |
| Ahn, CW | 1 |
| Cha, BS | 1 |
| Lim, SK | 1 |
| Kim, KR | 1 |
| Lee, HC | 1 |
| Huh, KB | 1 |
| Murdolo, G | 2 |
| Fogari, R | 2 |
| Kunesova, M | 2 |
| Bellisle, F | 1 |
| Hill, M | 1 |
| Braunerova, R | 1 |
| Wagenknecht, M | 2 |
| Filiz, M | 1 |
| Oztürk, A | 1 |
| Kilinç, E | 1 |
| Ekmekcioglu, C | 1 |
| Stewart, TM | 1 |
| Mersebach, H | 1 |
| Klose, M | 1 |
| Feldt-Rasmussen, U | 1 |
| Carraro, L | 3 |
| Vieira, A | 2 |
| Oliveira, J | 1 |
| Guedes, EP | 1 |
| Mattos, L | 1 |
| Rangel, C | 1 |
| Moreira, RO | 2 |
| Stimac, D | 1 |
| Ruzić, A | 1 |
| Majanović, SK | 1 |
| Bertone, G | 1 |
| Payer, J | 1 |
| Ondrejka, P | 1 |
| Kajtor, Z | 1 |
| Tankova, T | 1 |
| Dakovska, G | 1 |
| Lazarova, M | 1 |
| Dakovska, L | 1 |
| Kirilov, G | 1 |
| Koev, D | 1 |
| Norris, SL | 1 |
| Zhang, X | 1 |
| Gregg, E | 1 |
| Schmid, CH | 1 |
| Lau, J | 1 |
| Scholze, J | 4 |
| Risser, JA | 1 |
| Vash, PD | 1 |
| Nieto, L | 1 |
| Harrold, JA | 1 |
| Lawton, CL | 1 |
| Blundell, JE | 1 |
| Wu, J | 1 |
| Lei, MX | 1 |
| Chen, HL | 1 |
| Faria, AN | 2 |
| Ribeiro Filho, FF | 2 |
| Kohlmann, NE | 1 |
| Gouvea Ferreira, SR | 1 |
| McLoughlin, C | 1 |
| Doggrell, SA | 2 |
| Chaput, JP | 3 |
| Bérubé-Parent, S | 2 |
| Tremblay, A | 4 |
| Pereira Cunill, JL | 1 |
| Astorga Jiménez, R | 1 |
| Ferrer-Lorente, R | 1 |
| Cabot, C | 1 |
| Fernández-López, JA | 1 |
| Remesar, X | 1 |
| Alemany, M | 1 |
| Copeland, PM | 2 |
| Daley, TB | 2 |
| Borba, CP | 2 |
| Cather, C | 2 |
| Nguyen, DD | 2 |
| Louie, PM | 1 |
| Evins, AE | 2 |
| Freudenreich, O | 2 |
| Hayden, D | 2 |
| Goff, DC | 2 |
| de Simone, G | 2 |
| Romano, C | 1 |
| De Caprio, C | 1 |
| Contaldo, F | 1 |
| Salanitri, T | 2 |
| di Luzio Paparatti, U | 1 |
| Pasanisi, F | 1 |
| Gaciong, Z | 1 |
| Placha, G | 1 |
| Redmon, JB | 1 |
| Reck, KP | 1 |
| Raatz, SK | 1 |
| Swanson, JE | 1 |
| Kwong, CA | 1 |
| Ji, H | 1 |
| Thomas, W | 1 |
| Bantle, JP | 1 |
| Egri, Z | 1 |
| Birkenfeld, AL | 1 |
| Schroeder, C | 1 |
| Pischon, T | 1 |
| Tank, J | 3 |
| Luft, FC | 4 |
| Wang, TF | 1 |
| Pei, D | 2 |
| Li, JC | 1 |
| Tsai, WC | 1 |
| Tsai, CC | 1 |
| Yao, CY | 1 |
| Chang, ET | 1 |
| Hsieh, MC | 1 |
| Su, KY | 1 |
| Kuo, SW | 2 |
| Hung, YJ | 1 |
| Chen, YC | 1 |
| Hsieh, CH | 1 |
| Wu, LY | 1 |
| He, CT | 1 |
| Lee, CH | 1 |
| Fan, SC | 1 |
| Sheu, WH | 1 |
| Mathus-Vliegen, EM | 1 |
| Kennedy, RL | 1 |
| Khoo, EY | 1 |
| Cuppini, A | 1 |
| Matteini, P | 1 |
| DeLaet, D | 1 |
| Flum, D | 1 |
| Steinbeck, K | 1 |
| Mathys, M | 1 |
| Corrêa, LL | 1 |
| Platt, MW | 1 |
| Faria Júnior, R | 1 |
| Godoy-Matos, AF | 1 |
| Meirelles, RM | 1 |
| Póvoa, LC | 1 |
| Coutinho, WF | 2 |
| Tong, NW | 1 |
| Ran, XW | 1 |
| Li, QF | 1 |
| Tang, BD | 1 |
| Li, R | 1 |
| Yang, FY | 1 |
| Liu, YP | 1 |
| Li, XJ | 1 |
| Ramzi, F | 1 |
| Elias, D | 1 |
| Mona, S | 1 |
| Zreik, TG | 1 |
| Chounta, A | 1 |
| Tsiodras, S | 1 |
| Zouridakis, S | 1 |
| Doumas, M | 1 |
| Giamarellou, H | 1 |
| Phelan, S | 3 |
| Cato, RK | 2 |
| Osei, SY | 1 |
| Kaplan, R | 1 |
| Yanovski, SZ | 1 |
| Padwal, RS | 2 |
| Baranowska, B | 1 |
| Wolińska-Witort, E | 1 |
| Martyńska, L | 1 |
| Chmielowska, M | 1 |
| Mazurczak-Pluta, T | 1 |
| Boguradzka, A | 1 |
| Baranowska-Bik, A | 1 |
| Molnár, D | 1 |
| Toubro, S | 7 |
| Breum, L | 1 |
| Bruun, JM | 1 |
| Kang, HC | 1 |
| Kim, SS | 1 |
| Youn, BB | 1 |
| Sidhaye, A | 1 |
| Cheskin, LJ | 1 |
| Hewkin, AC | 3 |
| Letonturier, P | 1 |
| Blackburn, GL | 4 |
| Waltman, BA | 1 |
| Patel, MR | 1 |
| Donahue, M | 1 |
| Wilson, PW | 1 |
| Califf, RM | 1 |
| De Santis, M | 1 |
| Straface, G | 1 |
| Cavaliere, AF | 1 |
| Carducci, B | 1 |
| Caruso, A | 1 |
| Hamann, A | 2 |
| Nelson, DL | 1 |
| Gehlert, DR | 1 |
| Bauer, C | 1 |
| Fischer, A | 1 |
| Hedner, JA | 1 |
| Heusser, K | 3 |
| Diedrich, A | 2 |
| Klaua, S | 1 |
| Krüger, N | 1 |
| Strauss, A | 1 |
| Stoffels, G | 1 |
| Shechter, M | 1 |
| Beigel, R | 1 |
| Freimark, D | 1 |
| Matetzky, S | 1 |
| Feinberg, MS | 1 |
| Behn, A | 1 |
| Mancini, MC | 1 |
| Halpern, A | 1 |
| Fisas, A | 1 |
| Codony, X | 1 |
| Romero, G | 1 |
| Dordal, A | 1 |
| Giraldo, J | 1 |
| Mercé, R | 1 |
| Holenz, J | 1 |
| Sørensen, RV | 1 |
| Heal, D | 2 |
| Buschmann, H | 1 |
| Pauwels, PJ | 1 |
| Bush, EN | 1 |
| Shapiro, R | 1 |
| Brune, ME | 1 |
| Knourek-Segel, VE | 1 |
| Droz, BA | 1 |
| Fey, T | 1 |
| Jacobson, PB | 1 |
| Daniels, SR | 2 |
| Hoppin, AG | 1 |
| Owen, S | 1 |
| Perry, AC | 1 |
| Sothern, MS | 1 |
| Pirner, MA | 1 |
| Walch, JK | 2 |
| Jasinsky, O | 2 |
| Blakesley, VA | 1 |
| Dietz, WH | 1 |
| García-Morales, LM | 1 |
| Macias-Lara, CC | 1 |
| Lucio-Ortiz, C | 1 |
| Del-Rio-Navarro, BE | 1 |
| Dorantes-Alvárez, LM | 1 |
| Dixon, JB | 1 |
| Pi-Sunyer, FX | 1 |
| Lundquist, LM | 1 |
| Sirimaturos, M | 1 |
| Cannon, E | 1 |
| Hofbauer, KG | 2 |
| Nicholson, JR | 2 |
| Boss, O | 1 |
| Boenner, G | 1 |
| Di Caro, S | 1 |
| Hamad, GG | 1 |
| Schauer, PR | 1 |
| Bonanomi, G | 1 |
| Richardson, DK | 1 |
| Jones, RB | 1 |
| Bailey, CJ | 2 |
| Kabrnova, K | 1 |
| Aldhoon, B | 1 |
| Dahlin, A | 1 |
| Beermann, B | 1 |
| Majumdar, SR | 1 |
| Rotthoff, T | 1 |
| Scherbaum, WA | 1 |
| Guimarães, C | 1 |
| Pereira, LR | 1 |
| Iucif Júnior, N | 1 |
| Cesarino, EJ | 1 |
| de Almeida, CA | 1 |
| de Carvalho, D | 1 |
| Queiroz, RH | 1 |
| Fan, X | 1 |
| Zhang, H | 1 |
| Van Mil, EG | 1 |
| Westerterp, KR | 1 |
| Kester, AD | 1 |
| Delemarre-van de Waal, HA | 1 |
| Gerver, WJ | 1 |
| St-Pierre, S | 2 |
| Gursoy, A | 1 |
| Erdogan, MF | 1 |
| Cin, MO | 1 |
| Cesur, M | 1 |
| Baskal, N | 1 |
| Wiesner, S | 1 |
| Janke, J | 2 |
| Lee, M | 1 |
| Fernández, P | 1 |
| Peiró, AM | 1 |
| Lechin, F | 1 |
| van der Dijs, B | 1 |
| Dalmau Serra, J | 1 |
| Alonso Franch, M | 1 |
| Gómez López, L | 1 |
| Martínez Costa, C | 1 |
| Sierra Salinas, C | 1 |
| Di Francesco, V | 1 |
| Sacco, T | 1 |
| Zamboni, M | 1 |
| Bissoli, L | 1 |
| Zoico, E | 1 |
| Mazzali, G | 1 |
| Minniti, A | 1 |
| Cancelli, F | 1 |
| Rothman, R | 1 |
| Grimm, E | 1 |
| Herrmann, D | 1 |
| Unger, T | 1 |
| Kintscher, U | 1 |
| Formiguera, X | 1 |
| Sierra, A | 1 |
| Kezouh, A | 1 |
| Levine, M | 1 |
| Etminan, M | 1 |
| Williams, B | 1 |
| Srishanmuganathan, J | 1 |
| Patel, H | 1 |
| Car, J | 1 |
| Majeed, A | 1 |
| Rosenbohm, A | 1 |
| Bux, CJ | 1 |
| Connemann, BJ | 1 |
| Xu, J | 1 |
| Dz Chen, J | 1 |
| Vazquez Roque, MI | 1 |
| Tepoel, DA | 1 |
| Jensen, MD | 1 |
| Baxter, KL | 1 |
| McElroy, SL | 1 |
| Frye, MA | 1 |
| Altshuler, LL | 1 |
| Suppes, T | 1 |
| Hellemann, G | 1 |
| Black, D | 1 |
| Mintz, J | 1 |
| Kupka, R | 1 |
| Nolen, W | 1 |
| Leverich, GS | 1 |
| Denicoff, KD | 1 |
| Post, RM | 1 |
| Keck, PE | 1 |
| Early, JL | 1 |
| Apovian, CM | 2 |
| Frank, A | 1 |
| Greenway, FL | 2 |
| Heber, D | 2 |
| Kushner, RF | 1 |
| Cwik, KM | 1 |
| Blakesley, V | 2 |
| Tsouli, S | 1 |
| Konitsiotis, S | 1 |
| Long, B | 1 |
| Crow, S | 1 |
| Styne, D | 1 |
| Sothern, M | 1 |
| Vargas-Rodriguez, I | 1 |
| Harris, L | 1 |
| Walch, J | 1 |
| Cwik, K | 1 |
| Hewkin, A | 1 |
| Brennan, A | 1 |
| Sharma, A | 1 |
| Brisco, W | 1 |
| Deaton, R | 1 |
| Lindholm, Å | 1 |
| Bixo, M | 1 |
| Björn, I | 1 |
| Wölner-Hanssen, P | 1 |
| Eliasson, M | 1 |
| Larsson, A | 1 |
| Johnson, O | 1 |
| Poromaa, IS | 1 |
| Malone, M | 1 |
| Dunican, KC | 1 |
| Desilets, AR | 1 |
| Montalbano, JK | 1 |
| Hill, GR | 1 |
| Ashton, J | 1 |
| Harrison-Woolrych, M | 1 |
| Liou, TH | 1 |
| Chien, HC | 1 |
| Lin, WY | 1 |
| Lee, WJ | 1 |
| Chou, P | 1 |
| Erondu, N | 1 |
| Addy, C | 1 |
| Lu, K | 1 |
| Gantz, I | 1 |
| Proietto, J | 2 |
| Rissannen, AM | 1 |
| Tonstad, S | 2 |
| Gottesdiener, KM | 1 |
| Kaufman, KD | 1 |
| Amatruda, JM | 1 |
| Danielsson, P | 1 |
| Janson, A | 1 |
| Norgren, S | 1 |
| Marcus, C | 1 |
| Rubio, MA | 1 |
| Gargallo, M | 1 |
| Isabel Millán, A | 1 |
| Franz, MJ | 1 |
| VanWormer, JJ | 1 |
| Crain, AL | 1 |
| Boucher, JL | 1 |
| Histon, T | 1 |
| Caplan, W | 1 |
| Bowman, JD | 1 |
| Pronk, NP | 1 |
| Pisarik, P | 1 |
| Yilmaz, Y | 1 |
| Mannucci, E | 1 |
| Dicembrini, I | 1 |
| Rotella, F | 1 |
| Choi, S | 1 |
| Zieba, R | 1 |
| Suter, PM | 2 |
| Kolyvanos, NU | 1 |
| Käser, L | 1 |
| Vetter, W | 2 |
| Bodary, PF | 1 |
| Iglay, HB | 1 |
| Eitzman, DT | 1 |
| von Haehling, S | 1 |
| Lainscak, M | 1 |
| Anker, SD | 1 |
| Florentin, M | 1 |
| Perrio, MJ | 1 |
| Wilton, LV | 1 |
| Shakir, SA | 1 |
| Diamanti-Kandarakis, E | 1 |
| Nassis, GP | 1 |
| Karkanaki, A | 1 |
| Georgopoulos, N | 1 |
| Bönner, G | 1 |
| Yager, J | 1 |
| Kaila, B | 1 |
| Raman, M | 1 |
| Aylwin, S | 1 |
| Al-Zaman, Y | 1 |
| Rotstein, A | 1 |
| Inbar, O | 1 |
| Vaisman, N | 1 |
| Quilliot, D | 1 |
| Böhme, P | 1 |
| Ziegler, O | 2 |
| Gorzelniak, K | 1 |
| Bátkai, S | 1 |
| Pacher, P | 1 |
| Harvey-White, J | 1 |
| Horvath, K | 1 |
| Jeitler, K | 1 |
| Siering, U | 1 |
| Stich, AK | 1 |
| Skipka, G | 1 |
| Gratzer, TW | 1 |
| Siebenhofer, A | 1 |
| Baptista, T | 1 |
| Uzcátegui, E | 1 |
| Rangel, N | 1 |
| El Fakih, Y | 1 |
| Galeazzi, T | 1 |
| Beaulieu, S | 1 |
| de Baptista, EA | 1 |
| Neff, LM | 1 |
| Mashiko, S | 1 |
| Ishihara, A | 1 |
| Iwaasa, H | 1 |
| Moriya, R | 1 |
| Kitazawa, H | 1 |
| Mitobe, Y | 1 |
| Ito, J | 1 |
| Gomori, A | 1 |
| Matsushita, H | 1 |
| Takahashi, T | 1 |
| MacNeil, DJ | 1 |
| Van der Ploeg, LH | 1 |
| Fukami, T | 1 |
| Kanatani, A | 1 |
| Bischoff, A | 1 |
| Barratt, R | 1 |
| Frost, G | 1 |
| O'Boyle, A | 1 |
| Millward, J | 1 |
| Truby, H | 1 |
| D'Addeo, G | 1 |
| Kaiser, P | 1 |
| Gordon, D | 1 |
| Heidingsfelder, S | 1 |
| Cerise, F | 1 |
| Wilson, K | 1 |
| Lean, ME | 3 |
| Weiser, M | 1 |
| Frishman, WH | 1 |
| Michaelson, MD | 1 |
| Abdeen, MA | 1 |
| Jackson, HC | 2 |
| Needham, AM | 1 |
| Hutchins, LJ | 1 |
| Mazurkiewicz, SE | 1 |
| Seaton, TB | 4 |
| Mendel, CM | 7 |
| Weinstein, SP | 5 |
| Thomas, F | 3 |
| Jones, SP | 2 |
| Leutenegger, E | 3 |
| Shide, DJ | 1 |
| Thorwart, ML | 1 |
| Ulbrecht, JS | 1 |
| Seagle, HM | 1 |
| Bessesen, DH | 1 |
| Day, C | 1 |
| Borrell, L | 1 |
| Haddock, CK | 2 |
| Aspley, S | 1 |
| Prow, MR | 1 |
| Martin, KF | 1 |
| Cheetham, SC | 1 |
| Hansen, DL | 2 |
| Lundsgaard, C | 2 |
| Wauters, MA | 2 |
| Peiffer, FW | 3 |
| De Leeuw, IH | 3 |
| Rissanen, A | 1 |
| McNeely, W | 1 |
| Goa, KL | 1 |
| Schusdziarra, V | 1 |
| Ferguson, JM | 1 |
| Jain, AK | 1 |
| Mendels, J | 1 |
| Schwartz, SL | 1 |
| Scheinbaum, ML | 2 |
| Apfelbaum, M | 1 |
| Vague, P | 1 |
| Galasso, GJ | 1 |
| Maughan, KL | 1 |
| Bach, DS | 1 |
| Kelly, F | 1 |
| Patel, B | 1 |
| Armstrong, WF | 1 |
| Lean, M | 1 |
| Luque, CA | 2 |
| Rey, JA | 2 |
| Féry, F | 1 |
| Watrin, I | 1 |
| Greenberg, I | 1 |
| Chan, S | 1 |
| Walsh, KM | 1 |
| Leen, E | 1 |
| Macdonald, IA | 1 |
| Collazo-Clavell, ML | 1 |
| Cuellar, GE | 1 |
| Ruiz, AM | 1 |
| Monsalve, MC | 1 |
| Cortinas, L | 2 |
| Richter, WO | 1 |
| Hirsch, J | 1 |
| Mackintosh, RM | 1 |
| Schmidt, H | 1 |
| Plauth, M | 1 |
| McMahon, FG | 3 |
| Singh, BN | 1 |
| Rowe, E | 4 |
| Rolston, K | 1 |
| Johnson, F | 2 |
| Mooradian, AD | 2 |
| Agrawal, M | 1 |
| Worzniak, M | 1 |
| Diamond, L | 1 |
| Berke, EM | 1 |
| Morden, NE | 1 |
| Fabris, R | 1 |
| Granzotto, M | 1 |
| Pagano, C | 2 |
| Lombardi, AM | 1 |
| Ferretti, E | 1 |
| Marzolo, M | 1 |
| Scagnol, I | 1 |
| Federspil, G | 2 |
| Vettor, R | 3 |
| Birkeland, KI | 1 |
| Arnold, ME | 1 |
| Steinberg, CM | 1 |
| Imoberdorf, R | 1 |
| Ballmer, PE | 1 |
| Trakas, K | 2 |
| Leiter, L | 1 |
| Shear, NH | 2 |
| Weiss, D | 1 |
| Dunn-Meynell, AA | 1 |
| Magnati, G | 1 |
| Dei Cas, A | 1 |
| Taflinski, T | 1 |
| Chojnacka, J | 1 |
| Nakagawa, T | 1 |
| Ukai, K | 1 |
| Ohyama, T | 1 |
| Gomita, Y | 1 |
| Okamura, H | 1 |
| Prus-Wisniewski, R | 1 |
| Steinberg, C | 1 |
| Keipes, M | 1 |
| Fuente Martinez, M | 1 |
| Nicolay, L | 1 |
| Kuffer, V | 1 |
| Mersch, L | 1 |
| Klees, J | 1 |
| Jacqué, M | 1 |
| Czupryniak, L | 1 |
| Drzewoski, J | 1 |
| Bloom, SR | 1 |
| Frost, GS | 1 |
| Banks, LM | 1 |
| Griffiths, J | 1 |
| Jelinek, CA | 1 |
| Raskin, P | 1 |
| Lebovitz, HE | 1 |
| Bickerdike, MJ | 1 |
| Vickers, SP | 1 |
| Hazenberg, BP | 1 |
| Brown, M | 1 |
| Bing, C | 1 |
| King, P | 1 |
| Pickavance, L | 1 |
| Wilding, J | 1 |
| Hansen, D | 1 |
| Kopelman, P | 1 |
| Saris, W | 1 |
| James, W | 1 |
| Goulder, M | 1 |
| Starling, RD | 1 |
| Liu, X | 1 |
| Sullivan, DH | 1 |
| Després, JP | 1 |
| Smith, IG | 1 |
| Goulder, MA | 1 |
| Heine, RJ | 1 |
| McLaughlin, T | 2 |
| Abbasi, F | 2 |
| Kim, HS | 2 |
| Lamendola, C | 2 |
| Schaaf, P | 1 |
| Reaven, G | 1 |
| Reaven, GM | 1 |
| Boozer, CN | 1 |
| Leibel, RL | 1 |
| Love, RJ | 1 |
| Cha, MC | 1 |
| Prud'homme, D | 1 |
| Doucet, E | 1 |
| Yip, I | 1 |
| Go, VL | 1 |
| Hershman, JM | 1 |
| Wang, HJ | 1 |
| Elashoff, R | 1 |
| DeShields, S | 1 |
| Liu, Y | 1 |
| Dujovne, CA | 1 |
| Zavoral, JH | 1 |
| Krause, J | 1 |
| Samsa, GP | 1 |
| Kolotkin, RL | 1 |
| Williams, GR | 1 |
| Nguyen, MH | 1 |
| Fontaine, KR | 1 |
| Rothman, RA | 1 |
| Gokcel, A | 3 |
| Karakose, H | 3 |
| Ertorer, EM | 1 |
| Tanaci, N | 2 |
| Tutuncu, NB | 1 |
| Guvener, N | 2 |
| García-Luna, PP | 2 |
| Soto Moreno, AM | 1 |
| Jakicic, JM | 1 |
| Clark, K | 1 |
| Coleman, E | 1 |
| Donnelly, JE | 1 |
| Foreyt, J | 1 |
| Melanson, E | 1 |
| Volek, J | 1 |
| Volpe, SL | 1 |
| Stevenson, JH | 1 |
| Trojian, T | 1 |
| Jackson, EA | 1 |
| Zhao, Y | 1 |
| Yan, Z | 1 |
| Moyad, MA | 1 |
| Eisenberg, D | 1 |
| Pereira, JL | 1 |
| López-Pardo, F | 1 |
| Parejo, J | 1 |
| Astorga, R | 1 |
| Rodríguez-Puras, MJ | 1 |
| Sircar, AR | 1 |
| Kumar, A | 1 |
| Lal, M | 1 |
| Fontenelle, LF | 1 |
| Cabral, M | 1 |
| Sramek, JJ | 1 |
| Leibowitz, MT | 1 |
| Rowe, ED | 1 |
| Levy, B | 1 |
| Mullican, WS | 1 |
| Toth, PD | 1 |
| Cutler, NR | 1 |
| Ernst, KR | 1 |
| Dill, PL | 1 |
| Ericsson, M | 1 |
| Leopold, K | 1 |
| Wechsler, JG | 1 |
| Serrano-Rios, M | 1 |
| Melchionda, N | 1 |
| Moreno-Carretero, E | 1 |
| Gumurdulu, Y | 2 |
| Melek Ertorer, E | 1 |
| BascilTutuncu, N | 1 |
| Lerario, DD | 1 |
| Kohlmann, N | 1 |
| Ferreira, SR | 1 |
| Karademir, BM | 1 |
| Anarat, R | 1 |
| Rodrigues, AM | 1 |
| Suplicy, Hde L | 1 |
| De Almeida, SM | 1 |
| Niclewicz, PA | 1 |
| Sempere I Verdú, E | 1 |
| Palop Larrea, V | 1 |
| Hidalgo Mora, JJ | 1 |
| Martínez-Mir, I | 1 |
| Mustajoki, P | 1 |
| O'Meara, S | 1 |
| Riemsma, R | 1 |
| Shirran, L | 1 |
| Mather, L | 1 |
| ter Riet, G | 1 |
| Wooltorton, E | 1 |
| Verspohl, EJ | 1 |
| Golik, A | 2 |
| Rubio, A | 2 |
| Weintraub, M | 2 |
| Byrne, L | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sibutramine Cardiovascular Morbidity/Mortality Outcomes Study in Overweight or Obese Subjects at Risk of a Cardiovascular Event[NCT00234832] | Phase 3 | 10,777 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled, Investigator-initiated Study to Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine[NCT01184560] | 174 participants (Actual) | Interventional | 2010-02-28 | Completed | |||
| Treatment of Binge Eating in Obese Patients in Primary Care[NCT00537810] | Phase 4 | 104 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| Do Visuals of Symptom Change Increase Rates of Rapid Response in First Weeks of CBT for Eating Disorders?[NCT02940613] | 80 participants (Anticipated) | Interventional | 2016-12-31 | Active, not recruiting | |||
| Pharmacogenomics of Weight Loss With Sibutramine in Obese and Overweight Patients[NCT00433641] | Phase 4 | 181 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Efficacy of Sibutramine-induced Weight Loss vs. Continuous Positive Airway Pressure (CPAP) in the Treatment of Obese Patients With Obstructive Sleep Apnea[NCT00729963] | Phase 4 | 45 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| [NCT00482638] | Phase 2 | 0 participants | Interventional | 2004-05-12 | Completed | ||
| [NCT00482196] | Phase 2 | 173 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| The Efficacy and Safety of Electro-acupuncture for Abdominal Obesity: Original Study for a Multicenter, Randomized, Sham-controlled Trial[NCT04957134] | 66 participants (Actual) | Interventional | 2021-07-22 | Completed | |||
| Time Restricted Eating as a Treatment for Pediatric Obesity[NCT05124847] | 30 participants (Anticipated) | Interventional | 2021-09-27 | Recruiting | |||
| ADAPT+: Optimizing an Intervention to Promote Healthy Behaviors in Rural, Latino Youth With Obesity and Their Parents, Using Mindfulness Strategies[NCT04800432] | 108 participants (Actual) | Interventional | 2021-03-06 | Active, not recruiting | |||
| Exergaming for Health: Impact of a Community-Based Active Video Gaming Curriculum in Pediatric Weight Management[NCT02436330] | 84 participants (Actual) | Interventional | 2011-03-31 | Completed | |||
| Effect of Personal Activity Trackers on Weight Loss in Children Enrolled in a Comprehensive Behavioral Family Lifestyle Intervention (CBFLI) Program[NCT03215641] | 200 participants (Anticipated) | Interventional | 2015-08-31 | Enrolling by invitation | |||
| Double-blind, Randomized Clinical Trial to Evaluate Effect of Combination Therapy of Metformin and Sibutramine Versus Metformin or Sibutramine Monotherapy Over Weight, Adiposity, Glucose Metabolism and Inflammatory State in Obese Patients[NCT00941382] | Phase 3 | 60 participants (Anticipated) | Interventional | 2008-11-30 | Active, not recruiting | ||
| Weight Loss & Maintenance of Weight Loss Tracking Study (SUCCESS Tracking Study)[NCT01021917] | 332 participants (Anticipated) | Observational | 2008-03-31 | Terminated (stopped due to Given the length of time data was collected (i.e. 5 1/3 years), we do not anticipate a change any potential conclusions by completing the final survey.) | |||
| The Effect of Metabolism-Boosting Beverages on 24 Hr Energy Expenditure[NCT01029236] | 30 participants (Actual) | Interventional | 2007-06-30 | Completed | |||
| Efficacy of Medifast's 5 & 1 Program Compared to a Food-based Diet After a Period of Weight Loss and Weight Maintenance[NCT01011491] | 90 participants (Actual) | Interventional | 2008-03-31 | Completed | |||
| Cost Analysis of Bariatric Surgery in an Employee-based Healthcare System[NCT02381704] | 100 participants (Actual) | Observational | 2008-04-30 | Completed | |||
| Feasibility of a Campaign Intervention Compared to a Standard Behavioral Weight Loss Intervention in Overweight and Obese Adults[NCT01803737] | 26 participants (Actual) | Interventional | 2013-01-31 | Completed | |||
| A 12 Month Study to Assess Safety and Efficacy of Meridia (Sibutramine Hydrochloride Monohydrate) 10 and 15 mg in Obese Adolescents[NCT00261911] | Phase 3 | 498 participants (Actual) | Interventional | 2000-07-31 | Completed | ||
| A Study to Assess the Compliance and Impact on Weight of Kurbo, a Pediatric Centered Weight Loss App[NCT02880254] | 27 participants (Actual) | Interventional | 2016-09-30 | Completed | |||
| Metabolic and Neural Adaptations to Weight Loss, Plateau, and Regain[NCT02199483] | 0 participants (Actual) | Observational | 2014-07-21 | Withdrawn | |||
| Progressive Weight Loss and Metabolic Health[NCT01299519] | 59 participants (Actual) | Interventional | 2011-02-28 | Completed | |||
| Evaluation of the Effectiveness of Cryotherapy in Slimming of the Abdomen and Saddlebags[NCT04287153] | 30 participants (Actual) | Interventional | 2017-09-17 | Completed | |||
| Eat Well for Life: A Weight Loss Maintenance Study[NCT01849627] | 345 participants (Anticipated) | Interventional | 2014-08-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For each subject who died, the time to death was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 418 |
| Randomized Placebo | 404 |
For each subject, the first occurrence of a nonfatal MI included in the POE was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 200 |
| Randomized Placebo | 159 |
For each subject, the time to first occurrence of a nonfatal stroke included in the POE was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 127 |
| Randomized Placebo | 95 |
This outcome includes nonfatal MI, nonfatal stroke, resuscitated cardiac arrest, CV death (including events such as fatal MI and fatal stroke), and any of the following revascularization procedures: percutaneous transluminal coronary angioplasty, coronary artery bypass graft, coronary artery stent placement, cardiac transplant, peripheral vascular bypass or angioplasty, and carotid endarterectomy. For each subject, the POE or revascularization status (yes/no) and time to first occurrence of an event using time-to-event analysis were evaluated. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 927 |
| Randomized Placebo | 856 |
For each subject, the time to first occurrence of a resuscitated cardiac arrest included in the POE was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 11 |
| Randomized Placebo | 7 |
For each subject, the time to cardiovascular death included in the POE was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 223 |
| Randomized Placebo | 229 |
For each subject, POE status (with/without an event) and time to first occurrence of a POE using time-to-event analysis were evaluated. All POE confirmed by an independent adjudication committee were included in the analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Intent-to-treat population | |
| CV + DM Randomized to Placebo | 346 |
| CV + DM Randomized to Sibutramine | 403 |
| CV Only Randomized to Placebo | 66 |
| CV Only Randomized to Sibutramine | 77 |
| DM Only Randomized to Placebo | 77 |
| DM Only Randomized to Sibutramine | 79 |
| Randomized Placebo | 490 |
| Randomized Sibutramine | 561 |
BMI (kg/m^2) was measured 4 months after treatment. (NCT00537810)
Timeframe: 4 months
| Intervention | BMI (kg/m^2) (Mean) |
|---|---|
| Sibutramine | 38.4 |
| Placebo | 39.6 |
| Placebo/CBTsh | 35.9 |
| Sibutramine/CBTsh | 35.6 |
Remission from binge eating (zero binge episodes during previous 28 days) (NCT00537810)
Timeframe: 4 months treatment; 6 and 12 month follow up post treatment
| Intervention | participants (Number) | ||
|---|---|---|---|
| Remission at Post-treatment | Remission at 6 month follow up | Remission at 12 month follow up | |
| Placebo | 8 | 11 | 10 |
| Placebo/CBTsh | 6 | 10 | 10 |
| Sibutramine | 10 | 5 | 5 |
| Sibutramine/CBTsh | 6 | 13 | 11 |
Activity will be measured by pedometers (number of steps) during week 1 and week 24 for both groups. Subjects used the Yamax 200 pedometer to count the steps they took over 1 weeks time. (NCT02436330)
Timeframe: Change from week 1 to week 24
| Intervention | steps (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | -6626 |
| Didactic Health Teaching | -9059.5 |
Change in after school screen time (reported out as fraction of 1 hour) will be measured by subject response on questionnaire taken at baseline and at 6 months for both groups. After school screen time was defined as the amount of time spent on any screen, on the average weekday afternoon/evening, including: watching television, computer use (laptop, desk top, tablet) or playing video games on the television or other hand held device. (NCT02436330)
Timeframe: Change from baseline at 6 months
| Intervention | hours (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | -0.7589 |
| Didactic Health Teaching | 0.188 |
All subjects were asked to dress in light athletic clothing and have their weight and height measured at baseline (the first group session) and at 6 months. Research assistants were trained using guidelines from the National Health and Nutrition Examination Survey (NHANES) Anthropometry Procedures Manual and demonstrated accurate measures on 3 separate children. The Seca 217 portable stadiometer was used for all height measurements and the HealthOMeter 844 KL scale was used for all weight measurements. BMI z-scores were calculated using software available from the Children's Hospital of Philadelphia Research Institute (http://stokes.chop.edu/web/zcore). (NCT02436330)
Timeframe: Change from baseline at 6 months
| Intervention | z-score (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | -0.057 |
| Didactic Health Teaching | 0.005 |
Measure was only taken on the subjects who participated in the Intervention group (exergaming combined with didactic teaching). (NCT02436330)
Timeframe: Change from baseline BMI z-score at 1 year
| Intervention | z-score (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | -0.0775 |
The Block Alive FFQ: administered at the start and at 6 months to all participants in both groups. FFQ inquires about typical dietary patterns over the previous six months. Total % dietary carbohydrates is then estimated based upon participant responses. (NCT02436330)
Timeframe: Change from baseline at 6 months
| Intervention | percentage of carbohydrates (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | 2.10 |
| Didactic Health Teaching | -5.12 |
The Block Alive FFQ: administered at the start and at 6 months to all participants in both groups. FFQ inquires about typical dietary patterns over the previous six months. Total %dietary fat intake per day is then estimated based upon participant responses. (NCT02436330)
Timeframe: Change from baseline at 6 months
| Intervention | percentage of fat (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | -1.25 |
| Didactic Health Teaching | 3.00 |
The Block Alive FFQ: administered at the start and at 6 months to all participants in both groups. FFQ inquires about typical dietary patterns over the previous six months. Total number of fruit servings per day is then estimated based upon participant responses. (NCT02436330)
Timeframe: Change from baseline at 6 months
| Intervention | Servings (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | -0.13255 |
| Didactic Health Teaching | 0.663 |
The Block Alive FFQ: administered at the start and at 6 months to all participants in both groups. FFQ inquires about typical dietary patterns over the previous six months. Total number of sugar sweetened beverages per day is then estimated based upon participant responses. (NCT02436330)
Timeframe: Change from baseline at 6 months
| Intervention | servings (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | -2.572 |
| Didactic Health Teaching | -3.2374 |
The Block Alive FFQ: administered at the start and at 6 months to all participants in both groups. FFQ inquires about typical dietary patterns over the previous six months. Total number of vegetable servings per day is then estimated based upon participant responses. (NCT02436330)
Timeframe: Change from baseline at 6 months
| Intervention | servings (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | 0.0078 |
| Didactic Health Teaching | 0.8248 |
The Block Alive FFQ: administered at the start and at 6 months to all participants in both groups. FFQ inquires about typical dietary patterns over the previous six months. Total kcal/kg/day is then estimated based upon participant responses. (NCT02436330)
Timeframe: Change from baseline at 6 months
| Intervention | kcal/day (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | -292.92 |
| Didactic Health Teaching | -45 |
"The experimental group will answer a questionnaire at the end of the 6 month study period, measuring the importance of specific components of the curriculum and motivators which influenced enrollment and compliance with participation. Of interest is measuring the influence of the exergaming curriculum as compared to these other factors. This is a 16-item, 3-point Likert-scale (1 = least important and 3 = most important) questionnaire created specifically for this study. Results were reported based on % of participants rating 3 ,most important, for each curriculum component." (NCT02436330)
Timeframe: 6 months
| Intervention | percentage of subjects (Number) |
|---|---|
| Exergaming and Didactic Health Teaching | 71 |
(NCT02436330)
Timeframe: Change from 6 month Heart rate at 1 year
| Intervention | beats per minute (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | 2.7407 |
(NCT02436330)
Timeframe: Change from baseline at 6 months
| Intervention | beats per minute (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | -9.9 |
| Didactic Health Teaching | -7.0 |
Change in Saturday screen time (reported out as fraction of an hour) will be measured by subject response on questionnaire taken at baseline and at 6 months for both groups. Saturday screen time was defined as the amount of time spent on any screen, on an average Saturday, including: watching television, computer use (laptop, desk top, tablet) or playing video games on the television or other hand held device. (NCT02436330)
Timeframe: Change in hours from baseline at 6 months
| Intervention | hours (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | -1.4 |
| Didactic Health Teaching | -0.3438 |
CY-PSPP questionnaire was completed by participants in both groups at baseline and at 6 months. Change in the Global Self-worth scores, which was 1 of 6 sub-domains, is analyzed. This sub-domain contains 6 questions with responses ranging from 1-4 for each question with 1 being the minimum and 4 being the maximum (best) score. The sub-domain score is then calculated as the mean of the 6 responses (minimum to maximum of 1 to 4).The change in score from baseline to 6 months was compared. (NCT02436330)
Timeframe: Change from baseline to 6 months
| Intervention | scores on a scale (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | -0.238 |
| Didactic Health Teaching | -0.523 |
CY-PSPP questionnaire was completed by participants in both groups at baseline and at 6 months. Change in the Physical Self-worth scores, which was 1 of 6 sub-domains, is analyzed. This sub-domain contains 6 questions with responses ranging from 1-4 for each question with 1 being the minimum and 4 being the maximum (best) score. The sub-domain score is then calculated as the mean of the 6 responses (minimum to maximum of 1 to 4).The change in score from baseline to 6 months was compared. (NCT02436330)
Timeframe: Change from baseline at 6 months
| Intervention | scores on a scale (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | -0.218 |
| Didactic Health Teaching | -0.5 |
The shuttle run was completed again by participants in the Experimental group at 1 year. The shuttle run is a standardized field assessment that requires participants to run 20 meters within sequentially shortened time frames of recorded beeps. (NCT02436330)
Timeframe: Change in number from 6 month shuttle run at 1 year
| Intervention | number of runs (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | 0.10 |
The shuttle run was completed by participants at baseline (session 1) and at 6 months. The shuttle run is a standardized field assessment that requires participants to run 20 meters within sequentially shortened time frames of recorded beeps. (NCT02436330)
Timeframe: Change in number from baseline shuttle run at 6 months
| Intervention | number of runs (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | 0.213 |
| Didactic Health Teaching | -0.00085 |
(NCT02436330)
Timeframe: Change from 6 month Systolic BP at 1 year
| Intervention | mmHg (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | 3.5185 |
(NCT02436330)
Timeframe: Change from baseline Systolic BP at 6 months
| Intervention | mmHg (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | 1 |
| Didactic Health Teaching | 0 |
(NCT02436330)
Timeframe: Change from 6 month waist circumference at 1 year
| Intervention | cm (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | 1.52 |
(NCT02436330)
Timeframe: Change from baseline at 6 months
| Intervention | cm (Mean) |
|---|---|
| Exergaming and Didactic Health Teaching | -0.50 |
| Didactic Health Teaching | -0.51 |
Body weight will be measured on a digital scale to assess change in body weight over the 12-week intervention period. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | kg (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | -5.6 |
| Campaign Intervention (CI) | -3.1 |
A questionnaire will be used to assess self-reported food intake. This will be used to estimate calories, dietary fat, protein, and carbohydrates consumed. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | percentage of carbohydrate intake (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | 0.64 |
| Campaign Intervention (CI) | 0.90 |
A questionnaire will be used to assess self-reported food intake. This will be used to estimate calories, dietary fat, protein, and carbohydrates consumed. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | percentage of fat intake (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | -3.26 |
| Campaign Intervention (CI) | -0.00 |
A questionnaire will be used to assess self-reported food intake. This will be used to estimate calories, dietary fat, protein, and carbohydrates consumed. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | percentage of protein intake (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | 0.73 |
| Campaign Intervention (CI) | 0.44 |
A questionnaire will be used to assess self-reported food intake. This will be used to estimate calories, dietary fat, protein, and carbohydrates consumed. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | kcals/day (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | 474.8 |
| Campaign Intervention (CI) | 242.5 |
A questionnaire will be used to measure and quantify energy expenditure from physical activity. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | kcals/wk (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | 983.3 |
| Campaign Intervention (CI) | 776.3 |
Self-efficacy for weight loss was assessed at week 0 and 12 using a 20-item Weight Efficacy Lifestyle Questionnaire (WEL). The total score ranges from 0-180. Higher values represent greater beliefs toward the completion of weight management behaviors. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | units on a scale (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | 28.3 |
| Campaign Intervention (CI) | 16.3 |
The frequency that participants engaged in the self-monitoring of dietary intake and physical activity was assessed at week 12. The diaries were completed weekly throughout the study. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | percentage of diaries completed (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | 91.6 |
| Campaign Intervention (CI) | 60.1 |
At week 12, participants completed the 13-item TSRQ to assess motivation to continue to participate in the program if given the opportunity. The TSRQ represents participants' reasons for continuing participation in a weight loss program via participants' endorsement of statements of autonomous and controlled motivation. Responses were given using a 7-point Likert scale (1 = not at all true to 7 = very true). The responses on the autonomous items (5) and controlled items (8) were averaged. (NCT01803737)
Timeframe: Week 12
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Autonomous Motivation | Controlled Motivation | |
| Campaign Intervention (CI) | 5.3 | 2.9 |
| Standard Behavioral Weight Loss Intervention (SBWL) | 6.3 | 2.9 |
BMI zscore will be determined from mathematical calculations derived from subject's height and weight. Z score is the number of standard deviations from the mean. A Z score of 0 is the mean. A change in z score in the positive direction reflects an increase in BMI Z score. A change in z score in the negative direction reflects a decrease in BMI Z score. A decrease in BMI z score indicates a change in BMI that favors weight loss. (NCT02880254)
Timeframe: 3 months
| Intervention | z score (Mean) |
|---|---|
| Kurbo Only | 2.4 |
| Kurbo Plus PHC | 2.2 |
"A questionnaire will be handed out to each subject every month (see below) where applicable.we will utilize one-sample tests with a one-sided alpha of 0.025. One-sided tests will be used as we are only interested in whether the use of this app results in better outcomes than usual care. Compliance will utilize a binomial probability test to assess compliance against our known compliance of 50%.~Questionnaire is noted here:~Confidential Page 1 of 1 Kurbo Survey [baseline_arm_1][name], DOB [baseline_arm_1][dob] Please complete the survey below. Thank you! Group Allocation __________________________________ Who is completing this survey? Child / Patient Parent / Guardian Over the last month, abou" (NCT02880254)
Timeframe: 3 months
| Intervention | percent compliant (Number) | |
|---|---|---|
| compliance with food tracking | compliance with exercise tracking | |
| Kurbo Only | 0 | 0 |
| Kurbo Plus PHC | 14 | 7 |
183 reviews available for sibutramine and Obesity
| Article | Year |
|---|---|
Treatment options for children with monogenic forms of obesity.
Topics: Bariatric Surgery; Body Mass Index; Body Weight; Child; Cyclobutanes; Energy Metabolism; Heterozygot | 2013 |
Food ingredients as anti-obesity agents: a review.
Topics: Anti-Obesity Agents; Calcium, Dietary; Cyclobutanes; Diet; Dietary Fiber; Energy Metabolism; Exercis | 2013 |
Obesity drug therapy.
Topics: Anti-Obesity Agents; Appetite; Combined Modality Therapy; Comorbidity; Cost-Benefit Analysis; Cyclob | 2013 |
Pharmacotherapy for obesity in menopausal women.
Topics: Anti-Obesity Agents; Bariatric Surgery; Cyclobutanes; Diabetes Mellitus, Type 2; Exenatide; Female; | 2008 |
Sibutramine: current status as an anti-obesity drug and its future perspectives.
Topics: Adult; Appetite Depressants; Cyclobutanes; Humans; Obesity; Weight Loss | 2008 |
Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review.
Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Cost-Benefit Analysis; Cyclobutanes; Eur | 2008 |
Pharmacotherapy for eating disorders and obesity.
Topics: Adolescent; Anorexia Nervosa; Anticonvulsants; Antipsychotic Agents; Appetite Depressants; Behavior | 2009 |
Current pharmacotherapeutic concepts for the treatment of obesity in adults.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Combined Modality Therapy; Cyclobutanes; Enzyme In | 2009 |
Recent advances in obesity pharmacotherapy.
Topics: Animals; Anti-Obesity Agents; Cardiovascular Diseases; Cyclobutanes; Humans; Lactones; Obesity; Orli | 2009 |
[Association of obesity and depression].
Topics: Anti-Obesity Agents; Antidepressive Agents; Appetite Depressants; Appetite Regulation; Bipolar Disor | 2008 |
Effect of antiobesity medications in patients with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Body Weight; Cyclobutanes; Diabe | 2009 |
Can sibutramine alter systemic blood pressure in obese patients? Systematic review and meta-analysis.
Topics: Appetite Depressants; Blood Pressure; Cyclobutanes; Humans; Obesity; Randomized Controlled Trials as | 2008 |
Effectiveness of weight management programs in children and adolescents.
Topics: Adolescent; Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Behavior Therapy; Child; C | 2008 |
The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions.
Topics: Adolescent; Adult; Anti-Obesity Agents; Appetite Depressants; Clinical Trials as Topic; Cyclobutanes | 2009 |
The use of sibutramine in the management of obesity and related disorders: an update.
Topics: Adult; Appetite Depressants; Biomarkers; Blood Glucose; Cardiovascular Diseases; Child; Cyclobutanes | 2009 |
Efficacy of weight loss drugs on obesity and cardiovascular risk factors in obese adolescents: a meta-analysis of randomized controlled trials.
Topics: Adolescent; Anti-Obesity Agents; Cardiovascular Diseases; Cyclobutanes; Humans; Lactones; Lipids; Ob | 2010 |
Pharmacotherapy in pediatric obesity: current agents and future directions.
Topics: Anti-Obesity Agents; Child; Cyclobutanes; Drug Therapy; Humans; Metformin; Obesity | 2009 |
What are the risks and the benefits of current and emerging weight-loss medications?
Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Weight Loss | 2009 |
Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis.
Topics: Adolescent; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Child; Cognitive Behavioral | 2010 |
Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis.
Topics: Adolescent; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Child; Cognitive Behavioral | 2010 |
Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis.
Topics: Adolescent; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Child; Cognitive Behavioral | 2010 |
Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis.
Topics: Adolescent; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Child; Cognitive Behavioral | 2010 |
Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.
Topics: Adult; Anti-Obesity Agents; Blood Pressure; Cyclobutanes; Diabetes Mellitus, Type 2; Humans; Lactone | 2010 |
Effectiveness of weight management interventions in children: a targeted systematic review for the USPSTF.
Topics: Adolescent; Appetite Depressants; Behavior Therapy; Child; Child, Preschool; Counseling; Cyclobutane | 2010 |
Effectiveness of weight management interventions in children: a targeted systematic review for the USPSTF.
Topics: Adolescent; Appetite Depressants; Behavior Therapy; Child; Child, Preschool; Counseling; Cyclobutane | 2010 |
Effectiveness of weight management interventions in children: a targeted systematic review for the USPSTF.
Topics: Adolescent; Appetite Depressants; Behavior Therapy; Child; Child, Preschool; Counseling; Cyclobutane | 2010 |
Effectiveness of weight management interventions in children: a targeted systematic review for the USPSTF.
Topics: Adolescent; Appetite Depressants; Behavior Therapy; Child; Child, Preschool; Counseling; Cyclobutane | 2010 |
Effectiveness of weight management interventions in children: a targeted systematic review for the USPSTF.
Topics: Adolescent; Appetite Depressants; Behavior Therapy; Child; Child, Preschool; Counseling; Cyclobutane | 2010 |
Effectiveness of weight management interventions in children: a targeted systematic review for the USPSTF.
Topics: Adolescent; Appetite Depressants; Behavior Therapy; Child; Child, Preschool; Counseling; Cyclobutane | 2010 |
Effectiveness of weight management interventions in children: a targeted systematic review for the USPSTF.
Topics: Adolescent; Appetite Depressants; Behavior Therapy; Child; Child, Preschool; Counseling; Cyclobutane | 2010 |
Effectiveness of weight management interventions in children: a targeted systematic review for the USPSTF.
Topics: Adolescent; Appetite Depressants; Behavior Therapy; Child; Child, Preschool; Counseling; Cyclobutane | 2010 |
Effectiveness of weight management interventions in children: a targeted systematic review for the USPSTF.
Topics: Adolescent; Appetite Depressants; Behavior Therapy; Child; Child, Preschool; Counseling; Cyclobutane | 2010 |
Pharmacologic therapies for obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Cyclobutanes; | 2010 |
Office-based strategies for the management of obesity.
Topics: Adult; Anti-Obesity Agents; Bariatric Surgery; Body Mass Index; Child; Counseling; Cyclobutanes; Die | 2010 |
[Sibutramine and its adequate usage].
Topics: Appetite Depressants; Cyclobutanes; Humans; Metabolic Syndrome; Obesity | 2011 |
[Pharmacological concepts for the treatment of obesity - a therapeutic meander?].
Topics: Adverse Drug Reaction Reporting Systems; Appetite Depressants; Body Weight; Brain; Combined Modality | 2011 |
Is there a path for approval of an antiobesity drug: what did the Sibutramine Cardiovascular Outcomes Trial find?
Topics: Advisory Committees; Anti-Obesity Agents; Cardiovascular Diseases; Clinical Trials as Topic; Cyclobu | 2011 |
A systematic review and mixed treatment comparison of pharmacological interventions for the treatment of obesity.
Topics: Anti-Obesity Agents; Body Mass Index; Cyclobutanes; Humans; Lactones; Life Style; Obesity; Orlistat; | 2012 |
[The obesity and way for treatment].
Topics: Adult; Appetite Depressants; Child; Cyclobutanes; Health Education; Humans; Life Style; Obesity | 2011 |
What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.
Topics: Anti-Obesity Agents; Cost-Benefit Analysis; Cyclobutanes; Drug Costs; Exercise; Female; Humans; Lact | 2012 |
[The pharmacological treatment of obesity: past, present and future].
Topics: Amides; Anti-Obesity Agents; Anticonvulsants; Antidepressive Agents; Basal Metabolism; Benzazepines; | 2012 |
Obesity and diabetes.
Topics: Animals; Cyclobutanes; Diabetes Mellitus; Female; Humans; Incretins; Insulin; Lactones; Male; Metfor | 2012 |
An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action.
Topics: Anti-Obesity Agents; Biogenic Monoamines; Cyclobutanes; Eating; Energy Metabolism; Humans; Obesity; | 2000 |
Options for pharmacological management of obesity in patients treated with atypical antipsychotics.
Topics: Amantadine; Antipsychotic Agents; Cimetidine; Cyclobutanes; Fluoxetine; Fructose; Humans; Lactones; | 2002 |
Add-on combination and maintenance treatment: case series of five obese patients with different eating behavior.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Chemotherapy, Adjuvant; Cyclobutanes; Feeding Beha | 2002 |
Sibutramine lost and found.
Topics: Antidepressive Agents; Appetite Depressants; Cyclobutanes; Female; Humans; Italy; Obesity; Quality o | 2002 |
Sibutramine: its mode of action and efficacy.
Topics: Appetite Depressants; Cyclobutanes; Energy Metabolism; Humans; Obesity; Prognosis; Weight Loss | 2002 |
Metabolic benefits associated with sibutramine therapy.
Topics: Adipose Tissue; Appetite Depressants; Cyclobutanes; Diabetes Mellitus; Humans; Lipids; Obesity; Weig | 2002 |
Obesity, cardiovascular risk and pharmacotherapy.
Topics: Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Humans; Lactones; | 2002 |
Pharmacotherapy of obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; History, 20th Ce | 2002 |
The new role of pharmacotherapy for weight reduction in obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Life Style; Obesity; Orli | 2002 |
Pharmacological management of obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Humans; Lactones; | 2002 |
New pharmacological tools for obesity.
Topics: Animals; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Drug Industry; Humans; Lactones; O | 2002 |
New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
Topics: Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Clinical Trials as Topic; Controlled Clini | 2002 |
Weight management and current options in pharmacotherapy: orlistat and sibutramine.
Topics: Anti-Obesity Agents; Body Mass Index; Cyclobutanes; Dose-Response Relationship, Drug; Drug Interacti | 2003 |
Medical management of obesity: a clinical imperative?
Topics: Anti-Obesity Agents; Cyclobutanes; Diabetes Mellitus, Type 2; Diet; Exercise; Humans; Lactones; Life | 2003 |
[Weight loss via drug therapy].
Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Clinical Trials as Topic; Combined Modal | 2003 |
Pharmacological therapy of obesity: past, present, and future.
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Endocrinology; Humans; Lactones; Obesity; O | 2003 |
Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials.
Topics: Adult; Appetite Depressants; Blood Pressure; Cyclobutanes; Dose-Response Relationship, Drug; Double- | 2003 |
Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials.
Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Randomized Controlled Trials | 2003 |
Use of sibutramine to treat obesity.
Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Obesity; Randomized Controlled Trials as Topic | 2003 |
A benefit-risk assessment of sibutramine in the management of obesity.
Topics: Animals; Appetite Depressants; Cyclobutanes; Dose-Response Relationship, Drug; Humans; Obesity; Rand | 2003 |
Long-term pharmacotherapy for obesity and overweight.
Topics: Anti-Obesity Agents; Appetite Depressants; Body Weight; Cyclobutanes; Humans; Lactones; Obesity; Orl | 2003 |
[New therapeutic options in obesity].
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Clinical Trials as Topic; Cyclobu | 2003 |
[Effectiveness of therapeutic interventions in obesity].
Topics: Behavior Therapy; Combined Modality Therapy; Cross-Sectional Studies; Cyclobutanes; Diet, Reducing; | 2003 |
Obesity and pharmacologic therapy.
Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Weight Loss | 2003 |
Obesity and pharmacologic therapy.
Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Weight Loss | 2003 |
Obesity and pharmacologic therapy.
Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Weight Loss | 2003 |
Obesity and pharmacologic therapy.
Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Weight Loss | 2003 |
Obesity and pharmacologic therapy.
Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Weight Loss | 2003 |
Obesity and pharmacologic therapy.
Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Weight Loss | 2003 |
Obesity and pharmacologic therapy.
Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Weight Loss | 2003 |
Obesity and pharmacologic therapy.
Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Weight Loss | 2003 |
Obesity and pharmacologic therapy.
Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Weight Loss | 2003 |
Obesity management in patients with type 2 diabetes mellitus.
Topics: Cyclobutanes; Diabetes Mellitus, Type 2; Diet Therapy; Exercise; Gastric Bypass; Humans; Obesity; We | 2004 |
What role for weight-loss medication? Weighing the pros and cons for obese patients.
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Life Style; Obesity; Orli | 2004 |
Clinical use of sibutramine.
Topics: Chronic Disease; Clinical Trials as Topic; Contraindications; Cyclobutanes; Female; Humans; Hyperten | 2004 |
Sibutramine and the management of obesity.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Appetite Depressants; Cardiovascular System; Clinical Tria | 2004 |
The efficacy and safety of sibutramine for weight loss: a systematic review.
Topics: Appetite Depressants; Blood Pressure; Cyclobutanes; Heart Rate; Humans; Obesity; Randomized Controll | 2004 |
Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.
Topics: Anti-Obesity Agents; Behavior Therapy; Caloric Restriction; Cost-Benefit Analysis; Cyclobutanes; Die | 2004 |
[Sibutramine in treatment of obesity. Therapeutic premises in patients with essential hypertension, diabetes, hyperlipidemia].
Topics: Animals; Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Developed Countries; Diabetes | 2004 |
Long-term pharmacotherapy for obesity and overweight.
Topics: Anti-Obesity Agents; Appetite Depressants; Body Weight; Cyclobutanes; Humans; Lactones; Obesity; Orl | 2004 |
[Pharmacotherapy of obesity].
Topics: Appetite Depressants; Body Weight; Clinical Trials as Topic; Cyclobutanes; Diabetes Mellitus; Humans | 2004 |
Clinical pharmacotherapy for obesity: current drugs and those in advanced development.
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Energy Metabolism; Feeding Behavior; Fructo | 2004 |
Pharmacological and surgical treatment of obesity.
Topics: Adult; Appetite Depressants; Bupropion; Cyclobutanes; Diethylpropion; Fluoxetine; Fructose; Gastric | 2004 |
A perspective on the current strategies for the treatment of obesity.
Topics: Anti-Obesity Agents; Bariatrics; Chromium; Citrates; Cyclobutanes; Energy Intake; Ephedrine; Exercis | 2004 |
Obesity.
Topics: Adult; Appetite Depressants; Cyclobutanes; Diethylpropion; Fluoxetine; Humans; Lactones; Mazindol; O | 2003 |
Modern, new pharmacotherapy for obesity. A gastrointestinal approach.
Topics: Amylases; Androgens; Anti-Obesity Agents; Citrates; Cyclobutanes; Dietary Fats; Fat Substitutes; Fat | 2004 |
Medical management of obesity in women: office-based approaches to weight management.
Topics: Appetite Depressants; Body Mass Index; Cyclobutanes; Exercise; Female; Humans; Lactones; Obesity; Or | 2004 |
Obesity.
Topics: Adult; Appetite Depressants; Cyclobutanes; Diethylpropion; Fluoxetine; Humans; Lactones; Mazindol; O | 2004 |
Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Fluoxetin | 2005 |
Long-term pharmacotherapy for obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Random | 2004 |
Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity.
Topics: Animals; Anti-Obesity Agents; Appetite; Cyclobutanes; Eating; Humans; Neuropeptides; Nutritional Sta | 2005 |
A review of the metabolic effects of sibutramine.
Topics: Appetite Depressants; Blood Glucose; Cholesterol; Cyclobutanes; Diabetes Mellitus, Type 2; Glycated | 2005 |
Pharmacological treatments for obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Leptin; Obesity; Orlistat | 2005 |
Clinical evidence for drug treatments in obesity-associated hypertensive patients--a discussion paper.
Topics: Anti-Obesity Agents; Antihypertensive Agents; Appetite Depressants; Cyclobutanes; Humans; Hypertensi | 2005 |
Obesity and cardiovascular physiology: impact of some pharmacological agents.
Topics: Animals; Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Cardiovascular Physiolo | 2005 |
Managing type 2 diabetes mellitus in patients with obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Cyclobutanes; Diabetes Mellitus, Type 2; D | 2004 |
[Obesity and metabolic syndrome: clinical and therapeutic review].
Topics: Appetite Depressants; Body Mass Index; Body Weight; Cardiovascular Diseases; Cyclobutanes; Exercise; | 2005 |
Obesity.
Topics: Adult; Appetite Depressants; Cyclobutanes; Diethylpropion; Fluoxetine; Gastric Bypass; Gastroplasty; | 2005 |
Childhood obesity. Treatment options.
Topics: Adolescent; Anti-Obesity Agents; Behavior Therapy; Child; Child Behavior; Cyclobutanes; Diet, Reduci | 2005 |
Pharmacologic agents for the treatment of obesity.
Topics: Aged; Amphetamines; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Obesi | 2005 |
Pharmacotherapy for obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Cost of Illness; Cyclobutanes; Feeding Behavior; Humans; | 2006 |
New drug policy in childhood obesity.
Topics: Adolescent; Anti-Obesity Agents; Appetite Depressants; Child; Cyclobutanes; Drugs, Investigational; | 2005 |
[Drug treatment of obesity].
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diethylpropion; Enzyme Inhibitors; Humans; | 2006 |
Pharmacologic treatment of obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Fructose; Humans; Isoxazoles; Lactones; Obe | 2006 |
Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Combined Modality Therapy; Cyclobutanes; Diabetes | 2006 |
Pharmacotherapy to reduce visceral fat.
Topics: Anti-Obesity Agents; Coronary Disease; Cyclobutanes; Exercise; Feeding Behavior; Humans; Intra-Abdom | 2005 |
Clinical trial issues in weight-loss therapy.
Topics: Anti-Obesity Agents; Behavior Therapy; Cardiovascular Diseases; Clinical Trials as Topic; Comorbidit | 2006 |
[Pharmacotherapy in the treatment of obesity].
Topics: Anti-Obesity Agents; Appetite Depressants; Cannabinoid Receptor Antagonists; Clinical Trials as Topi | 2006 |
Central nervous system biogenic amine targets for control of appetite and energy expenditure.
Topics: Anti-Obesity Agents; Appetite; Appetite Depressants; Biogenic Amines; Central Nervous System; Cyclob | 2006 |
The obesity epidemic and its cardiovascular consequences.
Topics: Appetite Depressants; Body Fat Distribution; Body Mass Index; Cardiovascular Diseases; Cyclobutanes; | 2006 |
Pharmacological treatment of obesity.
Topics: Amphetamines; Anti-Obesity Agents; Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Ene | 2006 |
Weight loss medications--where do they fit in?
Topics: Anti-Obesity Agents; Chronic Disease; Cyclobutanes; Diethylpropion; Humans; Lactones; Obesity; Orlis | 2006 |
Emerging pharmacotherapy for treating obesity and associated cardiometabolic risk.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Pip | 2006 |
Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors.
Topics: Caloric Restriction; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus; Diet; Diet, Fat-Restr | 2006 |
Current and novel approaches to the drug therapy of obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Models, Biological; Obesi | 2006 |
Pharmacologic treatment for obesity. Options for today...and tomorrow.
Topics: Anti-Obesity Agents; Clinical Trials as Topic; Cyclobutanes; Drug Therapy, Combination; Humans; Lact | 2006 |
The obesity epidemic: current and future pharmacological treatments.
Topics: Anti-Obesity Agents; Cyclobutanes; Disease Outbreaks; Drug Design; Drugs, Investigational; Humans; L | 2007 |
Medical strategies for weight loss in the overweight and obese patient.
Topics: Anti-Obesity Agents; Appetite Depressants; Behavior Therapy; Body Mass Index; Cyclobutanes; Exercise | 2006 |
Sibutramine for obesity in adolescents.
Topics: Adolescent; Appetite Depressants; Body Mass Index; Clinical Trials as Topic; Cyclobutanes; Female; H | 2006 |
Pharmacotherapy of obesity.
Topics: Anti-Obesity Agents; Clinical Trials as Topic; Cyclobutanes; Drug Design; Energy Metabolism; Homeost | 2006 |
Metabolic syndrome treatment strategies.
Topics: Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Exercise; Humans; Metabolic Syndrome; O | 2006 |
Serotonin and norepinephrine reuptake inhibition and eating behavior.
Topics: Abdominal Fat; Antidepressive Agents; Appetite Depressants; Body Weight; Cyclobutanes; Depression; E | 2006 |
Drug treatments for obesity: orlistat, sibutramine, and rimonabant.
Topics: Anti-Obesity Agents; Blood Pressure; Cholesterol, HDL; Cyclobutanes; Half-Life; Humans; Lactones; Ob | 2007 |
[Pharmacotherapy of obesity].
Topics: Anti-Obesity Agents; Anticonvulsants; Cyclobutanes; Fructose; Humans; Lactones; Obesity; Orlistat; P | 2006 |
Currently available drugs for the treatment of obesity: Sibutramine and orlistat.
Topics: Anti-Obesity Agents; Body Weight; Cyclobutanes; Energy Metabolism; Exercise; Humans; Lactones; Obesi | 2007 |
Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction.
Topics: Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Cyclobutanes; Diabet | 2007 |
Therapeutic options for modifying cardiometabolic risk factors.
Topics: Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Humans; Hypoglycem | 2007 |
[Childhood obesity. Recommendations of the Nutrition Committee of the Spanish Association of Pediatrics. Part II. Diagnosis. Comorbidities. Treatment].
Topics: Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Child; Combined Modality Therapy | 2007 |
[New therapeutic aspects for the control of risk factors in obesity].
Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimo | 2007 |
Drug treatment of the overweight patient.
Topics: Animals; Anti-Obesity Agents; Clinical Trials, Phase II as Topic; Cyclobutanes; Humans; Lactones; Ob | 2007 |
Pharmacogenomics and serotonergic agents: research observations and potential clinical practice implications.
Topics: Appetite Depressants; Carbolines; Cyclobutanes; Dyspepsia; Gastrointestinal Agents; Genetic Variatio | 2007 |
Pharmacotherapeutic options for overweight adolescents.
Topics: Adolescent; Anti-Obesity Agents; Clinical Trials as Topic; Cyclobutanes; Humans; Hypoglycemic Agents | 2007 |
Obesity.
Topics: Appetite Depressants; Bariatric Surgery; Behavior Therapy; Body Mass Index; Body Weight; Chronic Dis | 2006 |
Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant.
Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Life Style; Obesity; Orlistat; Piperidines; Pyr | 2007 |
Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up.
Topics: Adult; Anti-Obesity Agents; Combined Modality Therapy; Cyclobutanes; Diet, Reducing; Exercise; Femal | 2007 |
Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up.
Topics: Adult; Anti-Obesity Agents; Combined Modality Therapy; Cyclobutanes; Diet, Reducing; Exercise; Femal | 2007 |
Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up.
Topics: Adult; Anti-Obesity Agents; Combined Modality Therapy; Cyclobutanes; Diet, Reducing; Exercise; Femal | 2007 |
Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up.
Topics: Adult; Anti-Obesity Agents; Combined Modality Therapy; Cyclobutanes; Diet, Reducing; Exercise; Femal | 2007 |
Orlistat and sibutramine beyond weight loss.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Humans; Hyp | 2008 |
The development of tolerance to drugs that suppress food intake.
Topics: Animals; Appetite Depressants; Body Weight; Cyclobutanes; Drug Tolerance; Eating; Fenfluramine; Huma | 2008 |
[Obesity: a review of currently used antiobesity drugs and new compounds in clinical development].
Topics: Anti-Obesity Agents; Clinical Trials as Topic; Cyclobutanes; Humans; Lactones; Neurotransmitter Agen | 2007 |
[Obesity in adults].
Topics: Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Body Mass Index; Cyclobut | 2007 |
Strategies to reduce vascular risk associated with obesity.
Topics: Adiponectin; Anti-Obesity Agents; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus, Type 2; | 2007 |
Sibutramine-associated adverse effects: a practical guide for its safe use.
Topics: Appetite Depressants; Cyclobutanes; Heart Rate; Humans; Hypertension; Obesity; Risk Assessment; Safe | 2008 |
[Pharmacotherapy of obesity].
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Piperi | 2008 |
Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and meta-analysis.
Topics: Anti-Obesity Agents; Cyclobutanes; Female; Humans; Lactones; Male; Obesity; Orlistat; Randomized Con | 2008 |
Obesity: a review of pathogenesis and management strategies.
Topics: Anti-Obesity Agents; Bariatric Surgery; Behavior Therapy; Caloric Restriction; Cyclobutanes; Dietary | 2008 |
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Baria | 2008 |
Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis.
Topics: Appetite Depressants; Blood Pressure; Cyclobutanes; Humans; Hypertension; Lactones; Obesity; Orlista | 2008 |
Pharmacotherapy for obesity.
Topics: Amyloid; Anti-Obesity Agents; Appetite Depressants; Body Weight; Chronic Disease; Comorbidity; Cyclo | 2007 |
Sibutramine: a novel new agent for obesity treatment.
Topics: Adolescent; Adult; Aged; Animals; Appetite Depressants; Cyclobutanes; Female; Humans; Male; Middle A | 1995 |
Sibutramine: a review of the pharmacology of a novel anti-obesity agent.
Topics: Adipose Tissue, Brown; Animals; Anti-Obesity Agents; Antidepressive Agents; Body Temperature Regulat | 1997 |
Sibutramine--a review of clinical efficacy.
Topics: Anti-Obesity Agents; Antidepressive Agents; Appetite Depressants; Body Weight; Cardiovascular Physio | 1997 |
The pharmacologic approach to the treatment of obesity.
Topics: Adrenergic beta-Agonists; Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Energy Metabo | 1997 |
Challenges in obesity management.
Topics: 1-Naphthylamine; Adrenergic beta-Agonists; Appetite Depressants; Behavior Therapy; Caffeine; Cyclobu | 1998 |
The cost implications of obesity for health care and society.
Topics: Appetite Depressants; Body Mass Index; Clinical Trials as Topic; Cyclobutanes; Health Care Costs; Hu | 1998 |
Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine.
Topics: Animals; Biogenic Monoamines; Cyclobutanes; Dextroamphetamine; Energy Metabolism; Fenfluramine; Huma | 1998 |
Sibutramine and energy balance.
Topics: Adrenal Glands; Cyclobutanes; Energy Metabolism; Humans; Obesity; Selective Serotonin Reuptake Inhib | 1998 |
Pharmacological intervention: the antiobesity approach.
Topics: Appetite Depressants; Blood Glucose; Controlled Clinical Trials as Topic; Cyclobutanes; Dexfenfluram | 1998 |
Modern medical management of obesity: the role of pharmaceutical intervention.
Topics: Appetite Depressants; Chronic Disease; Cyclobutanes; Enzyme Inhibitors; Humans; Lactones; Lipase; Ob | 1998 |
What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice.
Topics: Adrenergic beta-Agonists; Animals; Appetite Depressants; Caffeine; Central Nervous System Stimulants | 1998 |
Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment.
Topics: Adipose Tissue; Appetite Depressants; Blood Glucose; Blood Pressure; Cyclobutanes; Dexfenfluramine; | 1998 |
Sibutramine. A review of its contribution to the management of obesity.
Topics: Animals; Appetite Depressants; Controlled Clinical Trials as Topic; Cyclobutanes; Energy Intake; Fem | 1998 |
[Sibutramine, an upcoming drug for weight loss acting on energy consumption and energy expenditure].
Topics: Appetite; Appetite Depressants; Body Temperature Regulation; Clinical Trials as Topic; Cyclobutanes; | 1998 |
[What is the role of drugs in therapy of obesity?].
Topics: Appetite Depressants; Cyclobutanes; Enzyme Inhibitors; Humans; Lactones; Obesity; Orlistat; Treatmen | 1998 |
Cutting fat absorption to halt weight gain.
Topics: Anti-Obesity Agents; Cyclobutanes; Diet, Fat-Restricted; Family Practice; Humans; Intestinal Absorpt | 1998 |
Obesity and type 2 diabetes: a conflict of interests?
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Complications; Diabetes Mellitus; | 1999 |
Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity.
Topics: Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Humans; Neurotransmitter Uptake Inhibi | 1999 |
[New treatments for obesity].
Topics: Amphetamines; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Enzyme Inhibitors; Humans; La | 1999 |
Nonpharmacologic and pharmacologic management of weight gain.
Topics: Anti-Obesity Agents; Appetite Depressants; Behavior Therapy; Cyclobutanes; Diet, Reducing; Energy In | 1999 |
Safe and effective management of the obese patient.
Topics: Anti-Obesity Agents; Appetite Depressants; Cognitive Behavioral Therapy; Cyclobutanes; Exercise; Gas | 1999 |
The use of pharmacologic agents in the treatment of the obese patient.
Topics: Anti-Obesity Agents; Body Mass Index; Cyclobutanes; Female; Follow-Up Studies; Humans; Lactones; Mal | 1999 |
[Drug therapy of obesity. Strategies for general practice].
Topics: Appetite Depressants; Combined Modality Therapy; Contraindications; Cyclobutanes; Family Practice; H | 2000 |
Managing obesity like any other chronic condition. Long-term therapy may reduce comorbidity as well.
Topics: Anti-Obesity Agents; Appetite Depressants; Chronic Disease; Contraindications; Cyclobutanes; Humans; | 2000 |
Medical management of obesity.
Topics: Algorithms; Anti-Obesity Agents; Appetite Depressants; Basal Metabolism; Body Mass Index; Cyclobutan | 2000 |
[The obesity epidemics--do diet pills have a place in the treatment?].
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Fenfluramine; Humans; Lactones; Leptin; Obe | 2000 |
[Obesity: principles of drug therapy].
Topics: Aminorex; Anti-Obesity Agents; Appetite Depressants; Chronic Disease; Combined Modality Therapy; Cyc | 2000 |
Does drug therapy of obesity have a future?
Topics: Animals; Appetite Depressants; Cyclobutanes; Humans; Leptin; Mice; Mice, Obese; Obesity; Weight Loss | 2000 |
How to help your patients lose weight: current therapy for obesity.
Topics: Anti-Obesity Agents; Antidepressive Agents; Appetite Depressants; Behavior Therapy; Chronic Disease; | 2000 |
[SEEDO'2000 consensus for the evaluation of overweight and obesity and the establishment of criteria for therapeutic intervention. Sociedad Española para el Estudio de la Obesidad].
Topics: Adolescent; Adult; Age Factors; Aged; Anti-Obesity Agents; Appetite Depressants; Biliopancreatic Div | 2000 |
Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity.
Topics: Adrenergic Agents; Appetite Depressants; Cyclobutanes; Dexfenfluramine; Dextroamphetamine; Fenfluram | 2000 |
Thermogenic drugs as a strategy for treatment of obesity.
Topics: Adrenal Glands; Anti-Obesity Agents; Caffeine; Cyclobutanes; Energy Metabolism; Ephedrine; Humans; L | 2000 |
5-HT2C receptor modulation and the treatment of obesity.
Topics: Animals; Appetite Depressants; Cyclobutanes; Disease Models, Animal; Fenfluramine; Humans; Obesity; | 1999 |
Treating obesity: a new target for prevention of coronary heart disease.
Topics: Anti-Obesity Agents; Coronary Disease; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Randomized | 2001 |
Current pharmacological approaches to the treatment of obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Humans; Hyperlip | 2001 |
Obesity: a rational target for managing diabetes mellitus.
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Humans; Lactones | 2001 |
Epidemiology, morbidity, and treatment of overweight and obesity.
Topics: Adult; Aged; Antipsychotic Agents; Appetite Depressants; Body Height; Body Mass Index; Body Weight; | 2001 |
Obesity: a new paradigm in endocrinology.
Topics: Adipose Tissue; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Endocrinology; Humans; Lact | 2001 |
The advances on the knowledge base of obesity and future therapeutic directions.
Topics: Anti-Obesity Agents; Cyclobutanes; Energy Metabolism; Humans; Lactones; Neuropeptides; Obesity; Orli | 2001 |
American College of Sports Medicine position stand. Appropriate intervention strategies for weight loss and prevention of weight regain for adults.
Topics: Adult; Body Mass Index; Cyclobutanes; Diet Therapy; Dietary Fats; Energy Intake; Exercise Therapy; H | 2001 |
American College of Sports Medicine position stand. Appropriate intervention strategies for weight loss and prevention of weight regain for adults.
Topics: Adult; Body Mass Index; Cyclobutanes; Diet Therapy; Dietary Fats; Energy Intake; Exercise Therapy; H | 2001 |
American College of Sports Medicine position stand. Appropriate intervention strategies for weight loss and prevention of weight regain for adults.
Topics: Adult; Body Mass Index; Cyclobutanes; Diet Therapy; Dietary Fats; Energy Intake; Exercise Therapy; H | 2001 |
American College of Sports Medicine position stand. Appropriate intervention strategies for weight loss and prevention of weight regain for adults.
Topics: Adult; Body Mass Index; Cyclobutanes; Diet Therapy; Dietary Fats; Energy Intake; Exercise Therapy; H | 2001 |
Current methods used for defining, measuring, and treating obesity.
Topics: Absorptiometry, Photon; Anti-Obesity Agents; Body Composition; Body Constitution; Body Mass Index; C | 2001 |
Is sibutramine more than a slim hope?
Topics: Adult; Appetite Depressants; Chemotherapy, Adjuvant; Cyclobutanes; Diabetes Mellitus, Type 2; Diet, | 2001 |
Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials.
Topics: Amphetamines; Anti-Obesity Agents; Benzphetamine; Cyclobutanes; Fenfluramine; Humans; Obesity; Rando | 2002 |
Sibutramine in clinical practice.
Topics: Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Humans; Obesity; Practice Patterns, Ph | 2001 |
When, for whom and how to use sibutramine?
Topics: Adolescent; Adult; Aged; Appetite Depressants; Cyclobutanes; Drug Approval; Europe; Female; Humans; | 2001 |
Sibutramine in overweight/obese hypertensive patients.
Topics: Appetite Depressants; Blood Pressure; Cyclobutanes; Heart Rate; Humans; Hypertension; Obesity | 2001 |
The importance of obesity in diabetes and its treatment with sibutramine.
Topics: Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Obesity; | 2001 |
The role of sibutramine in weight management--towards a blueprint for a sibutramine weight management system.
Topics: Appetite Depressants; Cyclobutanes; Diet; Disease Management; Exercise; Humans; Obesity | 2001 |
How does sibutramine work?
Topics: Appetite Depressants; Cyclobutanes; Dose-Response Relationship, Drug; Energy Intake; Energy Metaboli | 2001 |
The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment.
Topics: Appetite Depressants; Cost-Benefit Analysis; Cyclobutanes; Humans; Obesity; Quality-Adjusted Life Ye | 2002 |
The discovery and status of sibutramine as an anti-obesity drug.
Topics: Animals; Anti-Obesity Agents; Appetite Depressants; Body Weight; Clinical Trials as Topic; Cyclobuta | 2002 |
Combining behavioral and pharmacological treatments for obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Behavior Therapy; Combined Modality Therapy; Cyclobutanes | 2002 |
[Weight reduction. Antiobesity drug treatment in type-2 diabetics].
Topics: Animals; Anti-Obesity Agents; Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Diabetes | 2002 |
168 trials available for sibutramine and Obesity
| Article | Year |
|---|---|
Metabolic and Inflammatory Changes with Orlistat and Sibutramine Treatment in Obese Malaysian Subjects.
Topics: Adiponectin; Adolescent; Adult; Aged; Asian People; Blood Glucose; Body Fat Distribution; Body Mass | 2017 |
Body Weight Reduction Associated with the Sibutramine Treatment: Overall Results of the PRIMAVERA Primary Health Care Trial.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Pressure; Body Weight; Cyclobutanes; Female; | 2018 |
Association of anemia with the risk of cardiovascular adverse events in overweight/obese patients.
Topics: Anemia; Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Cyclobutanes; Double-Blind Me | 2014 |
The effects of anti-obesity intervention with orlistat and sibutramine on microvascular endothelial function.
Topics: Adolescent; Adult; Aged; Anthropometry; Anti-Obesity Agents; Blood Pressure; Cholesterol; Cyclobutan | 2015 |
Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial.
Topics: Aged; Cardiovascular Diseases; Clinical Protocols; Cyclobutanes; Diabetes Mellitus, Type 2; Female; | 2013 |
A comparative study of five centrally acting drugs on the pharmacological treatment of obesity.
Topics: Adult; Amphetamines; Anti-Obesity Agents; Body Mass Index; Brazil; Cyclobutanes; Diet, Reducing; Die | 2014 |
Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease.
Topics: Appetite Depressants; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Cyclobutanes; Diabet | 2014 |
Influence of eating behaviors on short-term weight loss by orlistat and anorectic agent.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Double-Blind Method; Drug Therapy, C | 2014 |
Treatment of binge eating disorder in racially and ethnically diverse obese patients in primary care: randomized placebo-controlled clinical trial of self-help and medication.
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Binge-Eating Disorder; Black or African American; Body | 2014 |
Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial.
Topics: Aged; Appetite Depressants; Body Mass Index; Cardiovascular Diseases; Cyclobutanes; Diabetic Angiopa | 2015 |
Predicting meaningful outcomes to medication and self-help treatments for binge-eating disorder in primary care: The significance of early rapid response.
Topics: Adult; Anti-Obesity Agents; Binge-Eating Disorder; Cognitive Behavioral Therapy; Combined Modality T | 2015 |
Predicting meaningful outcomes to medication and self-help treatments for binge-eating disorder in primary care: The significance of early rapid response.
Topics: Adult; Anti-Obesity Agents; Binge-Eating Disorder; Cognitive Behavioral Therapy; Combined Modality T | 2015 |
Predicting meaningful outcomes to medication and self-help treatments for binge-eating disorder in primary care: The significance of early rapid response.
Topics: Adult; Anti-Obesity Agents; Binge-Eating Disorder; Cognitive Behavioral Therapy; Combined Modality T | 2015 |
Predicting meaningful outcomes to medication and self-help treatments for binge-eating disorder in primary care: The significance of early rapid response.
Topics: Adult; Anti-Obesity Agents; Binge-Eating Disorder; Cognitive Behavioral Therapy; Combined Modality T | 2015 |
Exposure-response model for sibutramine and placebo: suggestion for application to long-term weight-control drug development.
Topics: Adult; Anti-Obesity Agents; Cyclobutanes; Double-Blind Method; Female; Humans; Male; Middle Aged; No | 2015 |
Influence of sibutramine in addition to diet and exercise on the relationship between weight loss and blood glucose changes.
Topics: Appetite Depressants; Blood Glucose; Cyclobutanes; Diabetes Mellitus; Diet; Dose-Response Relationsh | 2017 |
Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients.
Topics: Adult; Antihypertensive Agents; Appetite Depressants; Blood Pressure; Body Weights and Measures; C-R | 2008 |
Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
Topics: Appetite Depressants; Blood Pressure; Cyclobutanes; Diabetes Mellitus, Type 2; Diabetic Angiopathies | 2009 |
A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults.
Topics: Adult; Appetite Depressants; Body Composition; Cyclobutanes; Feeding Behavior; Female; Gastric Empty | 2008 |
The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women.
Topics: Adult; Appetite Depressants; Cross-Over Studies; Cyclobutanes; Dose-Response Relationship, Drug; Dou | 2010 |
Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Topics: Appetite Depressants; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol, HDL; Cyclobutanes | 2008 |
Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial.
Topics: Appetite Depressants; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Cyclobutanes; Diabet | 2008 |
Changes in symptoms of depression with weight loss: results of a randomized trial.
Topics: Adult; Affect; Appetite Depressants; Behavior Control; Behavior Therapy; Cyclobutanes; Depression; F | 2009 |
Comparison of methods for delivering a lifestyle modification program for obese patients: a randomized trial.
Topics: Adult; Appetite Depressants; Behavior Therapy; Combined Modality Therapy; Counseling; Cyclobutanes; | 2009 |
Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.
Topics: Appetite Depressants; Blood Glucose; Blood Pressure; Cyclobutanes; Diabetes Mellitus, Type 2; Double | 2009 |
Sibutramine versus continuous positive airway pressure in obese obstructive sleep apnoea patients.
Topics: Adult; Appetite Depressants; Blood Pressure; Body Mass Index; Continuous Positive Airway Pressure; C | 2009 |
Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial.
Topics: Aged; Appetite Depressants; Bilirubin; Biomarkers; Cardiovascular Diseases; Confounding Factors, Epi | 2009 |
Predictors of attrition and weight loss success: Results from a randomized controlled trial.
Topics: Adult; Age Factors; Appetite Depressants; Body Weight; Combined Modality Therapy; Cyclobutanes; Depr | 2009 |
Achieving weight-loss maintenance.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Body Composition; Body Mass Index; Confidence Interva | 2001 |
Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy.
Topics: Acetamides; Adult; Aged; Appetite; Appetite Depressants; Cross-Over Studies; Cyclobutanes; Double-Bl | 2009 |
Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy.
Topics: Acetamides; Adult; Aged; Appetite; Appetite Depressants; Cross-Over Studies; Cyclobutanes; Double-Bl | 2009 |
Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy.
Topics: Acetamides; Adult; Aged; Appetite; Appetite Depressants; Cross-Over Studies; Cyclobutanes; Double-Bl | 2009 |
Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy.
Topics: Acetamides; Adult; Aged; Appetite; Appetite Depressants; Cross-Over Studies; Cyclobutanes; Double-Bl | 2009 |
Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial.
Topics: Aged; Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus | 2010 |
Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period.
Topics: Aged; Appetite Depressants; Blood Pressure; Cyclobutanes; Female; Humans; Male; Middle Aged; Obesity | 2010 |
Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women.
Topics: Adult; Appetite Depressants; C-Reactive Protein; Cyclobutanes; Drug Therapy, Combination; Female; Hu | 2010 |
Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial.
Topics: Adolescent; Adult; Appetite Depressants; Blood Pressure; Cyclobutanes; Drug Therapy, Combination; Fe | 2010 |
[Clinical observation on therapeutic effect of electric-heat needle combined with acupoint sticking therapy for treatment of simple obesity].
Topics: Acupuncture Points; Acupuncture Therapy; Adult; Cyclobutanes; Electroacupuncture; Female; Humans; Ma | 2010 |
Cardiac valve evaluation and adipokine levels in obese women treated with sibutramine.
Topics: Adipokines; Adiponectin; Adult; Appetite Depressants; C-Reactive Protein; Cyclobutanes; Diabetes Com | 2010 |
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
Topics: Aged; Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus | 2010 |
[Effect of sibutramine (meridia) on body composition, peptide YY3-36 and serotonin levels in patients with exogenous constitutional obesity].
Topics: Adult; Anthropometry; Appetite Depressants; Body Composition; Body Weight; Combined Modality Therapy | 2010 |
Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients.
Topics: Adiponectin; Appetite Depressants; Blood Glucose; Body Mass Index; Body Weight; C-Reactive Protein; | 2011 |
Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients.
Topics: Adult; Aged; Aged, 80 and over; Appetite Depressants; Blood Glucose; Body Mass Index; Body Weight; C | 2010 |
Changes of body weight and inflammatory markers after 12-week intervention trial: results of a double-blind, placebo-control pilot study.
Topics: Absorptiometry, Photon; Adiponectin; Adult; Anthraquinones; Anti-Inflammatory Agents; Appetite Depre | 2011 |
Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome.
Topics: Acute-Phase Proteins; Adolescent; Adult; Anti-Obesity Agents; Caloric Restriction; Combined Modality | 2012 |
Intragastric balloon in association with lifestyle and/or pharmacotherapy in the long-term management of obesity.
Topics: Adolescent; Adult; Appetite Depressants; Combined Modality Therapy; Cyclobutanes; Female; Gastric Ba | 2012 |
Serotonin receptor 2A -1438G/A promoter polymorphism in relation to obesity and response to sibutramine.
Topics: Alleles; Appetite Depressants; Body Composition; Body Mass Index; Body Weight; Cyclobutanes; Female; | 2012 |
Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.
Topics: Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus, Type 2; Double-Blind | 2012 |
Sibutramine promotes amygdala activity under fasting conditions in obese women.
Topics: Adult; Amygdala; Appetite Depressants; Brain; Case-Control Studies; Cross-Over Studies; Cyclobutanes | 2012 |
Prediction of weight loss and regain following dietary, lifestyle, and pharmacologic intervention.
Topics: Absorptiometry, Photon; Adult; Appetite Depressants; Body Composition; Body Weight; Calorimetry, Ind | 2012 |
Short-term effects of sibutramine on mineral status and selected biochemical parameters in obese women.
Topics: Adult; Calcium; Cholesterol; Copper; Cyclobutanes; Female; Ferritins; Glutathione Peroxidase; Humans | 2012 |
Sibutramine administration decreases serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome.
Topics: Adult; Anthropometry; Anti-Mullerian Hormone; Appetite Depressants; Caloric Restriction; Cyclobutane | 2012 |
Effect of the G-protein β3 subunit 825T allele on the change of body adiposity in obese female.
Topics: Adiposity; Adult; Alleles; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Drug Synergism; | 2013 |
Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Blood Pressure; Body Mass Index; Cyclobutanes; Double | 2002 |
A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin.
Topics: Appetite Depressants; Blood Glucose; Blood Pressure; Body Weight; Cyclobutanes; Diabetes Mellitus; D | 2003 |
Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial.
Topics: Adolescent; Appetite Depressants; Behavior Therapy; Biomarkers; Blood Pressure; Body Mass Index; Com | 2003 |
Short-term effects of sibutramine (Reductil) on appetite and eating behaviour and the long-term therapeutic outcome.
Topics: Adult; Aged; Analysis of Variance; Appetite; Appetite Depressants; Cross-Over Studies; Cyclobutanes; | 2003 |
Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial).
Topics: Adolescent; Adult; Anti-Obesity Agents; Body Mass Index; Cyclobutanes; Europe; Female; Humans; Leisu | 2003 |
Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein beta3 subunit gene (GNB3) C825T polymorphism.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Cyclobutanes; Genotype; GTP-Binding Protein beta Subu | 2003 |
Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial.
Topics: Adult; Appetite Depressants; Blood Pressure; Body Composition; Cyclobutanes; Double-Blind Method; Fe | 2003 |
The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Enzyme Inhibitors; Fatty Liver; Fema | 2003 |
Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Appetite Depressants; Blood Pressure; Body Constitution; Body Weight; C | 2003 |
A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder.
Topics: Adolescent; Adult; Antidepressive Agents; Appetite Depressants; Body Weight; Bulimia; Cyclobutanes; | 2003 |
Great expectations: "I'm losing 25% of my weight no matter what you say".
Topics: Adult; Appetite Depressants; Combined Modality Therapy; Cyclobutanes; Female; Follow-Up Studies; Hum | 2003 |
Effects of the sibutramine therapy on pulmonary artery pressure in obese patients.
Topics: Adult; Appetite Depressants; Blood Pressure; Cyclobutanes; Echocardiography; Female; Follow-Up Studi | 2004 |
Effect of low-dose metoprolol in combination with sibutramine therapy in normotensive obese patients: a randomized controlled study.
Topics: Adrenergic beta-Antagonists; Adult; Anthropometry; Appetite Depressants; Arrhythmias, Cardiac; Cyclo | 2004 |
Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes.
Topics: Adult; Aged; Appetite Depressants; Blood Glucose; Cyclobutanes; Diabetes Complications; Diabetes Mel | 2004 |
Food intake with an antiobesity drug (sibutramine) versus placebo and rorschach data: a crossover within-subjects study.
Topics: Adult; Appetite Depressants; Cross-Over Studies; Cyclobutanes; Eating; Female; Humans; Male; Middle | 2004 |
Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients?
Topics: Adult; Anthropometry; Anti-Obesity Agents; Body Mass Index; Body Weight; Combined Modality Therapy; | 2004 |
Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study.
Topics: Adult; Appetite Depressants; Blood Pressure; Body Mass Index; Cyclobutanes; Female; Heart Rate; Huma | 2004 |
The Long-term Outcomes of Sibutramine Effectiveness on Weight (LOSE Weight) study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization.
Topics: Adult; Appetite Depressants; Colorado; Cyclobutanes; Disease Management; Female; Health Maintenance | 2004 |
The effect of 1-yr sibutramine treatment on glucose tolerance, insulin sensitivity and serum lipid profiles in obese subjects.
Topics: Adolescent; Adult; Appetite Depressants; Blood Glucose; Body Constitution; Body Mass Index; Body Wei | 2004 |
Comparison of the acute pharmacodynamic responses after single doses of ephedrine or sibutramine in healthy, overweight volunteers.
Topics: Adult; Anti-Obesity Agents; Basal Metabolism; Blood Glucose; Blood Pressure; Body Composition; Body | 2004 |
[A multicenter and open study on efficacy and safety of sibutramine in obese subjects].
Topics: Adolescent; Adult; Appetite Depressants; Body Mass Index; Cyclobutanes; Female; Follow-Up Studies; H | 2004 |
Comparison of efficacy of sibutramine or orlistat versus their combination in obese women.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diet, Reducing; Female; Humans; Lact | 2004 |
Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
Topics: Adult; Aged; Appetite Depressants; Blood Glucose; Cyclobutanes; Diabetes Mellitus, Type 2; Double-Bl | 2004 |
Metformin versus sibutramine in the treatment of hyperinsulinemia in chronically anovulating women.
Topics: Adult; Anovulation; Appetite Depressants; Body Mass Index; Chronic Disease; Cyclobutanes; Diet, Redu | 2004 |
Sibutramine improves fat distribution and insulin resistance, and increases serum adiponectin levels in Korean obese nondiabetic premenopausal women.
Topics: Adiponectin; Adipose Tissue; Adult; Appetite Depressants; Body Mass Index; Cyclobutanes; Humans; Ins | 2004 |
Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
Topics: Anthropometry; Anti-Obesity Agents; Blood Pressure; Cyclobutanes; Diabetes Mellitus, Type 2; Double- | 2004 |
Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Body Mass Index; Cognitive Behavioral Therapy; Combin | 2005 |
Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients.
Topics: Adult; Body Mass Index; Cyclobutanes; Diet, Reducing; Drug Therapy, Combination; Female; Follow-Up S | 2004 |
Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study.
Topics: Adolescent; Appetite Depressants; Blood Pressure; Body Mass Index; Body Weight; Combined Modality Th | 2005 |
Sibutramine treatment in obesity: initial eating behaviour in relation to weight loss results and changes in mood.
Topics: Adult; Affect; Cyclobutanes; Depression; Feeding Behavior; Female; Humans; Male; Middle Aged; Obesit | 2005 |
Croatian experience with sibutramine in the treatment of obesity--multicenter prospective study.
Topics: Adult; Appetite Depressants; Croatia; Cyclobutanes; Female; Humans; Male; Obesity; Prospective Studi | 2004 |
Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
Topics: Analysis of Variance; Appetite Depressants; Blood Pressure; Cyclobutanes; Double-Blind Method; Femal | 2005 |
[Sibutramin in obesity treatment (multicenter, open, prospective 12-month-long study)].
Topics: Appetite Depressants; Cyclobutanes; Female; Humans; Middle Aged; Obesity | 2004 |
Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects.
Topics: Adipose Tissue; Adult; Appetite Depressants; Blood Glucose; Body Weight; Cyclobutanes; Diabetes Mell | 2004 |
[Serum leptin and insulin resistance in obesity and effects of sibutramine on them].
Topics: Adolescent; Adult; Appetite Depressants; Body Mass Index; Cyclobutanes; Double-Blind Method; Female; | 2003 |
Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients.
Topics: Adult; Antihypertensive Agents; Appetite Depressants; Chi-Square Distribution; Cyclobutanes; Drug Th | 2005 |
A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.
Topics: Adult; Antipsychotic Agents; Appetite Depressants; Behavior Therapy; Benzodiazepines; Combined Modal | 2005 |
Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects.
Topics: Adult; Aged; Appetite Depressants; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Cyclobu | 2005 |
Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study.
Topics: Adult; Appetite Depressants; Blood Pressure; Body Weight; Cardiovascular Diseases; Cyclobutanes; Dia | 2005 |
Two-year outcome of a combination of weight loss therapies for type 2 diabetes.
Topics: Appetite Depressants; Body Mass Index; Body Weight; Combined Modality Therapy; Cyclobutanes; Diabete | 2005 |
Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients--sibutramine and blood pressure.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Arrhythmias, Cardiac; Autonomic Nervous System; Baror | 2005 |
Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study.
Topics: Appetite Depressants; Blood Glucose; Cyclobutanes; Diabetes Mellitus, Type 2; Double-Blind Method; F | 2005 |
Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes.
Topics: Adiponectin; Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Body Weight; Cyc | 2005 |
Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
Topics: Adult; Appetite Depressants; Cyclobutanes; Diet, Reducing; Double-Blind Method; Energy Intake; Exerc | 2005 |
[Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents].
Topics: Adolescent; Appetite Depressants; Cyclobutanes; Double-Blind Method; Female; Humans; Male; Obesity; | 2005 |
[Effects of sibutramine on blood glucose and lipids, body fat mass and insulin resistance in obese patients: a multi-center clinical trial].
Topics: Adolescent; Adult; Aged; Appetite Depressants; Blood Glucose; Body Mass Index; Cyclobutanes; Double- | 2005 |
Randomized trial of lifestyle modification and pharmacotherapy for obesity.
Topics: Adult; Appetite Depressants; Cardiovascular Diseases; Combined Modality Therapy; Counseling; Cyclobu | 2005 |
Sibutramine therapy in obese women--effects on plasma neuropeptide Y (NPY), insulin, leptin and beta-endorphin concentrations.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Analysis of Variance; Appetite Depressants; Appetit | 2005 |
Influence of weight reduction by sibutramine on female sexual function.
Topics: Adult; Antidepressive Agents; Appetite Depressants; Behavior Therapy; Body Composition; Combined Mod | 2006 |
Effect of sibutramine and of cognitive-behavioural weight loss therapy in obesity and subclinical binge eating disorder.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Bulimia; Cognitive Behavioral Therapy; Combined Modal | 2006 |
Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects.
Topics: Adult; Baroreflex; Blood Pressure; Cross-Over Studies; Cyclobutanes; Double-Blind Method; Female; He | 2006 |
Short-term sibutramine therapy is associated with weight loss and improved endothelial function in obese patients with coronary artery disease.
Topics: Aged; Appetite Depressants; Brachial Artery; Coronary Disease; Cyclobutanes; Endothelium, Vascular; | 2006 |
Effects of sibutramine treatment in obese adolescents: a randomized trial.
Topics: Adolescent; Appetite Depressants; Behavior Therapy; Blood Pressure; Body Height; Body Mass Index; Ch | 2006 |
Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
Topics: Adolescent; Appetite Depressants; Cyclobutanes; Double-Blind Method; Female; Humans; Male; Mexico; O | 2006 |
Reduced left ventricular mass after treatment of obese patients with sibutramine: An echocardiographic multicentre study.
Topics: Adult; Appetite Depressants; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Body Composition | 2006 |
Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients.
Topics: Adolescent; Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Appetite Depressa | 2006 |
A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain.
Topics: Adult; Anthropometry; Antipsychotic Agents; Appetite Depressants; Blood Glucose; Body Mass Index; Bo | 2007 |
The effect of sibutramine on energy expenditure and body composition in obese adolescents.
Topics: Adolescent; Age Determination by Skeleton; Appetite Depressants; Blood Pressure; Body Composition; B | 2007 |
Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Combined Modality Therapy; Cyclobutanes; Diet, Red | 2006 |
Sympathetic vasomotor tone determines blood pressure response to long-term sibutramine treatment.
Topics: Adult; Appetite Depressants; Blood Pressure; Body Mass Index; Body Weight; Cyclobutanes; Female; Hum | 2007 |
Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study.
Topics: Adult; Appetite Depressants; Body Mass Index; Cyclobutanes; Double-Blind Method; Female; Humans; Mal | 2007 |
Impact of weight loss on the metabolic syndrome.
Topics: Adult; Aged; Appetite Depressants; Cyclobutanes; Female; Humans; Life Style; Male; Metabolic Syndrom | 2007 |
Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.
Topics: Adult; Aged; Antihypertensive Agents; Appetite Depressants; Blood Pressure; Body Weight; Cyclobutane | 2007 |
Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Body Mass Index; Chromatography, High Pressure Liquid | 2007 |
A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Appetite Depressants; Bipolar D | 2007 |
Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients.
Topics: Adolescent; Adult; Algorithms; Appetite Depressants; Behavior Therapy; Combined Modality Therapy; Cy | 2007 |
Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study.
Topics: Adult; Affect; Analysis of Variance; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Cyc | 2008 |
Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Appetite Depressants; Blood Pressure; Body Mass Index; Child; Cyclobutanes; Double-Blind | 2007 |
The cost-effectiveness of sibutramine in non-diabetic obese patients: evidence from four Western countries.
Topics: Adult; Age Distribution; Aged; Appetite Depressants; Cohort Studies; Coronary Disease; Cost-Benefit | 2007 |
Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial.
Topics: Aged; Appetite Depressants; Cyclobutanes; Diabetic Angiopathies; Double-Blind Method; Female; Humans | 2007 |
Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Appetite Depressants; Body Weight; Cardiovascular Diseases; Cyclobutanes; Double- | 2008 |
NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine.
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Cyclobutanes; Cyclohexanes; Double-Blind Method; Drug | 2007 |
Impact sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromes.
Topics: Absorptiometry, Photon; Adolescent; Adult; Antidepressive Agents; Body Weight; Child; Child, Prescho | 2007 |
The obese older female patient: CV risk and the SCOUT study.
Topics: Adult; Aged; Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Cyclobutanes; Exercise; | 2007 |
Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.
Topics: Adolescent; Adult; Androgens; Anthropometry; Appetite Depressants; Blood Glucose; Body Fat Distribut | 2008 |
The effect of sibutramine intake on resting and exercise physiological responses.
Topics: Adult; Analysis of Variance; Appetite Depressants; Basal Metabolism; Body Mass Index; Cyclobutanes; | 2008 |
Sympathetic-leptin relationship in obesity: effect of weight loss.
Topics: Adult; Appetite Depressants; Blood Pressure; Body Composition; Cyclobutanes; Female; Heart Rate; Hum | 2008 |
Peripheral endocannabinoid system activity in patients treated with sibutramine.
Topics: Abdominal Fat; Adolescent; Adult; Appetite Depressants; Arachidonic Acids; Biopsy; Body Weight; Cann | 2008 |
Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
Topics: Adult; Antipsychotic Agents; Appetite Depressants; Benzodiazepines; Body Mass Index; Chronic Disease | 2008 |
Sibutramine: a novel new agent for obesity treatment.
Topics: Adolescent; Adult; Aged; Animals; Appetite Depressants; Cyclobutanes; Female; Humans; Male; Middle A | 1995 |
A double-blind randomized placebo-controlled trial of sibutramine.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Body Mass Index; Body Weight; Combined Modality Ther | 1996 |
Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study.
Topics: Adult; Appetite Depressants; Cyclobutanes; Dose-Response Relationship, Drug; Double-Blind Method; Fe | 1998 |
Sibutramine reduces food intake in non-dieting women with obesity.
Topics: Appetite Depressants; Cross-Over Studies; Cyclobutanes; Dietary Carbohydrates; Dietary Fats; Dietary | 1998 |
Effects of sibutramine on resting metabolic rate and weight loss in overweight women.
Topics: Adolescent; Adult; Appetite Depressants; Basal Metabolism; Blood Pressure; Body Composition; Cyclobu | 1998 |
A comparison of sibutramine and dexfenfluramine in the treatment of obesity.
Topics: Adult; Appetite Depressants; Body Constitution; Body Mass Index; Body Weight; Cyclobutanes; Dexfenfl | 1998 |
Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction?
Topics: Adipose Tissue; Adult; Body Composition; Body Constitution; Cyclobutanes; Double-Blind Method; Femal | 1998 |
Sibutramine produces dose-related weight loss.
Topics: Adult; Appetite Depressants; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cyclob | 1999 |
Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine.
Topics: Adult; Appetite Depressants; Cyclobutanes; Diet, Reducing; Double-Blind Method; Energy Intake; Femal | 1999 |
Absence of cardiac valve dysfunction in obese patients treated with sibutramine.
Topics: Adult; Aged; Aortic Valve Insufficiency; Appetite Depressants; Body Mass Index; Cyclobutanes; Diabet | 1999 |
The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females.
Topics: Adult; Appetite Depressants; Basal Metabolism; Body Temperature Regulation; Cardiac Output; Cyclobut | 1999 |
The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction.
Topics: Adult; Appetite Depressants; Blood Pressure; Body Composition; Calorimetry, Indirect; Cyclobutanes; | 1999 |
Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Body Constitution; Body Mass Index; Cardiovascular Sy | 2000 |
A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity.
Topics: Administration, Oral; Adolescent; Adult; Aged; Appetite Depressants; Body Constitution; Body Mass In | 2000 |
The effects of drugs used to treat obesity on the autonomic nervous system.
Topics: Adrenergic beta-Antagonists; Adult; Appetite Depressants; Atropine; Autonomic Nervous System; Basal | 2000 |
Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial.
Topics: Adult; Aged; Appetite Depressants; Black People; Body Weight; Cyclobutanes; Double-Blind Method; Fem | 2000 |
Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Body Weight; Combined Modality Th | 2000 |
Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial.
Topics: Adult; Appetite Depressants; Combined Modality Therapy; Cyclobutanes; Diet, Reducing; Exercise Thera | 2001 |
Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Aged; Anthropometry; Anti-Obesity Agents; Blood Gluco | 2000 |
Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Blood Pressure; Body Mass Index; Cyclobutanes; Diabet | 2000 |
Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Body Mass Index; Cyclobutanes; Diastole; Double-Blin | 2000 |
Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Cyclobutanes; Diet, Reducing; Double-Blind Method; Fe | 2001 |
Influence of sibutramine on energy expenditure in African American women.
Topics: Adult; Appetite Depressants; Basal Metabolism; Black People; Cross-Over Studies; Cyclobutanes; Doubl | 2001 |
Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over.
Topics: Adolescent; Adult; Aged; Anthropometry; Appetite Depressants; Body Mass Index; Body Weight; Cross-Ov | 2001 |
[Sibutramine--antidepressive agent tested against obesity].
Topics: Antidepressive Agents, Second-Generation; Appetite Depressants; Body Mass Index; Cyclobutanes; Diet, | 2001 |
Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity.
Topics: Adult; Aged; Appetite Depressants; Behavior Therapy; Body Mass Index; Body Weight; Combined Modality | 2001 |
Insulin-leptin-visceral fat relation during weight loss.
Topics: Adipose Tissue; Adult; Appetite Depressants; Cyclobutanes; Diet, Reducing; Female; Humans; Insulin; | 2001 |
Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Body Weight; Cyclobutanes; Double-Blind Method; Femal | 2001 |
Long-term weight loss with sibutramine: a randomized controlled trial.
Topics: Adult; Aged; Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Cyclobutanes; Double-Bli | 2001 |
Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control.
Topics: Appetite Depressants; Blood Glucose; Cholesterol; Cyclobutanes; Diabetes Mellitus; Double-Blind Meth | 2001 |
[A randomized, double-blind, placebo-controlled, multicenter study on sibutramine in over-weighted and obese subjects].
Topics: Adolescent; Adult; Aged; Appetite Depressants; Cyclobutanes; Double-Blind Method; Female; Humans; Ma | 2001 |
Clinical evaluation of sibutramine in obese type 2 diabetic patients refractory to dietary management.
Topics: Adult; Aged; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Diet, Fat-Restricted; Do | 2001 |
An open-label trial of sibutramine in obese patients with binge-eating disorder.
Topics: Adult; Anxiety Disorders; Appetite Depressants; Bulimia; Comorbidity; Cyclobutanes; Depressive Disor | 2002 |
Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Appetite Depressants; Benzothiadiazines; Blood Pressure; C | 2002 |
Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Appetite Depressants; Benzothiadiazines; Blood Pres | 2002 |
Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy.
Topics: Appetite Depressants; Body Mass Index; Body Weight; Cholesterol; Cyclobutanes; Diabetes Mellitus; Di | 2002 |
Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Body Mass Index; Body Weight; Cyclo | 2002 |
Effects of sibutramine on the treatment of obesity in patients with arterial hypertension.
Topics: Antihypertensive Agents; Appetite Depressants; Blood Pressure; Cyclobutanes; Double-Blind Method; Dr | 2002 |
Effects of sibutramine in non-dieting obese women.
Topics: Adult; Appetite Depressants; Blood Glucose; Body Mass Index; C-Peptide; Cyclobutanes; Female; Glucos | 2002 |
The cerebrospinal fluid/serum leptin ratio during pharmacological therapy for obesity.
Topics: Adolescent; Adult; Amphetamines; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; La | 2002 |
Elevated serum liver enzymes in obesity: a dilemma during clinical trials.
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Antidepressive Agents; Aspartate Aminotransferase | 1991 |
Sibutramine in weight control: a dose-ranging, efficacy study.
Topics: Adult; Behavior Therapy; Body Weight; Cyclobutanes; Dose-Response Relationship, Drug; Double-Blind M | 1991 |
206 other studies available for sibutramine and Obesity
| Article | Year |
|---|---|
Melanin-Concentrating Hormone Receptor 1 Antagonists Lacking an Aliphatic Amine: Synthesis and Structure-Activity Relationships of Novel 1-(Imidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one Derivatives.
Topics: Animals; Anti-Obesity Agents; CHO Cells; Cricetulus; Dose-Response Relationship, Drug; Humans; Imida | 2016 |
Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition.
Topics: Animals; Anti-Obesity Agents; Benzimidazoles; Cytochrome P-450 CYP3A; Dose-Response Relationship, Dr | 2016 |
Sibutramine and its cardiovascular effects: A deadly combination.
Topics: Cyclobutanes; Double-Blind Method; Humans; Obesity | 2021 |
Tissue and Circulating MicroRNAs 378 and 142 as Biomarkers of Obesity and Its Treatment Response.
Topics: Biomarkers; Cyclobutanes; Humans; MicroRNAs; Obesity | 2023 |
Whole-brain activation signatures of weight-lowering drugs.
Topics: Animals; Anti-Obesity Agents; Body Weight; Brain; Cyclobutanes; Homeostasis; Imaging, Three-Dimensio | 2021 |
Positive association between the changes in chemerin and adiponectin levels after weight reduction.
Topics: Adiponectin; Adult; Anti-Obesity Agents; Appetite Depressants; Biomarkers; Body Mass Index; Chemokin | 2017 |
Diethylpropion and mazindol: An end to the discussion?
Topics: Amphetamines; Appetite Depressants; Brazil; Cyclobutanes; Diethylpropion; Drug Approval; Humans; Maz | 2017 |
Differential sensitivity of chronic high-fat-diet-induced obesity in Sprague-Dawley rats.
Topics: Animals; Cyclobutanes; Dexfenfluramine; Diet, High-Fat; Eating; Male; Obesity; Oxygen Consumption; R | 2018 |
The role of sibutramine in weight reduction.
Topics: Adult; Aged; Appetite Depressants; Cyclobutanes; Female; Humans; Male; Middle Aged; Obesity; Weight | 2013 |
MRI allows for longitudinal quantitative analysis of body fat composition in rats: an analysis of sibutramine-associated changes at the group level.
Topics: Adipose Tissue; Algorithms; Animals; Appetite Depressants; Body Composition; Body Fat Distribution; | 2013 |
Rats on a high-energy diet showing no weight gain present with ultrastructural changes associated with liver fibrosis.
Topics: Animals; Appetite Depressants; Body Mass Index; Cyclobutanes; Diet, High-Fat; Disease Models, Animal | 2013 |
Time series analyses of the effect of FDA communications on use of prescription weight loss medications.
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Cohort Studies; Cyclobutanes; Dr | 2014 |
Experimental study of the efficiency of Dietressa preparation on body weight reduction in mice feeding high-fat ration.
Topics: Animals; Anti-Obesity Agents; Antibodies; Appetite Depressants; Cannabinoid Receptor Antagonists; Cy | 2014 |
The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United Kingdom population-based cohort.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Case-Control Studies; Cyclobutane | 2015 |
The effect of sibutramine prescribing in routine clinical practice on cardiovascular outcomes: a cohort study in the United Kingdom.
Topics: Anti-Obesity Agents; Appetite Depressants; Cohort Studies; Contraindications; Cyclobutanes; Female; | 2015 |
Differential regulation of metabolic parameters by energy deficit and hunger.
Topics: Animals; Appetite Depressants; Appetite Regulation; Caloric Restriction; Cyclobutanes; Diet; Energy | 2015 |
Ferulic acid lowers body weight and visceral fat accumulation via modulation of enzymatic, hormonal and inflammatory changes in a mouse model of high-fat diet-induced obesity.
Topics: Adipose Tissue; Animals; Anti-Obesity Agents; Coumaric Acids; Cyclobutanes; Diet, High-Fat; Disease | 2017 |
Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats.
Topics: Amyloid; Animals; Anti-Obesity Agents; Body Composition; Body Weight; Cyclobutanes; Diet; Disease Mo | 2008 |
The effect of sibutramine therapy on occurrence of depression symptoms among obese patients.
Topics: Antidepressive Agents; Appetite Depressants; Body Mass Index; Cyclobutanes; Depression; Humans; Long | 2008 |
Sibutramine-associated QT interval prolongation and cardiac arrest.
Topics: Appetite Depressants; Cyclobutanes; Defibrillators, Implantable; Drug Monitoring; Electrocardiograph | 2008 |
[Sibutramine associated psychotic episode: a case report].
Topics: Adult; Antidepressive Agents; Cyclobutanes; Female; Humans; Obesity; Psychoses, Substance-Induced | 2008 |
[Pharmacological therapy of obesity].
Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Bradykinin; Cannabinoid Receptor Antagon | 2008 |
Comparison of lipid lowering effect of sibutramine in patients treated or not treated with statins--3 month follow-up.
Topics: Appetite Depressants; Cyclobutanes; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhib | 2007 |
Sibutramine-induced psychotic episode in an adolescent.
Topics: Adolescent; Antipsychotic Agents; Cyclobutanes; Humans; Kleine-Levin Syndrome; Male; Obesity; Psycho | 2008 |
Implementing antiobesity treatment in a patient with a mood disorder.
Topics: Adult; Anti-Obesity Agents; Antidepressive Agents; Antimanic Agents; Appetite Depressants; Cyclobuta | 2008 |
Fundamentals of cardiometabolic risk factor reduction: achieving and maintaining weight loss with pharmacotherapy or bariatric surgery.
Topics: Anti-Obesity Agents; Bariatric Surgery; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Cy | 2008 |
The endocannabinoid system as a target for obesity treatment.
Topics: Amides; Anti-Obesity Agents; Cannabinoid Receptor Modulators; Cyclobutanes; Depression; Endocannabin | 2008 |
Hypomanic episode secondary to sibutramine in a patient with type-I bipolar disorder.
Topics: Adult; Appetite Depressants; Bipolar Disorder; Cyclobutanes; Female; Humans; Obesity | 2008 |
[Obesity and oral health: risk factors of obese patients in dental practice].
Topics: Adult; Appetite Depressants; Child; Child, Preschool; Cyclobutanes; Dental Caries; Diabetes Mellitus | 2008 |
Melanin-concentrating hormone-1 receptor antagonism and anti-obesity effects of ethanolic extract from Morus alba leaves in diet-induced obese mice.
Topics: Adipose Tissue; Animals; Anti-Obesity Agents; Body Weight; Calcium; CHO Cells; Cricetinae; Cricetulu | 2009 |
Effect of sibutramine on weight reduction and insulin resistance in women with polycystic ovary syndrome.
Topics: Appetite Depressants; Body Mass Index; Body Weight; Cyclobutanes; Female; Humans; Insulin Resistance | 2009 |
Treating obesity in the family practice setting.
Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Cardiovascular Diseases; Cyclobutanes; H | 2001 |
Exploring synergies in the treatment of obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Behavior Therapy; Body Mass Index; Combined Modality Ther | 2001 |
Emerging strategies for weight management. Summary.
Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Cyclobutanes; Feeding Behavior; Health B | 2001 |
Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene.
Topics: Adipose Tissue; Adolescent; Adult; Aged; Appetite Depressants; Body Mass Index; Cyclobutanes; Female | 2009 |
Sibutramine--its impact on health-related quality of life and depression among adult obese non-diabetic patients.
Topics: Adult; Aged; Cyclobutanes; Depressive Disorder; Female; Humans; Male; Middle Aged; Obesity; Quality | 2009 |
What extent of weight loss can benefit the health-related quality of life in motivated obese Chinese?
Topics: Adolescent; Adult; Anti-Obesity Agents; Appetite Depressants; Combined Modality Therapy; Cyclobutane | 2009 |
Evaluation of anti-obesity activity of duloxetine in comparison with sibutramine along with its anti-depressant activity: an experimental study in obese rats.
Topics: Adiposity; Animals; Anti-Obesity Agents; Antidepressive Agents; Appetite Regulation; Blood Pressure; | 2009 |
Changes in regional adiposity and cardio-metabolic function following a weight loss program with sibutramine in obese men with obstructive sleep apnea.
Topics: Adipose Tissue; Adiposity; Adult; Aged; Appetite Depressants; Biomarkers; Cardiovascular Diseases; C | 2009 |
Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study.
Topics: Adolescent; Age Distribution; Anti-Obesity Agents; Child; Child, Preschool; Cyclobutanes; Drug Presc | 2009 |
Withdrawal of sibutramine leaves European doctors with just one obesity drug.
Topics: Appetite Depressants; Cyclobutanes; Drug Recalls; Europe; Humans; Obesity | 2010 |
Acute coronary syndrome in a young woman treated with sibutramine.
Topics: Acute Coronary Syndrome; Adult; Anti-Obesity Agents; Cyclobutanes; Female; Humans; Hypertension; Myo | 2010 |
Withdrawal of sibutramine in Europe.
Topics: Aged; Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Europe; Humans; Middle Aged; Obes | 2010 |
[Questions surrounding sibutramine for obesity].
Topics: Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Humans; Obesity | 2010 |
Withdrawal of sibutramine. Editorial is judgment in advance of the facts.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Clinical Trials as Topic; Cyclobutanes; Humans; Obesit | 2010 |
Withdrawal of sibutramine. Magic bullets now uncontrolled.
Topics: Advertising; Anti-Obesity Agents; Cardiovascular Diseases; Cyclobutanes; Fraud; Humans; Obesity; Saf | 2010 |
Effect of the common -866G/A polymorphism of the uncoupling protein 2 gene on weight loss and body composition under sibutramine therapy in an obese Taiwanese population.
Topics: Adipose Tissue; Adult; Body Composition; Cyclobutanes; Demography; Female; Humans; Ion Channels; Mal | 2010 |
The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant.
Topics: Adipose Tissue; Animals; Appetite; Biogenic Monoamines; Blood Glucose; Bridged Bicyclo Compounds, He | 2010 |
An obesity drug sibutramine reduces brain natriuretic peptide (BNP) levels in severely obese patients.
Topics: Appetite Depressants; Biomarkers; Body Mass Index; Cholesterol, LDL; Cyclobutanes; Female; Humans; M | 2010 |
Long-term characterization of the diet-induced obese and diet-resistant rat model: a polygenetic rat model mimicking the human obesity syndrome.
Topics: Analysis of Variance; Animals; Appetite Depressants; Blood Glucose; Cyclobutanes; Diet; Disease Mode | 2010 |
Controversy about the cardiovascular safety of sibutramine.
Topics: Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Humans; Obesity; Risk | 2010 |
European Medicines Agency withdrawal for sibutramine.
Topics: Adolescent; Appetite Depressants; Cyclobutanes; Europe; Female; Humans; Licensure; Male; Obesity; Sa | 2010 |
Withdrawal of sibutramine for weight loss: where does this leave clinicians?
Topics: Appetite Depressants; Cyclobutanes; Drug Approval; Humans; Obesity; Risk Factors | 2010 |
Drug management of obesity--efficacy versus safety.
Topics: Anti-Obesity Agents; Benzazepines; Contraindications; Cyclobutanes; Drug Approval; Fenfluramine; Hum | 2010 |
Elevation of QT dispersion after obesity drug sibutramine.
Topics: Adult; Anti-Obesity Agents; Arrhythmias, Cardiac; Caloric Restriction; Combined Modality Therapy; Cy | 2010 |
Fat attack.
Topics: Anti-Obesity Agents; Appetite Depressants; Benzazepines; Brain; Cyclobutanes; Humans; Lactones; Obes | 2010 |
Sibutramine--another flawed diet pill.
Topics: Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Humans; Myocardial Infarction; Obesity; | 2010 |
Weight loss maintenance.
Topics: Anti-Obesity Agents; Cyclobutanes; Diet, Reducing; Exercise; Gastric Bypass; Humans; Lactones; Obesi | 2010 |
No compelling evidence that sibutramine prolongs life in rodents despite providing a dose-dependent reduction in body weight.
Topics: Animals; Appetite Depressants; Cyclobutanes; Dose-Response Relationship, Drug; Eating; Longevity; Mi | 2011 |
[Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review].
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Cyclobuta | 2011 |
Proteome changes in rat plasma in response to sibutramine.
Topics: Adipose Tissue; Animals; Appetite Depressants; Appetite Regulation; Blood Proteins; Body Weight; Car | 2011 |
Inverse agonism at α2A adrenoceptors augments the hypophagic effect of sibutramine in rats.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Appetite Depressants; Cyclobutanes | 2011 |
Hepatic PTP1B expression involvement in the effects of Chinese medicine formula xiao-gao-jiang-zhuo using an obese rat model.
Topics: Abdominal Fat; Animals; Anti-Obesity Agents; Body Weight; Cholesterol; Cyclobutanes; Dietary Fats; D | 2011 |
Pharmacological treatment of obesity: a public health perspective.
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Obesity | 2011 |
Comparative efficiency and safety of pharmacological approaches to the management of obesity.
Topics: Anti-Obesity Agents; Bridged Bicyclo Compounds, Heterocyclic; Cyclobutanes; Humans; Lactones; Obesit | 2011 |
Drug treatment for obesity in the post-sibutramine era.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Child; Cy | 2011 |
Sibutramine: balanced judgment or prejudice?
Topics: Appetite Depressants; Blood Pressure; Body Weight; Cyclobutanes; Humans; Judgment; Obesity; Prejudic | 2011 |
Use of a pharmaceutically adulterated dietary supplement, Pai You Guo, among Brazilian-born women in the United States.
Topics: Adolescent; Adult; Anti-Obesity Agents; Brazil; Child; China; Cross-Sectional Studies; Cyclobutanes; | 2012 |
Adherence to weight loss medications; post-marketing study from HMO pharmacy data of one million individuals.
Topics: Adult; Analysis of Variance; Anti-Obesity Agents; Body Mass Index; Comorbidity; Cyclobutanes; Diabet | 2011 |
Hypogonadotropic hypogonadism in a homozygous MC4R mutation carrier and the effect of sibutramine treatment on body weight and obesity-related health risks.
Topics: Adult; Appetite Depressants; Body Composition; Body Weight; Cyclobutanes; Gonadotropins; Homozygote; | 2011 |
[Adverse drug reactions of a slimming product contaminated with sibutramine].
Topics: Adult; Appetite Depressants; Cyclobutanes; Drug Contamination; Female; Humans; Liver; Obesity; Psych | 2011 |
Cost-effectiveness of pharmacotherapy to reduce obesity.
Topics: Anti-Obesity Agents; Australia; Cost-Benefit Analysis; Cyclobutanes; Drug Costs; Humans; Lactones; O | 2011 |
Topiramate induces weight loss and improves insulin sensitivity in dietary obese rats: comparison to sibutramine.
Topics: Animals; Anti-Obesity Agents; Blood Glucose; Blood Pressure; Cyclobutanes; Female; Fructose; Insulin | 2011 |
Long-term health benefits of appetite suppressants remain unproven.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Clinical Trials as Topic; | 2011 |
Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DIO-rats.
Topics: Animals; Anti-Obesity Agents; Body Weight; Cyclobutanes; Eating; Glucagon-Like Peptide 1; Glucose To | 2012 |
Management of obesity in the National Health and Nutrition Examination Survey (NHANES), 2007-2008.
Topics: Adult; Anti-Obesity Agents; Cyclobutanes; Exercise; Female; Humans; Life Style; Male; Middle Aged; N | 2012 |
What cost weight loss?
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Cyclobutanes; Fructose; Humans; Naltrexone; Obesity; P | 2012 |
The perils of pharmacological treatment for obesity: a case of sibutramine-associated cardiomyopathy and malignant arrhythmias.
Topics: Amiodarone; Anti-Arrhythmia Agents; Appetite Depressants; Cardiomyopathy, Hypertrophic; Cyclobutanes | 2012 |
Food and Drug Administration's Obesity Drug Guidance Document: a short history.
Topics: Adolescent; Adult; Advisory Committees; Aged; Anti-Obesity Agents; Bariatric Medicine; Body Mass Ind | 2012 |
Evaluation of body fat composition after linagliptin treatment in a rat model of diet-induced obesity: a magnetic resonance spectroscopy study in comparison with sibutramine.
Topics: Adiposity; Animals; Appetite Depressants; Body Composition; Cyclobutanes; Disease Models, Animal; Fe | 2012 |
Safety assessment of an anti-obesity drug (sibutramine): a retrospective cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Obesity Agents; Child; Child, Preschool; Cohort Stu | 2012 |
Experimental study of the effects of Dietressa, a new weight-reducing drug.
Topics: Animals; Anti-Obesity Agents; Antibodies; Cyclobutanes; Drug Evaluation, Preclinical; Eating; Male; | 2012 |
Assessment of maximum weight change and duration of therapeutic effect for non-surgical treatment of obesity using an exponential model.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Benzazepines; Body Mass Index; Body Weight; Cyclob | 2012 |
Appetite suppressants in pregnancy.
Topics: Abnormalities, Multiple; Abortion, Spontaneous; Appetite Depressants; Cyclobutanes; Czech Republic; | 2012 |
[Extra pounds despite sports and diets. Genetics can also be involved].
Topics: Appetite Depressants; Combined Modality Therapy; Cyclobutanes; Diet, Reducing; Energy Metabolism; Ge | 2002 |
Mechanism of the thermogenic effect of Metabolite 2 (BTS 54 505), a major pharmacologically active metabolite of the novel anti-obesity drug, sibutramine.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Anti-Obesity Agents; Appetite De | 2002 |
[The anti-obesity drug sibutramine for overweight diabetic patients. "Blood pressure is not elevated")].
Topics: Appetite Depressants; Blood Pressure; Cyclobutanes; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hu | 2002 |
[Weight loss lowers blood pressure, lipids and blood glucose. Sibutramine also helps diabetics with weight loss].
Topics: Appetite Depressants; Blood Glucose; Blood Pressure; Cyclobutanes; Diabetes Mellitus; Diabetes Melli | 2002 |
Effectiveness of sibutramine.
Topics: Appetite Depressants; Cyclobutanes; Humans; Obesity | 2002 |
Obesity drug pipeline not so fat.
Topics: Agouti-Related Protein; alpha-MSH; Animals; Anti-Obesity Agents; Appetite; Arcuate Nucleus of Hypoth | 2003 |
Phenylethanolamine N-methyltransferase G-148A genetic variant and weight loss in obese women.
Topics: Aged; Appetite Depressants; Behavior Therapy; Body Constitution; Case-Control Studies; Cyclobutanes; | 2003 |
Experimental drugs take aim at obesity.
Topics: Animals; Anti-Obesity Agents; Ciliary Neurotrophic Factor; Cyclobutanes; Drug Evaluation; Drugs, Inv | 2003 |
[Overweight patient has tried many times to lose weight. What helps against stubborn fat padding?].
Topics: Anti-Obesity Agents; Appetite Depressants; Contraindications; Cyclobutanes; Diet, Reducing; Exercise | 2003 |
Sibutramine decreases body weight gain and increases energy expenditure in obese Zucker rats without changes in NPY and orexins.
Topics: Adipose Tissue; Animals; Appetite Depressants; Body Composition; Carrier Proteins; Cyclobutanes; Dri | 2003 |
[Abuse potential of sibutramine].
Topics: Appetite Depressants; Central Nervous System Stimulants; Cyclobutanes; Dextroamphetamine; Female; Hu | 2003 |
Potential for sibutramine-yohimbine interaction?
Topics: Animals; Cardiovascular Diseases; Chemotherapy, Adjuvant; Cyclobutanes; Drug Interactions; Humans; H | 2003 |
Interaction between sibutramine and cyclosporine.
Topics: Adult; Appetite Depressants; Cyclobutanes; Cyclosporine; Drug Interactions; Female; Graft Rejection; | 2003 |
[A drug help in reducing? Risk profile decides whether and how].
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Body Mass Index; Cyclobutanes; Diab | 2003 |
Sibutramine sensitivity assay revealed a unique phenotype of bombesin BB3 receptor-deficient mice.
Topics: Animals; Appetite Depressants; Cyclobutanes; Disease Models, Animal; Feeding Behavior; Female; Hyper | 2003 |
Sibutramine in the management of obesity.
Topics: Appetite Depressants; Cyclobutanes; Humans; Obesity | 2003 |
Management of the overweight patient with Type 2 diabetes.
Topics: Anti-Obesity Agents; Cyclobutanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Hum | 2003 |
[What effect does losing weight have on hypertension?].
Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Clinical Trials as Topic; Contraindicati | 2003 |
Sibutramine treatment in obesity: predictors of weight loss including rorschach personality data.
Topics: Adult; Cyclobutanes; Female; Humans; Linear Models; Male; Middle Aged; Obesity; Personality; Rorscha | 2003 |
Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines.
Topics: Abdomen; Adipocytes; Adult; Anti-Obesity Agents; Appetite Depressants; Body Constitution; Cyclobutan | 2004 |
[Sustained weight reduction after cessation of obesity treatment with Sibutramine].
Topics: Appetite Depressants; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Cyclobuta | 2004 |
Prediction of successful weight reduction under sibutramine therapy.
Topics: Appetite Depressants; Cyclobutanes; Genotype; GTP-Binding Protein beta Subunits; Humans; Obesity; Po | 2004 |
Exposure to sibutramine during pregnancy: a case series.
Topics: Anti-Obesity Agents; Cyclobutanes; Female; Humans; Maternal Exposure; Obesity; Pregnancy; Pregnancy | 2004 |
[Sibutramine administration in polycystic ovary syndrome treatment].
Topics: Adolescent; Appetite Depressants; Cyclobutanes; Diet, Fat-Restricted; Female; Humans; Obesity; Polyc | 2004 |
Quantitative body composition analysis in awake mice and rats by magnetic resonance relaxometry.
Topics: Animals; Anti-Obesity Agents; Body Composition; Calibration; Cross-Sectional Studies; Cyclobutanes; | 2004 |
[Pharmacotherapy of obesity].
Topics: Anti-Obesity Agents; Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Evidence-Based Me | 2004 |
Combined dietary and pharmacological weight management in obese hypopituitary patients.
Topics: Adult; Anthropometry; Appetite Depressants; Blood Glucose; Body Composition; Cholesterol; Combined M | 2004 |
Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials.
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Antihypertensive Agents; Blood Pressure; Body Mass Ind | 2005 |
Does prior authorization of sibutramine improve medication compliance or weight loss?
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diet, Reducing; Female; Humans; Insurance, | 2005 |
[Obesity pharmacological treatment].
Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat | 2005 |
Effects of oleoyl-estrone with dexfenfluramine, sibutramine or phentermine on overweight rats.
Topics: Animals; Anti-Obesity Agents; Body Weight; Cyclobutanes; Dexfenfluramine; Drug Interactions; Drug Th | 2005 |
Sibutramine and the sympathetic nervous system in obese humans.
Topics: Appetite Depressants; Blood Pressure; Clinical Trials as Topic; Cyclobutanes; Heart Rate; Humans; Hy | 2005 |
New options for drug treatment of obesity in patients with Type 2 diabetes.
Topics: Anti-Obesity Agents; Appetite Depressants; Cannabinoids; Cyclobutanes; Diabetes Mellitus, Type 2; Hu | 2005 |
Sibutramine in pregnancy.
Topics: Adult; Appetite Depressants; Cyclobutanes; Female; Humans; Infant, Newborn; Male; Obesity; Pregnancy | 2005 |
Sibutramine use associated with reversible hepatotoxicity.
Topics: Appetite Depressants; Chemical and Drug Induced Liver Injury; Cyclobutanes; Female; Humans; Liver Fu | 2005 |
Pharmacotherapy for obesity--promise and uncertainty.
Topics: Anti-Obesity Agents; Appetite Depressants; Cannabinoid Receptor Antagonists; Cyclobutanes; Dyslipide | 2005 |
Trends in obesity and overweight-related office visits and drug prescriptions in Canada, 1998 to 2004.
Topics: Adult; Aged; Anti-Obesity Agents; Canada; Cyclobutanes; Drug Prescriptions; Female; Humans; Lactones | 2005 |
[Reducing obesity].
Topics: Adolescent; Adult; Appetite Depressants; Body Mass Index; Cardiovascular Diseases; Child; Cyclobutan | 2006 |
Early first-trimester sibutramine exposure : pregnancy outcome and neonatal follow-up.
Topics: Abnormalities, Drug-Induced; Adult; Appetite Depressants; Body Mass Index; Counseling; Cyclobutanes; | 2006 |
The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea.
Topics: Adult; Aged; Appetite Depressants; Blood Pressure; Cohort Studies; Cyclobutanes; Heart Rate; Humans; | 2007 |
Keeping weight-loss drugs in perspective. If you're dangerously overweight, diet pills may help--but not without major lifestyle changes.
Topics: Anti-Obesity Agents; Cyclobutanes; Eating; Female; Humans; Lactones; Obesity; Orlistat; Overweight; | 2006 |
Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats.
Topics: Animals; Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Body Weight; Cell Line; Condition | 2006 |
Chronic treatment with either dexfenfluramine or sibutramine in diet-switched diet-induced obese mice.
Topics: Animals; Anti-Obesity Agents; Body Weight; Cyclobutanes; Dexfenfluramine; Diet, Fat-Restricted; Ghre | 2006 |
Summaries for patients. Effects of drug treatment for obesity in adolescence.
Topics: Adolescent; Appetite Depressants; Behavior Therapy; Body Height; Body Mass Index; Child; Combined Mo | 2006 |
What constitutes successful weight management in adolescents?
Topics: Adolescent; Appetite Depressants; Behavior Therapy; Combined Modality Therapy; Cyclobutanes; Female; | 2006 |
The primary amine metabolite of sibutramine stimulates lipolysis in adipocytes isolated from lean and obese mice and in isolated human adipocytes.
Topics: Adipocytes; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Amines; Animals; Appet | 2006 |
Incorrect use of orlistat and sibutramine in clinical practice.
Topics: Anti-Obesity Agents; Appetite Depressants; Contraindications; Cyclobutanes; Guideline Adherence; Hum | 2007 |
A sibutramine-induced delusional disorder relapse.
Topics: Anti-Obesity Agents; Cyclobutanes; Delirium; Humans; Male; Middle Aged; Obesity; Recurrence; Schizop | 2007 |
Acute effects of sibutramine administration on the autonomic nervous system in obese subjects.
Topics: Appetite Depressants; Autonomic Nervous System; Cyclobutanes; Humans; Hypertension; Norepinephrine; | 2007 |
Long-term persistence with orlistat and sibutramine in a population-based cohort.
Topics: Adult; Anti-Obesity Agents; British Columbia; Cyclobutanes; Epidemiologic Methods; Female; Humans; L | 2007 |
The obese hypertensive: the weight of evidence against beta-blockers.
Topics: Adrenergic beta-Antagonists; Appetite Depressants; Cost-Benefit Analysis; Cyclobutanes; Humans; Hype | 2007 |
National trends in the use and costs of anti-obesity medications in England 1998-2005.
Topics: Anti-Obesity Agents; Cyclobutanes; Drug Costs; Drug Therapy; England; Humans; Lactones; Obesity; Orl | 2007 |
Psychosis with sibutramine.
Topics: Adult; Appetite Depressants; Cyclobutanes; Female; Humans; Male; Middle Aged; Obesity; Psychoses, Su | 2007 |
Effects of sibutramine on gastric emptying, intestinal motility and rectal tone in dogs.
Topics: Administration, Oral; Animals; Appetite Depressants; Compliance; Cyclobutanes; Disease Models, Anima | 2008 |
Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success.
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Appetite; Appetite Depressants; Body Weight; Cyclobuta | 2008 |
The obesity pandemic--how did we get here?
Topics: Anti-Obesity Agents; Bariatric Surgery; Cyclobutanes; Disease Outbreaks; Humans; Lactones; Obesity; | 2007 |
Sibutramine usage in New Zealand: an analysis of prescription data by the Intensive Medicines Monitoring Programme.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Appetite Depressants; Cohort Studies; C | 2007 |
Anti-obesity drug use before professional treatment in Taiwan.
Topics: Adolescent; Adult; Age Distribution; Anti-Obesity Agents; Body Mass Index; Combined Modality Therapy | 2007 |
[Pharmacotherapy for weight loss in patients with type 2 diabetes].
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Evidence-Based M | 2007 |
Cardiovascular effects of sibutramine.
Topics: Appetite Depressants; Blood Pressure; Body Mass Index; Cyclobutanes; Heart Rate; Humans; Obesity; Ra | 2007 |
Psychopathology in the context of obesity: the adiponectin hypothesis.
Topics: Adiponectin; Anxiety; Cyclobutanes; Depression; Headache; Humans; Migraine Disorders; Models, Biolog | 2008 |
Sibutramine in cardiovascular disease: is SCOUT the new STORM on the horizon?
Topics: Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Double-Blind Method; Humans; Obesity; R | 2007 |
The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Adverse Drug Reaction Reporting Systems; | 2007 |
[Effect of weight loss on blood pressure].
Topics: Appetite Depressants; Behavior Therapy; Blood Pressure; Body Mass Index; Cyclobutanes; Diet, Reducin | 2007 |
Binge eating disorder: the search for better treatments.
Topics: Anti-Obesity Agents; Appetite Depressants; Bulimia Nervosa; Comorbidity; Cyclobutanes; Female; Fruct | 2008 |
Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine.
Topics: Adiposity; Animals; Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Body Weight; Caloric R | 2008 |
[Struggle about the best reducing diet, Fat gone by means of more fat?].
Topics: Adolescent; Adult; Anti-Obesity Agents; Antidepressive Agents; Appetite Depressants; Body Mass Index | 2004 |
Use of sibutramine to assist obese women with weight loss can be successful in dietitian-led clinics: another tool in the dietitian's toolbox.
Topics: Adult; Appetite Depressants; Body Mass Index; Combined Modality Therapy; Cyclobutanes; Diabetes Mell | 2008 |
Sibutramine: balancing weight loss benefit and possible cardiovascular risk.
Topics: Antidepressive Agents; Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Eating; Evidence | 2008 |
Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat.
Topics: Animals; Cyclobutanes; Cyclohexanols; Eating; Fenfluramine; Fluoxetine; Male; Neurotransmitter Uptak | 1997 |
Obesity.
Topics: Cyclobutanes; Humans; Neurotransmitter Uptake Inhibitors; Obesity | 1998 |
New obesity drug approved.
Topics: Antidepressive Agents; Appetite Depressants; Cyclobutanes; Humans; Obesity; United States; United St | 1998 |
American Heart Association urges caution on new diet drug.
Topics: American Heart Association; Appetite Depressants; Cyclobutanes; Drug Evaluation; Humans; Hypertensio | 1998 |
Sibutramine for obesity.
Topics: Appetite Depressants; Cyclobutanes; Drug Costs; Drug Interactions; Heart Rate; Humans; Hypertension; | 1998 |
Is the new anti-obesity drug Meridia safer than fen-phen?
Topics: Appetite Depressants; Cyclobutanes; Humans; Obesity | 1998 |
Caution for new diet drug.
Topics: Appetite Depressants; Cyclobutanes; Humans; Obesity | 1998 |
Anti-obesity drugs.
Topics: Adrenergic Agonists; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Lipa | 1998 |
Weighing in on Meridia.
Topics: Appetite Depressants; Cyclobutanes; Female; Humans; Obesity | 1998 |
Effect of the antiobesity agent sibutramine in obese-diabetic ob/ob mice.
Topics: Animals; Appetite Depressants; Blood Glucose; Cyclobutanes; Diabetes Mellitus; Fatty Acids, Nonester | 1998 |
Studies confirm link between fen-phen and heart-valve disease.
Topics: Appetite Depressants; Cyclobutanes; Dexfenfluramine; Drug Combinations; Fenfluramine; Heart Valve Di | 1998 |
Conference report--obesity: new directions, June 27-29, 1998, Charleston, South Carolina.
Topics: Appetite Depressants; Behavior Therapy; Cyclobutanes; Diet, Reducing; Disease Outbreaks; Female; Glo | 1999 |
Does sibutramine keep the weight off?
Topics: Cyclobutanes; Diet, Reducing; Double-Blind Method; Energy Intake; Humans; Obesity; Randomized Contro | 1999 |
Orlistat for obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Double-Blind Meth | 1999 |
New pharmacological directions for the treatment of overweight and obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Body Weight; Cyclobutanes; Enzyme Inhibi | 1999 |
[How safe are the new obesity drugs? Indications and contraindications of orlistat and sibutramine].
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Clinical Trials as Topic; Contraindications; Cyclo | 1999 |
[No progress without the physician in therapy of obesity].
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Life Style; Obesity; Orli | 2000 |
Effect of sibutramine on glucose metabolism in genetically obese (fa/fa) Zucker rats.
Topics: Animals; Appetite Depressants; Blood Glucose; Body Weight; Cyclobutanes; Eating; Glucose Clamp Techn | 2000 |
Prevention and management of obesity: pharmacology .
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Obesity; Orlistat | 2000 |
Sibutramine alters the central mechanisms regulating the defended body weight in diet-induced obese rats.
Topics: Adipose Tissue; Animals; Appetite Depressants; Arcuate Nucleus of Hypothalamus; Body Weight; Cyclobu | 2000 |
Energy homeostasis and body weight in obesity: new physiopathological and therapeutic considerations.
Topics: Appetite Depressants; Body Weight; Brain; Cyclobutanes; Energy Intake; Homeostasis; Humans; Leptin; | 2000 |
Sibutramine-associated psychotic episode.
Topics: Adult; Antipsychotic Agents; Appetite Depressants; Cyclobutanes; Female; Humans; Obesity; Paranoid D | 2000 |
Effects of chronic administration of sibutramine on body weight, food intake and motor activity in neonatally monosodium glutamate-treated obese female rats: relationship of antiobesity effect with monoamines.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adipose Tissue; Animals; Animals, Newborn; Appetite Depressants; Arc | 2000 |
[Evolution and weight and body composition determination after therapy for pathological obesity for measuring compliance in (re)-education].
Topics: Anti-Obesity Agents; Body Composition; Body Weight; Cyclobutanes; Diet, Reducing; Electric Impedance | 2000 |
[The role of pharmacotherapy for treatment of obesity in adults].
Topics: Adult; Animals; Anti-Obesity Agents; Chlorphentermine; Cyclobutanes; Dexfenfluramine; Dopamine Agoni | 2000 |
Serotonin syndrome risk with antiobesity drug.
Topics: Adult; Appetite Depressants; Canada; Cyclobutanes; Drug Interactions; Female; Humans; Middle Aged; O | 2000 |
Diet drug helps keep weight off.
Topics: Appetite Depressants; Cyclobutanes; Hypertension; Obesity; Weight Loss | 2001 |
[Clinical study of the month. After the storm over central anorectic agents, the "STORM" study of sibutramine].
Topics: Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Double-Blind Method; Europe; Humans; Mu | 2001 |
Toward optimal health: the experts discuss weight control drugs. Interview by Jodi Godfrey Meisler.
Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Counseling; Cyclobutanes; Diet, Reducing | 2001 |
Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide Y.
Topics: Adipose Tissue; Animals; Appetite Depressants; Body Weight; Cyclobutanes; Diet; Feeding Behavior; Hy | 2001 |
[Weight reduction. Doubly effective with drug support].
Topics: Appetite Depressants; Clinical Trials as Topic; Combined Modality Therapy; Cyclobutanes; Diet, Reduc | 2001 |
[Observational study. Sibutramine in general practice].
Topics: Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Family Practice; Humans; Obesity | 2001 |
Drug treatment for obesity. We need more studies in men at higher risk of coronary events.
Topics: Adult; Appetite Depressants; Cardiovascular Diseases; Cholesterol, LDL; Cyclobutanes; Female; Humans | 2001 |
Drug therapy for management of obesity.
Topics: Appetite Depressants; Cholesterol, HDL; Cyclobutanes; Humans; Obesity; Randomized Controlled Trials | 2001 |
Relationship between insulin resistance, weight loss, and coronary heart disease risk in healthy, obese women.
Topics: Appetite Depressants; Body Mass Index; Coronary Disease; Cyclobutanes; Energy Intake; Fasting; Femal | 2001 |
Metabolic changes following sibutramine-assisted weight loss in obese individuals: role of plasma free fatty acids in the insulin resistance of obesity.
Topics: Adipose Tissue; Appetite Depressants; Blood Glucose; Body Mass Index; Cyclobutanes; Fatty Acids, Non | 2001 |
Synergy of sibutramine and low-dose leptin in treatment of diet-induced obesity in rats.
Topics: Animals; Body Composition; Body Weight; Cyclobutanes; Diet; Drug Synergism; Energy Intake; Energy Me | 2001 |
Obesity treatment with a progressive clinical tri-therapy combining sibutramine and a supervised diet--exercise intervention.
Topics: Adult; Basal Metabolism; Blood Pressure; Body Weight; Cyclobutanes; Diet, Reducing; Energy Metabolis | 2001 |
Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomized trials of sibutramine vs placebo.
Topics: Adult; Appetite Depressants; Cyclobutanes; Double-Blind Method; Female; Humans; Male; Middle Aged; O | 2001 |
Weight loss and health-related quality of life.
Topics: Appetite Depressants; Cyclobutanes; Humans; Obesity; Placebos; Quality of Life; Randomized Controlle | 2001 |
Long-term medication use and weight loss maintenance: an observational study.
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Female; Humans; Longitudinal Studies; Obesi | 2001 |
[Pharma-clinics. Medication of the month. Sibutramine (Reductil)].
Topics: Appetite Depressants; Blood Pressure; Clinical Trials as Topic; Constipation; Cyclobutanes; Diabetes | 2001 |
[Drugs for obesity. Why are obese patients diferent?].
Topics: Adult; Anti-Obesity Agents; Child; Cyclobutanes; Female; Humans; Insurance, Pharmaceutical Services; | 2001 |
Does long-term use of sibutramine (Meridia) result in continued weight loss in short-term responders?
Topics: Adolescent; Adult; Aged; Appetite Depressants; Body Mass Index; Cyclobutanes; Dose-Response Relation | 2001 |
Risk factor modification through weight loss enhanced with pharmacotherapy.
Topics: Appetite Depressants; Body Weight; Clinical Trials as Topic; Cyclobutanes; Humans; Hyperlipidemias; | 2002 |
[Study of heart valve function on obese patients treated with sibutramine].
Topics: Adult; Appetite Depressants; Cyclobutanes; Female; Heart Valve Diseases; Humans; Male; Middle Aged; | 2002 |
Sibutramine and blood pressure: a therapeutic dilemma.
Topics: Appetite Depressants; Blood Pressure; Cyclobutanes; Humans; Obesity | 2002 |
[Obesity: gradual-schedule therapy and long-term results].
Topics: Adult; Aged; Appetite Depressants; Behavior Therapy; Child; Clinical Trials as Topic; Cyclobutanes; | 2001 |
[Treatment of obesity in practice - more necessary than ever].
Topics: Appetite Depressants; Cyclobutanes; Humans; Obesity; Product Surveillance, Postmarketing; Treatment | 2002 |
[Sibutramine in clinical practice - a PMS-study with positive effects on blood pressure and metabolic parameters].
Topics: Adult; Appetite Depressants; Blood Glucose; Blood Pressure; Body Constitution; Body Mass Index; Cycl | 2002 |
[Anti-obesity drugs: sibutramine and orlistat].
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Obesity; Orlistat | 2002 |
[New drugs for the treatment of obesity].
Topics: Anti-Obesity Agents; Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Diet; Humans; Lac | 1999 |
Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias.
Topics: Appetite Depressants; Arrhythmias, Cardiac; Cyclobutanes; Humans; Hypertension; Obesity | 2002 |